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Abstract	
Nuclear receptors (NRs) have been targets of intensive drug development for 
decades due to their roles as key regulators of multiple developmental, 
physiological and disease processes. In the normal breast, a number of NRs are 
reported to be differentially expressed in different epithelial breast cell 
lineages and likely play a role in the differentiation and maintenance of the 
normal breast epithelial cell lineages. In breast cancer, expression of the 
estrogen and progesterone receptors remains clinically important in predicting 
prognosis and determining therapeutic strategies. More recently, there is 
growing evidence suggesting the involvement of multiple nuclear receptors 
other than the estrogen and progesterone receptors, in the regulation of 
various processes important to the initiation and progression of breast cancer.  
Identification of key NRs and the pathways they govern in the normal breast 
and breast cancer is important to our understanding of normal breast 
development and pave the way for rational design of prognostic and 
therapeutic targets for breast cancer. This thesis systematically investigates the 
expression and co-expression networks of NRs in the normal breast and how 
they are perturbed in breast cancer with a focus on the identification of 
network-based prognostic markers for breast cancer. This is done through 
analysis of multiple expression datasets, both publicly available and in-house 
generated, of primary normal breast and breast cancer tissues. Among the 
main findings of this work is the identification of NRs differentially expressed 
in normal breast epithelial cells at single cell level and the observation that 
there are major changes in the NR co-expression networks in breast cancer 
compared to the normal breast. We showed that cancer associated changes in 
NR co-expression networks are clinically relevant and that these changes can 
be used to identify NRs with prognostic values in estrogen receptor negative 
(ER-), HER2 and Basal subgroups of breast cancer. In addition, we 
demonstrated the utility of co-expression analysis in the identification of 
potential crosstalk in the signalling networks of different NRs by investigating 
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the potential crosstalk of of MR and RARB in the normal breast and breast 
cancer. 
  
 7 
Publications	and	authorship	attribution	
statements	
PAPER 1 
Section 1.2 of this thesis is published as a review in the Journal of Molecular 
Endocrinology: 
Doan, T.B., J. Graham, and C. Clarke, Emerging functional roles of nuclear 
receptors in breast cancer. J Mol Endocrinol, 2017. [1]. 
Followings are my contributions to this publication 
• Study design 
• Literature review 
• Writing the manuscript 
• Associated administrative work. 
 
PAPER 2 
Chapter 3 of this thesis is published as a research article in the Journal of 
Molecular Oncology:  
Doan, T.B., et al., Breast cancer prognosis predicted by nuclear receptor-
coregulator networks. Molecular Oncology, 2014. 8(5): p. 998-1013. [2]. 
Following are my contributions to this publication 
• Curation of microarray data from public repositories 
• All data analysis and interpretation 
• Preparation of all figures, tables and supplementary materials 
• Writing the manuscript 
 8 
In addition to the statements above, in cases where I am not the 
corresponding author of a published item, permission to include the published 
material has been granted by the corresponding author. 
 February 28th, 2017 
Tram Bich Doan 
 
As supervisor for the candidature upon which this thesis is based, I can 
confirm that the authorship attribution statements above are correct.  
 February 28th, 2017 
Christine L. Clarke 
 
 
	 	
 9 
List	of	abbreviations	
Abbreviation Details 
AF1 N-terminal	A/B	domain	with	activation	function1 
ALDO Aldosterone 
cDNA Complementary	deoxyribonucleic	acid 
ChIP-chip Chromatin	immunoprecipitation	followed	by	microarray	hybridization 
ChIP-Seq Chromatin	immunoprecipitation	followed	by	high-throughput	sequencing 
Ct Threshold	cycle 
CV Coefficient	of	variation 
DBD DNA	binding	domain 
DCt Delta	Ct 
DE Differentially	expressed 
DHS DNAse	I	hypersensitive	site 
DNA Deoxyribonucleic	acid 
DSS Disease-specific	survival 
E2 Estradiols 
ENCODE Encyclopedia	of	DNA	Elements 
ER- Estrogen	receptor	negative 
ER+ Estrogen	receptor	positive 
ESR1	 Estrogen	receptor	alpha	
FDR False	discovery	rate 
FDR-BH	 False	discovery	rate	as	determined	by	the	Benjamini-Hochberg	procedure	
FE Fold	enrichment 
fRMA Frozen	Robust	Multi-array	Analysis 
FWER Family	wise	error	rate 
GO Gene	Ontology 
GRE Glucocorticoid	receptor	response	element 
GRO-Seq Global	Run-On	sequencing 
GSEA Gene	set	enrichment	analysis 
HCL Hierarchical	clustering 
LBD Ligand-binding	domain 
MR Mineralocorticoid	receptor 
mRNA Messenger	RNA 
MSigDB The	Molecular	Signatures	Database 
nGRE Negative	glucocorticoid	receptor	response	element 
NPI Nottingham	Prognostic	Index 
NR Nuclear	receptor 
NURSA Nuclear	Receptor	Signalling	Atlas 
PCA Principal	Component	Analysis 
PCR Polymerase	chain	reaction 
PGR	 Progesterone	receptor	
PPI Protein-protein	interaction 
qRT-PCR Quantitative	Real-time	Polymerase	Chain	Reaction 
RA Retinoic	acid 
RAR Retinoic	acid	receptor 
RNA Ribonucleic	acid 
RNA-Seq RNA	sequencing 
 10 
Abbreviation Details 
SCCA Sparse	Canonical	Correlation	Analysis 
TCGA The	Cancer	Genome	Atlas 
TLDA TaqMan	low-density	array 
TNBC Triple-negative	breast	cancer 
TPM Transcripts	Per	Million 
WGCNA Weighted	Gene	Co-expression	Network	Analysis 
 	
 11 
Table	of	Contents	
Declarations	of	Authorship	.....................................................................................	2	
Acknowledgements	................................................................................................	3	
Abstract	..................................................................................................................	5	
Publications	and	authorship	attribution	statements	..............................................	7	
List	of	abbreviations	...............................................................................................	9	
Table	of	Contents	..................................................................................................	11	
List	of	Figures	........................................................................................................	15	
List	of	Tables	.........................................................................................................	17	
1	 Introduction	....................................................................................................	18	
1.1	Overview	........................................................................................................	19	
1.2	Nuclear	receptors	and	breast	cancer	.............................................................	19	
1.2.1	 Breast	cancer:	a	hormone-dependent	disease	..............................................	19	
1.2.2	 The	human	family	of	nuclear	receptors	.........................................................	20	
1.2.3	 Mechanisms	of	nuclear	receptor	action	.........................................................	26	
1.2.4	 NR	expression	in	the	normal	breast	and	breast	cancer	.................................	33	
1.2.5	 NR	expression	in	breast	cancer	subtypes	.......................................................	34	
1.2.6	 Emerging	functional	roles	of	NR	in	breast	cancer	..........................................	35	
1.2.7	 Summary	........................................................................................................	37	
1.3	Data	and	analytical	methods	.........................................................................	38	
1.3.1	 Gene	expression	regulation	and	profiling	technologies	.................................	38	
1.3.2	 Breast	cancer	prognostication	.......................................................................	43	
1.3.3	 Identifying	biologically	perturbed	NR-regulated	networks	in	breast	cancer	.	49	
1.4	Hypotheses	and	Aims	.....................................................................................	57	
1.4.1	 Hypotheses	.....................................................................................................	57	
1.4.2	 Aims	of	this	study	...........................................................................................	57	
1.5	 Thesis	chapters	...............................................................................................	57	
2	 Materials	and	Methods	...................................................................................	60	
2.1	NR	nomenclature	...........................................................................................	61	
2.2	Datasets	used	in	this	thesis	............................................................................	62	
2.2.1	 Dataset	1:	TLDA	arrays	of	human	primary	breast	tissues	..............................	62	
 12 
2.2.2	 Dataset	2:	Microarray	meta-dataset	(Affymetrix	HG133A)	............................	62	
2.2.3	 Dataset	3:	Breast	cancer	microarrays	from	the	METABRIC	study	..................	63	
2.2.4	 Dataset	4:	TCGA	Breast	Invasive	Carcinoma	RNA-Seq	data	...........................	64	
2.2.5	 Dataset	5:	Single-cell	RNA-seq	expression	of	normal	breast	epithelial	cells	..	64	
2.3	 TLDA	profiling	of	human	breast	tissues	..........................................................	65	
2.3.1	 Human	breast	tissue	cohorts	.........................................................................	65	
2.3.2	 Taqman	low-density	array	expression	profiling	.............................................	65	
2.3.3	 Processing	of	TaqMan	low-density	arrays	......................................................	66	
2.4	 Single	cell	expression	profiling	of	normal	breast	cells	....................................	67	
2.4.1	 Processing	of	normal	breast	tissue	................................................................	67	
2.4.2	 Processing	of	single-cell	sequencing	data	......................................................	67	
2.4.3	 Cell	type	classification	from	single	cell	RNA-Sequencing	data	.......................	69	
2.5	Microarray	expression	profiling	of	MR-inducible	breast	cancer	cells	.............	71	
2.6	 Prognostication	and	survival	analysis	............................................................	71	
2.6.1	 Assessing	prognostic	utility	of	a	gene	signature	............................................	71	
2.7	 Co-expression	and	differential	co-expression	analysis	...................................	73	
2.7.1	 Co-expression	analysis	...................................................................................	73	
2.7.2	 Differential	co-expression	analysis	.................................................................	77	
2.8	Ontology	and	gene	set	over-representation	analysis	.....................................	81	
2.8.1	 Gene	ontology	(GO)	over-representation	analysis	.........................................	81	
2.8.2	 Gene	set	enrichment	analysis	(GSEA)	............................................................	81	
3	 Breast	cancer	prognosis	predicted	by	nuclear	receptor-coregulator	networks	.	82	
4	 Identification	of	co-expressed	and	differentially	co-expressed	NR	networks	in	
the	normal	breast	and	breast	cancer	...............................................................	99	
Overview	.............................................................................................................	100	
4.1	 Chapter	hypothesis	and	aims	.......................................................................	101	
4.2	NR	co-expression	networks	in	the	normal	breast	and	breast	cancer	...........	101	
4.2.1	 NR	co-expression	networks	in	the	normal	breast	........................................	103	
4.2.2	 NR	co-expression	network	in	breast	cancer	.................................................	107	
4.2.3	 NR-NR	interactions	inferred	through	co-expression	analysis	......................	113	
4.2.4	 Section	summary	..........................................................................................	116	
4.3	 Identification	of	NR	networks	altered	in	breast	cancer	................................	117	
4.3.1	 Approach	1	...................................................................................................	117	
 13 
4.3.2	 Approach	2	...................................................................................................	125	
4.3.3	 Section	summary	..........................................................................................	131	
5	 Single-cell	analysis	of	NR	expression	and	co-expression	networks	in	normal	
breast	epithelial	cells.	...................................................................................	133	
5.1	Overview	......................................................................................................	134	
5.2	Aims	.............................................................................................................	137	
5.3	Results	..........................................................................................................	137	
5.3.1	 Descriptive	analysis	of	the	single	cell	population	under	studied	.................	138	
5.3.2	 Classification	of	cell	types	............................................................................	141	
5.3.3	 Characterization	of	NR	expression	in	normal	breast	cell	lineages	...............	144	
5.3.4	 NR	co-expression	networks	in	different	normal	breast	cell	lineages	...........	153	
5.3.5	 Chapter	summary	.........................................................................................	159	
6	 The	functional	roles	of	the	mineralocorticoid	receptors	in	breast	cancer	......	160	
6.1	Overview	......................................................................................................	161	
6.2	 Potential	crosstalk	between	MR	and	RAR	signalling	in	the	breast	...............	162	
6.2.1	 Analysis	of	NR-coregulator	associations	identified	potential	functional	
crosstalk	between	MR	and	RAR	signalling	...................................................	162	
6.2.2	 Data	mining	reveals	connections	between	MR	and	RARB	co-expression	
networks	.......................................................................................................	164	
6.2.3	 Summary	......................................................................................................	165	
6.3	 Inference	of	the	functional	roles	of	MR	through	co-expression	analysis	......	165	
6.4	Activation	of	MR	and	RAR	signalling	through	ligand	treatment	of	MR-
inducible	MCF-7	breast	cancer	cells	.............................................................	171	
6.4.1	 Identification	of	differentially	expressed	genes	...........................................	172	
6.4.2	 Overlap	between	DE	genes	and	co-expressed	genes	...................................	173	
6.4.3	 Examining	the	concordance	in	direction	of	change	in	expression	on	ligand	
treatment	with	that	predicted	by	co-expression	analysis.	...........................	175	
6.4.4	 Gene	ontology	enrichment	analysis	.............................................................	177	
6.4.5	 Effect	of	MR	and	RAR	signalling	on	glucose	metabolism	and	oxidative	
phosphorylation	...........................................................................................	183	
6.4.6	 Effect	of	MR	and	RAR	signalling	on	breast	cancer	cell	proliferation	and	
patient	survival	.............................................................................................	186	
6.5	 Chapter	summary	.........................................................................................	189	
 14 
7	 Discussion	.....................................................................................................	191	
7.1	Distinction	of	the	approaches	utilized	in	this	thesis	.....................................	193	
7.2	Main	research	outcomes	..............................................................................	194	
7.3	 Limitations	of	this	study	and	direction	for	future	research	..........................	199	
Appendices	.......................................................................................................	201	
Appendix	A	–	Paper	1	..............................................................................................	201	
Appendix	B	–	Supplementary	Materials	to	Paper	2	................................................	223	
Bibliography	......................................................................................................	234	
 
 	
 15 
List	of	Figures	
Figure	1:	Structural	and	functional	organization	of	nuclear	receptors.	...............................................	22	
Figure	2:	A	typical	microarray	experiment.	..........................................................................................	40	
Figure	3:	A	typical	RNA-seq	experiment.	.............................................................................................	42	
Figure	4:	Common	approaches	to	studying	gene	expression	data.	.....................................................	49	
Figure	5:	Common	steps	involved	in	co-expression	and	differential	co-expression	analysis.	.............	51	
Figure	6:	Distribution	of	the	average	read	counts	of	genes.	................................................................	69	
Figure	7:	Distribution	of	Pearson	correlation	coefficients	in	normal	and	cancer	samples.	.................	75	
Figure	8:	Quantile-quantile	plot	of	pair-wise	Pearson's	r,	z'	and	standardized	z	values.	.....................	76	
Figure	9:	First	approach	to	differential	co-expression	analysis.	...........................................................	78	
Figure	10:	Second	approach	to	differential	co-expression	analysis	.....................................................	79	
Figure	11:	Numbers	of	NR	co-expressed	genes	in	normal	and	cancer.	..............................................	102	
Figure	12:	NR	co-expression	networks	in	the	normal	breast.	............................................................	104	
Figure	13:	NR	co-expression	network	in	breast	cancer.	.....................................................................	109	
Figure	14:	Co-expression	based	identification	potential	functional	crosstalk	between	NRs.	............	115	
Figure	15:	Cancer	associated	changes	in	NR	co-expression	networks	identified	by	Approach	1.	.....	119	
Figure	16:	Prognostic	value	of	NR	groups	identified	based	on	differential	co-expression.	...............	123	
Figure	17:	Kaplan	Meier	analysis	of	Group	6	NRs.	.............................................................................	124	
Figure	18:	Distribution	of	differential	co-expression	values	..............................................................	126	
Figure	19:	Cancer	associated	changes	in	NR	co-expression	network	identified	by	Approach	2.	.......	127	
Figure	20:		Normal	breast	epithelial	cell	lineages.	.............................................................................	135	
Figure	21:	Comparison	of	single-cell	and	bulk	measurements.	.........................................................	136	
Figure	22:	Number	of	genes	expressed	in	each	of	the	126	cells.	.......................................................	138	
Figure	23:	Number	of	genes	expressed	plotted	against	the	number	of	cells.	...................................	139	
Figure	24:	Cumulative	number	of	genes	against	number	of	cells	plot.	..............................................	139	
Figure	25:	Quantiles	of	the	number	of	cells	genes	are	expressed	in	.................................................	140	
Figure	26:		Boxplot	of	expression	level	of	genes	categorized	by	the	number	of	cells	.......................	140	
Figure	27:	Classification	of	breast	epithelial	cells	into	different	cell	lineages.	...................................	142	
Figure	28:	Numbers	of	NRs	expressed	in	each	single	cell.	.................................................................	146	
Figure	29:	Boxplot	of	the	number	of	NRs	expressed	in	each	cell	categorized	by	cell	lineage.	..........	146	
Figure	30:	Heatmap	of	NR	expression	across	the	studied	population	of	single	cells.	........................	147	
Figure	31:	Pairwise	correlations	of	NRs	at	single	cell	level.	...............................................................	148	
Figure	32:	NR	expression	in	different	cell	types	of	the	normal	breast.	..............................................	149	
Figure	33:	Distribution	of	NRs	in	different	cell	types	of	the	normal	breast	epithelium.	....................	149	
Figure	34:	Differences	in	the	distribution	and	expression	of	NRs	between	Basal	and	Luminal	cells.	151	
Figure	35:	Distribution	and	expression	of	NRs	in	progenitor	and	differentiated	cells.	......................	151	
 16 
Figure	36:	Number	of	NR	co-expressed	genes	identified	in	the	Luminal	and	Basal	cell	types.	..........	154	
Figure	37:	NR	co-expression	network	in	Luminal	cells.	......................................................................	155	
Figure	38:	NR	co-expression	networks	in	basal	cells.	.........................................................................	156	
Figure	39:	Difference	in	distribution	of	NR	correlations	for	single	cell	and	bulk	measurements.	.....	158	
Figure	40:	SCCA	analysis	of	TLDA	data	...............................................................................................	163	
Figure	41:	Co-expression	based	identification	potential	crosstalk	between	MR	and	RARB.	.............	164	
Figure	42:	Expression	of	MR,	RARB,	RARG	and	RARA	in	normal	breast	and	breast	cancer	...............	165	
Figure	43:	GO	terms	enriched	in	genes	co-expressed	with	MR	and	RARB	in	normal	breast	tissues.	167	
Figure	44:	GO	terms	enriched	in	genes	co-expressed	with	MR	and	RARB	in	breast	cancer	tissues.	.	168	
Figure	45:	Overlap	of	MR	and	RARB	co-expressed	genes.	.................................................................	170	
Figure	46:	Differentially	expressed	genes	in	ALDO,	RA	and	ALDO+RA	treated	MCF-7	cells.	.............	173	
Figure	47:	Overlaps	between	co-expressed	and	differentially	expressed	genes	...............................	174	
Figure	48:	Expected	versus	observed	changes	in	the	direction	of	gene	expression.	.........................	177	
Figure	49:	GO	terms	enriched	in	genes	differentially	expressed	on	ligand	treatments	.....................	178	
Figure	50:	Biological	processes	GO	terms	enriched	in	differentially	expressed	gene	clusters.	.........	181	
Figure	51:	Effect	of	ALDO+RA	treatment	on	cellular	metabolism.	.....................................................	183	
Figure	52:	Features	of	the	reverse	Warburg	effect	............................................................................	185	
Figure	53:	Effect	of	MR	and	RAR	signalling	on	breast	cancer	cell	proliferation.	................................	187	
Figure	54:	Survival	analysis	of	breast	cancer	tissues	expression	high	MR	and	RARB.	........................	188	
 
	 	
17 
List	of	Tables	
Table	1:	Human	nuclear	receptors	.......................................................................................................	23	
Table	2:	NR	effects	on	cancer-related	biological	processes	.................................................................	36	
Table	3:	NR	nomenclature	...................................................................................................................	61	
Table	4:	List	of	microarray	breast	cancer	datasets	used	in	survival	analyses	......................................	63	
Table	5:	Treatment	and	sample	information	of	the	126	cells	sequenced	by	single	cell	RNA-seq	.......	64	
Table	6:	Top	10	GO	terms	enriched	in	NR	co-expressed	gene	modules	identified	in	normal	breast	105	
Table	7:	Top	10	GO	terms	enriched	in	NR	co-expression	gene	modules	of	breast	cancers	...............	110	
Table	8:	Top	10	GO	terms	associated	with	each	gene	cluster	in	Figure	15.	.......................................	120	
Table	9:	Top	10	GO	terms	enriched	in	gene	clusters	identified	in	Figure	19.	....................................	128	
Table	10:	Top	5	biological	processes	over-represented	in	gene	cluster	C1-C6.	.................................	143	
Table	11:	Expression	of	34	NRs	in	breast	epithelial	cells.	..................................................................	145	
Table	12:	NR	significantly	differentially	expressed	in	different	normal	breast	cell	types.	.................	152	
Table	13:	Categories	of	MR	or	RARB	co-expressed	genes	analysed	in	GO	enrichment	analyses.	.....	166	
Table	14:	Categories	of	MR	co-expressed genes.........................................................................................177	
Introduction 
 18 
 
 	
1 Introduction 
Introduction 
 19 
1.1 Overview	
This chapter reviews our current understanding of the roles of nuclear 
receptors (NR) in breast cancer (please refer to Section 2.1 for the list of all 
human NRs) and describes the datasets and analytical methods used in this 
thesis. First, we give an overview of breast cancer and the human NR 
superfamily in Section 1.2. Secondly, the approaches used to evaluate the 
prognostic values of gene signatures and infer altered regulatory networks 
from expression data are described in Section 1.3. Then, in Section 1.4, we 
outline the hypotheses and aims for this body of work, which focuses on the 
application of bioinformatics techniques to identify NR and NR-regulated 
biological processes that are either altered in breast cancer or differentially 
regulated in different breast cell lineages. Finally, in Section 1.5, we give an 
overview of the structure of this thesis by describing the focus and significance 
of each result chapter. 
1.2 Nuclear	receptors	and	breast	cancer	
1.2.1 Breast	cancer:	a	hormone-dependent	disease	
Breast cancer is the most common cancer diagnosed in women worldwide [3]. 
Over the past decades, substantial progress towards treatment of primary 
estrogen receptor-positive (ER+) breast cancer has been made with the 
development of endocrine therapies targeting the estrogen biosynthesis and 
signalling pathways. Despite the success of endocrine therapies, there remain 
subgroups of women for whom available treatment offers little help. These 
include patients with ER+ breast tumours that develop endocrine treatment 
resistance [4], patients with estrogen receptor-negative (ER-) breast cancers 
[5] and cancers that recur in all age groups [6]. Women in these subgroups 
currently face the challenge of living with advanced disease, therefore, there 
exists the need to develop rational treatments targeting these subgroups of 
breast cancer.  
Introduction 
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In this context, nuclear receptors (NRs) are potential promising targets due to 
the importance of NRs as master regulators of nearly all physiological aspects 
of life and the availability of drugs targeting NRs that resulted from intensive 
drug development targeting NRs for a range of pathological conditions. 
A number of NRs have been prominent in breast cancer diagnosis and 
treatment. It is recognized that the estrogen receptor and progesterone 
receptor (PGR) play critical roles in the development and progression of breast 
cancer, and moreover, their expression in a breast tumour remains a robust 
predictor of disease outcome. Consequently, measurement of ESR1 and PGR 
expression in breast cancers is a mainstay of clinical management programs 
and treatments targeting the estrogen signaling axis are standard of care for 
ER+ disease [7]. More recently, the androgen receptor (AR), which is 
frequently expressed in primary breast tumors [8, 9], has emerged both as a 
marker of outcome and as a potential treatment target [7, 10]. A number of 
other nuclear receptors, including the vitamin D3 receptor (VDR) [11, 12] and 
the glucocorticoid receptor (GR) [13, 14] have also been investigated for their 
anti-proliferative, anti-apoptotic effect in breast cancer. Members of the 
retinoid receptor subfamily have also received considerable attention, 
particularly the crosstalk between the retinoic acid receptor alpha (RARA) and 
estrogen signalling [15, 16], and the anti-migratory effect of the retinoic acid 
receptor beta (RARB) in breast cancer [17, 18]. However, the functional roles of 
the majority of the remaining members of the human NR family in the normal 
breast and breast cancer have largely been unexplored.  
1.2.2 The	human	family	of	nuclear	receptors	
The human NR superfamily consists of 48 highly evolutionarily conserved 
transcription factors with the ability to act as molecular sensors of 
physiological and environmental stimuli [19]. These transcription factors 
include the receptors for steroid hormones, thyroid hormones, lipophilic 
vitamins and cholesterol metabolites including retinoic acid and oxysterols 
[19]. Members of the NR superfamily are identified through their highly 
evolutionarily conserved structural organization [20], which consists of four 
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major domains: The N-terminal A/B domain with activation function 1 (AF1); 
the DNA-binding domain (DBD) consisting of two zinc finger motifs which 
confers response element specificity;  the hinge region linking the DBD to the 
ligand-binding domain (LBD), which may or may not have an AF2 region that 
mediates coactivator interaction [19, 21, 22] (Figure 1A). The 48 human NRs are 
organized into six evolutionary groups based on sequence alignment and 
phylogenetic tree construction [23, 24]. Organization of NRs into functional 
groupings is also feasible, based on profiling the anatomical expression of NRs. 
In the mouse this revealed a hierarchical organization of NRs into integrated 
physiologic functional groups (Figure 1B, which partially reflect the functional 
groupings observed in human, especially for NRs that are involved in circadian 
and metabolic pathways. 
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Figure 1: Structural and functional organization of nuclear receptors. 
(A) Schematic diagram of the structural organization of nuclear receptors. (reproduced from 
Gronemeyer et al., 2004, with permission from Elsevier). The evolutionary conserved regions C 
and E are indicated as boxes (green and orange, respectively), and a black bar represents the 
divergent regions A/B, D and F. Domain functions are depicted above and below the scheme 
(AD, activation domain; AF1, activation function 1; NLS, nuclear localization signal). (B) 
Hierarchical clustering of NR tissue expression profiles (reproduced from Bookout et al., 2006 
[142], with permission from Elsevier). The relationship between receptor expression, function, 
and physiology is depicted as a circular dendrogram using the hierarchical, unsupervised 
clustering of NR tissue expression distribution profiles in mouse. The analysis reveals the 
existence of a higher-order network tying nuclear receptor function to reproduction, 
development, central and basal metabolic functions, dietary-lipid metabolism, and energy 
homeostasis.  
 
A
B
B
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Approximately half of the NRs are designated as orphans because endogenous 
physiological ligands for these NRs have not been found. If an endogenous 
ligand is found, the orphan receptor is then classified as adopted orphans. 
Table 1 lists all human nuclear receptors, their ligands and what is known 
about their expression in breast cancer compared to the normal breast.  
Table 1: Human nuclear receptors. NURSA stands for the systematic naming of nuclear receptors 
by the Nuclear Receptor Signaling Atlas Consortium. 
Name NURSA 
Common 
Name 
Ligands 
Expression 
in BC 
versus 
Normal 
Association 
with ESR1 
expression 
Steroid hormone receptors 
Estrogen receptor 
NR3A1	 ESRa	 Estrogens Increased Yes1,2 
NR3A2	 ESRb	 Estradiols Decreased  
3-Ketosteroid 
receptor 
NR3C1	 GR	 Cortisols (hydrocortisone) Increased  
NR3C2	 MR	 Aldosterone Decreased  
NR3C3	 PR	 Progesterone 
Expressed 
in BC 
Yes1,2 
NR3C4	 AR	
Testosterone, 
dihydrotestosterone 
Increased Yes1,2 
Non-steroid hormone receptors 
Thyroid hormone 
receptor 
NR1A1	 TRa	
Thyroxine (T4), 
Triiodothyronine (T3) 
Decreased  
NR1A2	 TRb	
Thyroxine (T4), 
Triiodothyronine (T3) 
Decreased Yes1,2 
Retinoic acid 
receptor 
NR1B1	 RARa	
All-trans and 9-cis retinoic 
acid 
Increased Yes1,2 
NR1B2	 RARb	
All-trans and 9-cis retinoic 
acid 
Decreased  
NR1B3	 RARg	
All-trans and 9-cis retinoic 
acid 
Decreased  
RAR-related orphan NR1F1	 RORa	 Oxysterols Decreased  
                                                
1	Muscat	et	al.,	2013	[62]	2	Lin	et	al.,	2015	[63]	
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Name NURSA 
Common 
Name 
Ligands 
Expression 
in BC 
versus 
Normal 
Association 
with ESR1 
expression 
receptor 
NR1F2	 RORb	
Cholesterol, cholesteryl 
sulphate 
Decreased Yes2 
NR1F3	 RORg	 Retinoic acid Decreased Yes2 
Vitamin D receptor NR1I1	 VDR	
Calcitriol (1',25' dihydroxy 
vitamin D3) 
Decreased  
Adopted orphans 
Peroxisome 
proliferator-
activated receptor 
NR1C1	 PPARa	 Fatty acids Decreased Yes2 
NR1C2	 PPARd	 Fatty acids Decreased  
NR1C3	 PPARg	 Fatty acids Decreased  
Rev-erbs 
NR1D1	 REV-ERBa	 Heme Decreased  
NR1D2	 REV-ERBb	 Heme Decreased  
Liver X receptor-like 
NR1H2	 LXRb	 Retinoic acid Decreased  
NR1H3	 LXRa	 Oxysterols Decreased  
NR1H4	 FXRa	 Bile acids 
Not 
expressed 
 
Vitamin D receptor-
like 
NR1I2	 PXR	 Bile acids Decreased  
NR1I3	 CAR	 Androstanol, androstenol 
Not 
expressed 
 
Retinoid X receptor 
NR2B1	 RXRa	 9-cis-retinoic acid Decreased  
NR2B2	 RXRb	 9-cis-retinoic acid Decreased  
NR2B3	 RXRg	 9-cis-retinoic acid Decreased  
Steroidogeneic 
factor-like 
NR5A1	 SF-1	 Phospholipids 
Not 
expressed 
 
NR5A2	 LRH-1	 Phospholipids Decreased Yes2 
Orphan nuclear receptors 
DSS-AHC Critical 
Region On The X 
Chromosome, gene 1 
NR0B1	 DAX-1	 Not known 
Not 
expressed 
Yes2 
Short heterodimeric 
partner 
NR0B2	 SHP	 CD437 Retinoids 
Not 
expressed 
 
Hepatocyte nuclear 
factor 4 
NR2A1	 HNF4a	 Fatty acids 
Not 
expressed 
 
NR2A2	 HNF4g	 Fatty acids Decreased  
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Name NURSA 
Common 
Name 
Ligands 
Expression 
in BC 
versus 
Normal 
Association 
with ESR1 
expression 
Testicular orphan 
receptors 
NR2C1	 TR2	 All-trans retinoic acid Decreased  
NR2C2	 TR4	 All-trans retinoic acid Decreased  
Tailess-related 
receptor 
NR2E1	 TLX	 Not known 
Not 
expressed 
Yes2 
Photoreceptor cell-
specific receptor 
NR2E3	 PNR	 Benzimidazoles Decreased Yes1,2 
Chicken ovalbumin 
upstream promoter-
transcription factor 
NR2F1	 COUP-TF1	 Not known Decreased  
NR2F2	 COUP-TF2	 Retinol/ATRA Decreased  
ErbA2-related gene 
2 
NR2F6	 EAR2	 Not known Increased  
Estrogen receptor-
related receptor 
NR3B1	 ERRa	
Isoflavones, 
Diethylstilbestrol, 
Chlordane 
Decreased  
NR3B2	 ERRb	
Isoflavones, 
Diethylstilbestrol,4-
Hydroxy tamoxifen 
Decreased  
NR3B3	 ERRg	
Isoflavones, 
Diethylstilbestrol,4-
Hydroxy tamoxifen 
Decreased Yes2 
Nerve growth factor 
IB-like 
NR4A1	 NUR77	
Cyclosporone-B, 
Diindolylmethane Analogs 
Increased  
NR4A2	 NURR1	
6-Mercaptopurine, 
Benzimidazoles, C-DMIs 
Increased  
NR4A3	 NOR1	
6-Mercaptopurine, 
Prostaglandin A2 
Increased  
Germ cell nuclear 
factor 
NR6A1	 GCNF	 Not known Decreased  
 
 
 	
Introduction 
 26 
1.2.3 Mechanisms	of	nuclear	receptor	action	
Alterations in normal transcriptional programs are a fundamental feature of 
cancer pathogenesis and progression. Nuclear receptors are important 
regulators that directly couple small-molecule signalling with transcriptional 
regulation. An understanding of their mechanisms of action at the genomic 
and network level, and how these processes are altered in breast cancer, is of 
fundamental importance to our understanding of breast cancer development. 
The development of technologies such as ChIP-chip, ChIP-Seq and GRO-Seq 
has enabled profiling of the genomic locations of NR binding in an unbiased, 
genome-wide manner. Studies employing these methods have revealed new 
insights into the mechanisms of action of nuclear receptors and highlight the 
complexity of nuclear receptor regulatory networks in breast cancer. In this 
sub-section, we review new insights into NR mechanisms of action in breast 
cancer made possible by these genomic methods. 
1.2.3.1 Shifts	from	the	“classical”	model	of	NR	action	
Traditionally, studies on nuclear receptor action at hormone responsive genes 
gave rise to the model that NRs binds proximally to the promoters of target 
genes, through recognition of stringent paired half-sites with highly specific 
orientation [19]. However, these classical models have been challenged by 
recent studies that profiled the genome-wide binding sites of several nuclear 
receptors and transcription factors using ChIP-chip or ChIP-Seq. In the 
context of breast cancer, genome-wide mapping of ESR1 genomic localization 
in the MCF-7 breast cancer cell line showed that most ESR1 binding occurs at 
distal regions of the genome and that many ESR1 sites did not contain the 
canonical ESR1 binding motif [25]. Kittler et al. examined the genomic 
distribution of the binding sites of 24 NRs in MCF-7 cells and found that NRs 
vary significantly in their genomic localization, with both proximal-biased and 
distal-biased NRs being observed [26]. The observation that NRs localize not 
only to proximal promoter regions but also to distal regions and the 
prevalence of non-canonical motif and half-site recognition is also confirmed 
in a meta-analysis of NR cistromes in different cell types [27]. NR binding at 
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non-canonical response elements can be a mechanism to fine tune 
transcriptional responses of NRs. For example, the glucocorticoid receptor 
(GR) is capable of binding a negative response element (nGRE) that confers 
transrepression in addition to the canonical glucocorticoid response element 
(GRE) that confers transactivation to liganded GR in epidermis and intestinal 
epithelial cells [28]. Furthermore, NRs are capable of mediating long-range 
transcriptional regulation that involves chromatin looping as illustrated by 
studies on ER-mediated long-range chromatin interactions [29]. Together, 
these studies suggest a more complex model of NR genomic action in which 
NRs frequently act on long-range enhancers whose actions can be fine-tuned 
by recognition of different response elements.  
1.2.3.2 Cell	type-specificity	and	the	chromatin	landscape	
Studies investigating NR cistromes highlight the remarkable difference in the 
genome-wide binding profiles of the same NR in different cell types [30, 31].  In 
addition to the influence of coregulators in determining the cell type-specific 
transcriptional response of NRs (discussed in the next section), another major 
aspect of NR action illuminated through advances in genomic technologies is 
the dynamic and complex interactions between NR and the chromatin 
landscape of the cell. It is becoming clear that chromatin, existing in a 
dynamic continuum of condensation states, regulates as well as is regulated 
by, NR actions, and that NR-chromatin interaction is a major determinant of 
NR cell-type specific transcriptional regulation. Due to the widely accepted 
model of NR binding to DNA only after conformational changes induced upon 
ligand binding, several groups have investigated the question of pre-induction 
versus post-induction chromatin accessibility as a determinant of NR action. 
Genome-wide screening of DNAse I hypersensitive sites (DHS) in breast cells 
revealed that the majority (>70%) of GR binding occurs at pre-induction DHS 
sites, whereas only ~20% of GR binding occurs at hormone-induced remodeled 
chromatin [32]. A recent study of long-range interactions pre- and post-
dexamethasone induction in HeLa cells found that, similar to breast cells, the 
majority of GR binding occurs at pre-accessible chromatin. Binding of GR to a 
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subset of sites containing the consensus GRE results in formation of active 
enhancers and increased long-range interactions [33]. Profiling of ESR1 
revealed a similar pattern. The majority of ESR1 binding sites coincide with 
pre-existing open chromatin, co-occurrence of other transcription factor 
binding, and correspond to cell-type-specific gene regulation, whereas ESR1 
binding sites shared by multiple cell types are characterized by inaccessible 
chromatin containing high affinity estrogen response elements [34]. Profiling 
of the PGR by DNase and MNase followed by next-generation sequencing 
showed that PGR binding upon hormone stimulation corresponds with DHS 
regions that still exhibit high nucleosome occupancy. Upon hormone 
treatment, remodeling of nucleosomes containing functional PGR binding 
sites occurs and progesterone-responsive genes are associated with PGR 
binding sites that show strong nucleosome remodeling upon hormone 
induction [35]. The chromatin landscape of the cell therefore plays an 
important role in determining the genomic binding profiles of specific NRs. 
While some NRs such as ESR1 and GR rely mostly on pre-programmed sites 
made accessible by other cell- and tissue-specific pioneer DNA-binding 
factors, other NRs such as PGR require ligand-dependent active chromatin 
remodeling. 
1.2.3.3 Pioneer	factors	and	coregulators	as	modulators	of	
NR	function	
Pioneer factors are transcription factors that can bind condensed chromatin 
and influence transcription by facilitating subsequent recruitment of other 
transcriptional regulators. Recent studies have highlighted the importance of 
pioneer factors in facilitating chromatin accessibility and also in determining 
the cell type specific response of NRs. This is exemplified by the dependence of 
ESR1 on FOXA1 in breast cancer. FOXA1 expression is luminal-restricted [36] 
and is thought to function as a pioneer factor [37]. FOXA1 has been observed 
to influence genome-wide chromatin accessibility and is a key determinant of 
cell type specific ESR1 genomic localization [38, 39], reflecting the importance 
of interaction with other factors on control of cell-specificity of ESR1. Similarly, 
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AP-1 has been shown to recruit GR to regions of the genome that are basally 
accessible prior to hormonal treatment. AP-1 is thought to maintain chromatin 
accessibility for GR binding as well as recruiting GR indirectly in the absence 
of a canonical GR motif [40].  
In addition to pioneer factors, coregulators interact with NRs and other 
transcription factors to facilitate transcription of target genes. According to 
the Nuclear Receptor Signaling Atlas (NURSA: www.nursa.org), there are 320 
NR coregulators identified to date. However, this number is likely to be a gross 
underestimation according to a recent proteomic study [41]. Coregulators can 
assist in transcriptional regulation of NRs by facilitating chromatin 
accessibility, stabilizing NR-DNA interaction or facilitating indirect NR-DNA 
interaction through tethering [42, 43].  
Selective recruitment of coregulators to subsets of NR binding sites can also be 
a mechanism through which transcriptional regulation of subsets of NR target 
genes are fine-tuned. An early study of ESR1 and the steroid receptor 
coactivator protein (SRC) binding using promoter tiling arrays showed E2-
dependent recruitment of ESR1 and SRC to E2-stimulated genes while absence 
of SRC was observed at E2-repressed genes [44]. In a subsequent study, Zwart 
et al. mapped the genome-wide binding sites of several ESR1 coregulators 
(SRC1, SRC2, SRC3, p300 and CBP) in MCF-7 cells and showed a complex 
network of ESR1-coregulator binding, with preferential binding sites for each 
coregulator. They identified a subset of ESR1 regulated genes that are co-
occupied by SRC3, but not SRC1 or SRC2, that predicts poor or good survival 
outcome depending on whether the genes were up or down-regulated [45]. 
Lupien et al. also identified another subset of E2-induced, FOXA1-
independent, ESR1 and CARM1 co-occupied sites that result primarily in 
repression of expression [46]. These studies demonstrate that selective 
interaction with different coregulators at specific subsets of target genes may 
be an important mechanism through which the specificity of NR action is 
modulated. 
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Due to their central role in regulating NR-mediated transcription, many 
coregulators are known to be involved in human diseases [47, 48]. In the 
breast, changes in expression levels of coregulators have been implicated in 
the tissue-specific response to tamoxifen [49]. The majority of coregulators 
show differential expression between breast cancer and normal breast tissues, 
as well as between ER+ and ER- breast cancers. This is accompanied by 
changes in expression correlations between subsets of coregulators and 
specific NRs, whose expression showed prognostic value in breast cancer [2].  
Coregulators are therefore critical determinants of NR-mediated 
transcriptional regulation in the breast and disruptions in the normal NR-
coregulator interaction network are potentially an important aspect of breast 
cancer biology. 
1.2.3.4 Combinatorial	control	of	gene	expression	by	NRs	in	
breast	cancer	
Recent large-scale integrative analyses of transcription factor genomic 
localization data from the ENCODE project highlighted the extraordinary 
complexity of transcriptional regulation and the extensive functional crosstalk 
between transcription factors [50-52].  This observation also holds for NRs in 
breast cancer. Kittler et al. [26] built a regulatory map from cistromic data of 
24 NRs and 14 breast-cancer-associated coregulators in MCF-7 breast cancer 
cells.  They showed that the resulting network is highly inter-connected and 
there are many regions in the genome coordinately occupied by multiple NRs 
(HOT regions). These HOT regions are enriched with features associated with 
active regulatory elements, including active chromatin marks and increased 
chromatin accessibility. These regions are also enriched with breast cancer-
relevant genes and are hypothesized to be important active regulatory regions 
in breast cancer cells.  
On a smaller scale, other studies have also revealed convergence in genomic 
binding between ESR1 and various other NRs in breast cancer cells by 
individually comparing the overlap of their cistromes. ESR1 is known to drive 
growth and proliferation in the majority of breast tumors. Mounting evidence 
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indicates that ESR1 does not act on its own and that other transcription 
factors, including other NRs, are important determinants of ESR1 action in 
breast cancer cells. For example, retinoic acid has been known to inhibit 
proliferation in breast cancer cells and antagonize the growth stimulation 
effect of estrogen [53]. Studies of ESR1 and RARA cistromes showed that ESR1 
and RARA share very similar binding profiles, although whether the 
interaction is antagonistic or co-operative is still controversial [15, 16]. 
Likewise, cistromic profiling of ESR1 and GR in mouse mammary epithelial cell 
lines revealed significant co-operation of these two NRs, through an assisted-
loading mechanism, in which binding of one NR facilitates chromatin 
remodeling thereby enabling access to DNA for the other NR [54]. Another 
study profiling ESR1 and GR genomic localization in MCF-7 cells revealed that, 
although GR co-occupies several ESR1 binding sites in cells treated with both 
E2 and dexamethasone, GR recruitment to these sites is associated with 
displacement of ESR1, leading to repression of ESR1-mediated transcriptional 
activation of target genes [55]. Therefore, although ESR1 co-occupies many 
target genes with RARA as well as GR, the nature of their interaction is 
reported to be both co-operative and antagonistic, perhaps reflecting different 
time, target and cell-specific modes of co-operation between these NRs. 
In addition to RARA and GR, ESR1 was reported to share genomic binding sites 
with PGR and LRH-1. In the presence of both estrogen and progesterone, PGR 
was shown to be recruited to the ESR1 complex and to redirect ESR1 binding 
events, resulting in a gene expression profile associated with better clinical 
outcome [56]. However, in the presence of estrogen alone, unliganded PGRB 
activated a subset of ER-target genes by acting as a molecular scaffold for the 
formation of a transcriptional complex with ESR1 and PELP1, resulting in a 
more aggressive proliferative response to estrogen [57]. It is likely that the 
action of ESR1 and PGR and their crosstalk are highly context-dependent. 
Furthermore, the majority of data are derived from cell line models and the 
implications for breast cancer in vivo are yet to be established. LRH-1 was 
reported to share a substantial portion (~ 35%) of its binding sites with that of 
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ESR1 and synergistically regulate a subset of estrogen-responsive genes in 
MCF-7 cells [58]. 
 These studies highlight the complexity of cross talk, particularly between ER 
and other NRs, in gene regulatory networks and the utility of integrated, 
genome-wide analyses in unraveling this complexity. Whether the studies so 
far reflect transcriptional plasticity that is particularly a feature of ER, or 
whether data will emerge supporting this as a mechanism common to other 
NRs is still to be determined, nevertheless these insights into the functional 
interactions between NRs in breast cancer have the potential to lead to novel 
therapeutic strategies. 
1.2.3.5 Reprogramming	of	NR	binding	and	disease	
progression	
It is becoming increasingly evident that transcriptional regulation is a highly 
dynamic process with transcription factors displaying temporal, cell type 
specific, and disease-associated shifts in their genomic binding profiles. The 
transcriptional targets of PGR in T-47D breast cancer cells and AB-32 
immortalized normal breast cells display remarkably low overlap [31], 
reflecting cancer-associated and cell type specific changes in PGR 
transcriptional regulation. Recent studies have highlighted the effect of 
changes in NR transcriptional programs and their association with breast 
cancer disease progression and clinical outcomes. Ross-Innes and colleagues 
performed ChIP-seq of ESR1 in clinical samples with different prognoses to 
directly explore the correlation between ESR1 binding and cancer progression 
[59]. They observed high signal intensity at ESR1 binding sites in metastatic 
samples while lower ESR1 signal intensity was observed in samples with good 
prognosis. Further, they showed that ESR1 binding is a highly dynamic process, 
with distinct ESR1 binding regions observed in samples with different 
outcomes. This dynamic change in ESR1 action was shown to be influenced by 
the action of other NRs, such as PGR [56], as well as the signaling context 
leading to ESR1 activation. For example, ESR1 displayed distinct genomic 
binding profiles depending on whether ESR1 was activated by estrogen or 
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through the epidermal growth factor (EGF) pathway [60]. The EGF-induced 
ESR1 cistrome specifically regulates genes that are overexpressed in ERBB2-
positive breast cancers and associated with poor clinical outcomes. The EGF 
pathway can therefore be an alternative activator for ESR1 signaling in breast 
cancer and provide a molecular explanation for the endocrine therapy 
resistance often seen in ER+ERBB2+ breast cancers. Analysis of ESR1 and 
ESRRA cistromes in tamoxifen-sensitive versus resistant breast cancer cells 
showed that despite regulating distinct transcriptional networks, their 
cistromes are reprogramed in tamoxifen-resistant breast cancer cells towards 
regulation of genes functionally relevant to resistance [61]. These studies show 
that NR binding profiles can be shifted in a context-dependent manner, 
resulting in altered transcriptional networks that affect disease progression 
and outcome. 
1.2.4 NR	expression	in	the	normal	breast	and	breast	
cancer	
Recent studies have begun to provide a global view of the functional roles and 
expression of the NR superfamily in primary normal breast [62] and breast 
cancer tissues [62, 63]. Muscat et al. found that the majority of NRs (41 of 48) 
are expressed in the breast. Many NRs showed differential expression in breast 
cancer compared to the normal breast indicative of potential involvement in 
breast cancer biology [62]. In particular, breast cancer is associated with 
overexpression of the NR4A subgroup as well as EAR2, and pan-repression of 
the majority of NRs relative to the normal breast. High expression of the NR4A 
subgroup in breast cancer was also observed by Lin et al. [63]. In addition to 
ESR1, PGR and AR, expression levels of other NRs were shown to be associated 
with histological grade (THRB, NUR77, RORC, COUP-TF2, LRH-1), to classify 
breast tissues (THRA, ESR1, NURR77, EAR2, RARG) and to predict metastasis-
free survival in tamoxifen-treated patients (THRB, COUP-TF2, MR, PPARG). 
Thirty three of the 48 human NRs were also observed to be expressed in 
stromal cells, and four of these (RORA, THRB, VDR and PPARG) were shown 
to have differential expression profiles in cancer-associated fibroblasts 
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compared to normal breast adipose fibroblasts [64]. Together, these studies 
highlight that multiple members of the NR family are likely to play important 
roles in breast cancer growth and development and to have discriminant and 
prognostic value in breast cancer. 
1.2.5 NR	expression	in	breast	cancer	subtypes	
Breast cancer is a heterogeneous disease encompassing multiple subtypes with 
distinct molecular profiles, therapeutic response and clinical outcomes [65]. 
Several NRs have been shown to either act co-operatively with ESR1 and/or 
have differential actions in ER+ versus ER- breast cancers. For instance, AR has 
different roles in ER+ versus ER- breast cancers. AR has been investigated 
extensively as a therapeutic target in ER- breast cancer. It was reported that in 
ER-/HER2+ breast tumours, AR stimulates oncogenic Wnt and HER2 signaling 
pathways thereby stimulating cancer cell growth [66]. However, the role of 
androgen signaling in ER+ breast cancer is less clear. Expression of AR is 
associated with good prognosis in ER+ breast cancer [67, 68], with anti-
estrogenic and anti-proliferative effects in ER+ breast cancer being reported 
[69, 70]. The anti-proliferative effect of AR is partly attributed to its inhibitory 
effect on ESR1 signaling in ER+ breast cancer cells [70, 71].  However, AR has 
also been reported to contribute to resistance to hormonal therapies in ER+ 
breast cancer cells over-expressing AR, with increase in AR to ESR1 ratio 
associated with worse outcome for tamoxifen-treated patients [72] and 
increased agonist activity of Tam in AR over-expressing cells. In this context, 
AR reportedly increased tamoxifen agonist activity via activation of EGFR in 
ESR1+ breast cancer, and this was blocked by dual treatment with the anti-
androgen Enzalutamide and EGFR inhibitor gefitinib [73]. In addition, AR 
appears to promote proliferation of molecular apocrine breast cancer – a 
subset of TNBC expressing AR, through activation of genes that are normally 
regulated by ESR1 in ER+ cancer. [74].  
Similarly, the expression of GR has been shown to be differentially associated 
with survival in ER+ versus ER- breast cancers. In ER+ breast cancers, high GR 
expression is associated with better survival [14, 75] while in ER- breast cancers 
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high GR expression is correlated with poorer breast cancer specific survival [14, 
75]. 
Recent studies profiling the expression of NRs in ER+ and ER- cancers have 
also identified other NRs whose expression levels differ significantly between 
ER+ and ER- breast cancers (Table 1). In particular, AR, PGR, PNR, RARA and 
THRB were reported to be significantly differentially expressed between ER+ 
and ER- breast cancers [62] and significantly associated with ESR1 expression 
[63]. The expression of DAX-1, LRH-1, PPARA, RORB, RORC and TLX were 
also reported to be significantly associated with ESR1 expression in multiple 
microarray datasets [63]. 
1.2.6 Emerging	functional	roles	of	NR	in	breast	cancer	
It is now clear that a number of NRs are implicated in breast cancer growth 
and development [76]. It is emerging that, in addition to influencing cell 
growth and proliferation, NRs also play important roles in other aspects of 
breast cancer biology including metastasis, metabolic control and circadian 
regulation.  
Table 2 summarizes reported involvement of NRs in selected aspects of breast 
cancer biology. For further information, please see the review by Conzen [76] 
for discussion of the involvement of NRs in breast cancer proliferation and 
apoptosis and Appendix A for a detailed review of NR involvement in breast 
cancer metastasis, metabolic regulation and circadian regulation. 
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Table 2: NR effects on cancer-related biological processes based on studies in breast primary 
tissue or cell lines. The influence of NR on breast cancer proliferation, apoptosis, migration, 
metabolism as well as involvement in circadian regulation/response is tabulated. Coloured 
boxes indicate reported involvement. 
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NR3C4	 AR	 		 		 		 		 	 		 		 		 		 	 		
NR1B1	 RARa	 		 		 		 		 	 		 		 		 		 	 		
NR1B2	 RARb	 		 		 		 		 	 		 		 		 		 	 		
NR1B3	 RARg	 		 		 		 		 	 		 		 		 		 	 		
NR1F1	 RORa	 		 		 		 		 	 		 		 		 		 	 		
NR1F2	 RORb	 		 		 		 		 	 		 		 		 		 	 		
NR1F3	 RORg	 		 		 		 		 	 		 		 		 		 	 		
NR1I1	 VDR	 		 		 		 		 	 		 		 		 		 	 		
NR1C1	 PPARa	 		 		 		 		 	 		 		 		 		 	 		
NR1C2	 PPARd	 		 		 		 		 	 		 		 		 		 	 		
NR1C3	 PPARg	 		 		 		 		 	 		 		 		 		 	 		
NR1D1	 REV-ERBa	 		 		 		 		 	 		 		 		 		 	 		
NR1D2	 REV-ERBb	 		 		 		 		 	 		 		 		 		 	 		
NR2B1	 RXRa	 		 		 		 		 	 		 		 		 		 	 		
NR2B2	 RXRb	 		 		 		 		 	 		 		 		 		 	 		
NR2B3	 RXRg	 		 		 		 		 	 		 		 		 		 	 		
NR2F1	 COUP-TF1	 		 		 		 		 	 		 		 		 		 	 		
NR2F2	 COUP-TF2	 		 		 		 		 	 		 		 		 		 	 		
NR3B1	 ERRa	 		 		 		 		 	 		 		 		 		 	 		
NR3B3	 ERRg	 		 		 		 		 	 		 		 		 		 	 		
NR4A1	 NUR77	 		 		 		 		 	 		 		 		 		 	 		
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1.2.7 Summary	
Advances in genomic technologies have enabled more integrated insights into 
the roles of NRs in breast cancer biology - their expression, genomic 
distribution, mechanisms of action, as well as the complexity of their 
functional interactions. Expression profiling studies have shown that many 
NRs, in addition to ESR1, PGR and AR, are expressed and potentially functional 
in breast cancer, yet their functional roles in both the normal breast and breast 
cancer are largely unexplored. Cistromic profiling studies highlight the 
complexity of NR transcriptional regulation, how multiple NRs often work 
together as well as with other co-regulators and the chromatin landscape to 
fine tune the cell-specific expression of target genes, and how changes in the 
gene regulatory programs of NR are associated with the tumour state. Finally, 
it is emerging that in addition to regulating proliferation and apoptosis, NRs 
are critical regulators of a diverse range of other cancer-associated biological 
processes including the circadian clock, metabolic reprogramming and 
migration and metastasis. 
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1.3 Data	and	analytical	methods	
This section describes the major data types and analytical methods utilized in 
this thesis. First, gene expression profiling technologies and data are described 
in Section 1.3.1, followed by an overview of approaches to breast cancer 
prognostication in Section 1.3.2. Finally, Section 1.3.3 introduces gene co-
expression and differential co-expression analyses and their application to the 
study of breast cancer gene expression data.  
1.3.1 Gene	expression	regulation	and	profiling	
technologies		
1.3.1.1 Gene	expression	regulation	
To understand the significance of findings based on gene expression data, it is 
mandatory to have insight into the central dogma of biology [77], namely the 
process by which information encoded in genes is converted into proteins, 
which are the functional molecular machinery of all living cells. Briefly, in this 
process, DNA is transcribed to pre-mRNA by means of DNA Polymerase, 
which is then usually modified via RNA splicing into messenger RNA (mRNA) 
and then translated via ribosomes into proteins. The expression of a particular 
gene is defined as the level of mRNA produced by the transcription of this 
gene and the complement of all expressed genes is referred to as the 
transcriptome. 
Gene expression is a process regulated by elaborate control mechanisms that 
have been shaped through evolution to dynamically and often specifically 
regulate the temporal and spatial expression level of each gene. At the level of 
gene transcription, this is controlled through the concerted co-operation of 
cis-acting transcriptional regulatory elements (such as promoters, enhancers, 
insulators, silencers) with trans-acting regulators such as transcription factors, 
co-activators and co-repressors[78]. Genome-wide expression profiling studies 
have also identified that concerted transcriptional responses regulate genes 
that are required to be expressed simultaneously – such as genes belonging to 
the same biological pathways - to produce a coordinated biological response. 
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Given the centrality of transcription to the maintenance of biological 
homoeostasis, it is not unexpected that misregulation of gene regulatory 
programs has the potential to lead to diseases including cancer [79, 80]. The 
main hallmarks of cancer are associated with the functions of pathways that 
regulate cell proliferation, differentiation, apoptosis, angiogenesis and 
metastasis [81], therefore misregulation in the gene regulatory program 
underlying these pathways lies at the heart of cancer initiation and 
progression. In breast cancer, dysregulation of the expression and/or function 
of several transcription factors and nuclear receptors are observed [82]. Also, 
as described in Section 1.2, the expression of many nuclear receptors is altered 
in breast cancer compared to the normal breast and also different in breast 
cancer subtypes. Surveying and characterizing the co-expression and 
differential co-expression networks of nuclear receptors hold the potential for 
identification of novel biomarkers and therapeutic targets as well as bringing 
new insights into the biological pathways regulated by nuclear receptors in 
breast cancer. 
1.3.1.2 Advances	in	gene	expression	profiling	and	
availability	of	breast	cancer	expression	data	
From the 1990s, new high throughput technologies have allowed genome-wide 
expression profiling and enabled diseases to be studied at a molecular level. 
Unlike traditional molecular and genetic profiling methods, which focus on a 
few genes at a time, technologies such as microarrays and RNA-sequencing 
allow evaluation of the expression of thousands of genes simultaneously. The 
technological advance has enabled large-scale expression profiling of breast 
cancer samples either by microarrays (METABRIC study [83]) or RNA-
Sequencing (The Cancer Genome Atlas (TCGA), 
http://cancergenome.nih.gov/). As a result, we have relatively complete 
molecular portraits of thousands of breast cancer samples at the gene 
expression level. The large numbers of samples have enabled identification of 
breast cancer molecular subtypes and hold promise for the identification of 
gene signatures with prognostic values in different subtypes of breast cancer. 
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Furthermore, the ability to simultaneously evaluate thousands of genes across 
a large group of samples allows inference of gene co-expression networks. 
Such networks have the potential to provide the cellular context that is lacking 
when genes are studied separately and to allow identification of specific sub-
networks that are dysfunctional in the diseased state or differentially regulated 
in specific biological contexts. Below, we give a brief overview of the 
microarray-based and RNA-sequencing technologies and describe the data 
obtained from these technologies, which form the basis for many of the 
analyses and findings discussed in this thesis.  
 
 
Figure 2: A typical microarray experiment. Re-used from Schulze et al. [84], with permission 
from Nature Publishing Group. 
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A typical microarray assay is composed of several steps as shown in Figure 2. 
First, mRNA is isolated from the samples of interest and converted into cDNA 
via reverse transcription.  Then, if cDNA microarrays are used, cDNA samples 
are labelled with different fluorescent dyes followed by competitive 
hybridization onto the microarray. The microarray is then scanned by high-
resolution confocal fluorescent scanning with two different wavelengths 
corresponding to the dyes used to provide relative signal intensities and ratios 
of mRNA abundance for the two samples of interest. For high-density 
oligonucleotide microarrays, usually biotin labelling is incorporated into the 
synthesized cDNA molecules and target hybridization is detected by staining 
with fluorescent dye coupled to streptavidin. Each sample is hybridized onto a 
separate array and the signal intensities of probes on different arrays are used 
to calculate relative mRNA abundance. 
Microarray technologies have several limitations. These include high 
background noise due to cross hybridization, reliance on existing knowledge 
of the sequence of the genome and restricted dynamic range of detection due 
to background and signal saturation. 
1.3.1.3 RNA-sequencing	technology	
RNA-sequencing is a relatively new technology to quantify the transcriptome 
that has clear advantage over existing approaches such as microarrays. Firstly, 
unlike microarrays, RNA-Seq is not limited to knowledge of existing genomic 
sequences therefore enabling discovery of novel transcripts and also applicable 
to non-model organisms that do not yet have assembled reference genomes. 
Secondly, RNA-Seq can potentially reveal information about transcript 
splicing, sequence variations and structural re-arrangements that is not 
possible with microarrays.  Thirdly, while microarrays suffer from relatively 
high background signal due to issues with hybridization (cross-hybridization), 
RNA-Seq has very low background signals because sequencing reads can be 
mapped unambiguously to the reference genome to eliminate experimental 
noise. Fourthly, RNA-seq offers large dynamic ranges because RNA-Seq 
quantifies discrete sequence reads hence there is no upper limit for 
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quantification. Finally, with RNA-seq, the sequencing coverage depth can be 
increased as required to detect rare transcripts or weakly expressed genes. 
 
Figure 3: A typical RNA-seq experiment. Re-used from Wang et al. [85], with permission from 
Nature Publishing Group. 
In a typical RNA-Seq experiment (Figure 3), a population of RNA extracted 
from the sample of interest is converted to a cDNA library with adapters 
attached to both ends. Each cDNA fragment – with or without amplification – 
is sequenced from either one end (single-ended sequencing) or both ends 
(paired-end sequencing). Sequencing read lengths typically range from 50 – 
150 base pairs, however 150 read length is not the upper limit. The resulting 
sequenced reads are then aligned to the reference genome or transcriptome 
and the count of reads aligned to a genomic feature (genes, transcripts, exons 
etc.) is used to generate an expression profile representing the abundance in 
expression of that genomic feature. 
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1.3.2 Breast	cancer	prognostication	
The goal of prognostication is to predict at the time of diagnosis the survival of 
a patient or risk of metastasis. Prognostic factors are usually indicators of the 
tumour’s growth, invasion and metastatic potential. As such, prognostic 
factors are important tools used to forecast patient outcome and can be used 
to help refine patient treatment. 
1.3.2.1 Approaches	based	on	clinicopathological	features	
Traditionally, clinicopathological parameters have predominantly been used as 
prognostic factors in breast cancer. The most commonly used prognostic 
parameters include nodal status, tumour size, histological grade, menopause 
status and patient age. Two commonly used breast cancer prognostic tools, the 
Nottingham Prognostic Index (NPI) [86] and Adjuvant! Online [87] utilize a 
combination of clinicopathological variables in their prognostic models. The 
NPI is computed based on tumour size, nodal status and histological grade 
while the Adjuvant! Online model for survival estimation takes into account 
multiple variables including age, menopausal status, ER status, tumour size, 
tumour grade, nodal status as well as comorbidities.  
In addition to the clinical parameters above, immunohistochemical detection 
of ER and PGR, overexpression or amplification status of the HER2 gene, as 
well as proliferation rate of tumours have also been used as molecular markers 
[88]. It is now well established that only tumours expressing ER are likely to 
respond to anti-estrogen therapy and these are associated with good 10-year 
survival outcome. It has been reported that tumours expressing both ER and 
PGR have a lower risk of mortality compared to those expressing only one, or 
lacking both receptors [89]. Overexpression or amplification of HER2 is 
associated with higher risk of relapse and poorer survival and is an indicator of 
likely response to anti-HER2 therapy [90]. Finally, the proliferation rate of 
tumours is also regarded as a good predictor of outcome, especially in ER+ 
tumours, and the expression of Ki67 by immunohistochemistry is often used to 
assess proliferation in these tumours [90, 91].  
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However, prognostication models using these traditional clinicopathological 
parameters only have limited ability to predict patient outcome. Markedly 
different outcomes are often observed for patients with the same 
clinicopathological parameters. Despite efforts to find reliable 
clinicopathological prognostic markers, it is still a challenge for clinicians to 
distinguish with confidence patients who need adjuvant systemic therapy from 
those that could be spared such treatment. As a result, many women are over-
treated with chemotherapy and are subjected to the adverse effects of 
chemotherapy unnecessarily. 
1.3.2.2 Breast	cancer	intrinsic	subtypes	
The application of large scale molecular analyses to breast cancers have now 
revealed that the categories of breast cancer identified by classical 
clinicopathological markers may be insufficiently detailed. Breast cancer is 
now regarded as a heter0genous disease consisting of different subtypes with 
different morphologies, molecular profiles and clinical outcomes. Studies by 
Sorlie et al. [36, 92] utilizing microarray expression data identified 5 intrinsic 
molecular subtypes of breast cancers with distinct clinical outcomes: Luminal 
A, Luminal B, HER2 over-expression, basal-like and normal-like breast 
tumours. Luminal A and Luminal B tumours both express ER and are 
distinguished largely based on proliferation. Basal-like tumours in which ER, 
PR and HER2 are not expressed, are the most aggressive and have the worst 
prognosis. Following the identification of the 5 intrinsic subtypes, Parker et al. 
have developed the PAM50 assay that can be used to classify tumours based on 
the intrinsic subtypes as well as predict the risk of relapse for node negative 
patients without adjuvant therapy [93]. It should be noted that although the 5 
intrinsic subtypes are regarded as the standard for intrinsic breast cancer 
categorization, other classifications exist. For examples, Fan et al. used a 70-
gene signature to classify breast tumours into 4 groups [94] while Sotiriou et al 
identified 6 groups using a 706 gene signature [95]. More recently, studies 
utilizing both expression and copy number variation data have identified 10 
subtypes of breast cancer [83]. Classification of breast cancers based on the 10 
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IntClust subtypes were shown to be reproducible in a large meta-analysis and 
the IntClust subtypes were shown to be significantly associated with relapse-
free survival as well as associated with distinct patterns of chemosensitivity 
[96]. It appears that classification of breast cancers based on molecular profiles 
is still an evolving model that requires further improvements before reaching 
clinical practice. Nevertheless, molecular profiling has changed the way we 
understand and classify breast cancer and highlights the need for alternative 
prognostic and therapeutic tools tailored for different breast cancer subtypes. 
1.3.2.3 Multigene	molecular	prognostic	markers	
In addition to enabling insights into breast cancer molecular subtypes, high 
throughput expression profiling technologies have also enabled discovery of 
gene signatures with prognostic value, with the aim of improving upon 
existing traditional clinicopathological markers. Two conceptual approaches 
have been employed by different groups to discover prognostic gene 
signatures: hypothesis-driven approaches, and un-biased screening of genes 
for association between expression survival. The hypothesis-driven approach 
first identifies gene expression profiles linked to a biological phenotype then 
tests these expression profiles for association with survival. The second 
approach involves screening of genes for association with survival without any 
prior biological assumption.  
Until now, several prognostic gene signatures have been developed including: 
PAM50 and the Intrinsic signature for classifying tumours into the intrinsic 
subtypes [93]; the 70 genes Mammaprint signature for predicting metastasis 
free survival over 5 years period [97], the 76-gene signature for predicting 
distant metastasis in lymph node negative, untreated breast cancer [98-100]; 
the genomic grade index (GGI) for reclassifying histological grade [95]; the 21-
gene Oncotype DX signature for predicting 10 years recurrence for tamoxifen-
treated patient [101]; the 11-gene EndoPredict signature for predicting 10 years 
recurrence for patient treated with adjuvant hormonal therapy [102]; the 
Wound-Response (WR) signature for classifying patient according the wound 
response state (active or quiescent) [103]. The usefulness of molecular gene 
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expression profiling as prognostic tools in a clinical setting has been under 
debate [104, 105]. However, recent preliminary results from large prospective 
clinical trials assessing the usefulness of the Mammaprint (MINDACT) and 
Oncotype DX (TAILORx) gene signatures show that molecular gene 
expression signatures provide additional prognostic information independent 
of clinicopathological parameters. Both gene signatures were shown to be 
useful in identifying patients with low genomic risk of recurrence that could 
be spared chemotherapy that would otherwise be recommended 
chemotherapy on the basis of clinicopathological features. For example, 
patients not treated with chemotherapy on the basis of the Mammaprint test 
although having a high clinical risk had a 5-year rate of survival without 
distant metastasis that was only 1.5 percentage points lower than the rate with 
chemotherapy [97, 106]. 
It has been observed that most breast cancer gene signatures overlap quite 
poorly at the gene level. The lack of overlap at the gene level could be due to 
the high heterogeneity of breast cancers, high degree of correlation among 
genes and the difference in the sample cohorts used for training prognostic 
models. This is demonstrated in a study by Ein-Dor et al. [107] which showed 
that many equally predictive gene signatures could be produced using the 
same dataset using the same analytical method. They reasoned that three main 
properties of the breast cancer expression data explain this: (1) many genes are 
correlated with survival; (2) the differences between these correlations are 
small; (3) the correlations fluctuate strongly when measured over different 
subsets of patients. As a result, the rank order of prognostic genes can be very 
unstable resulting in different sets of genes being selected. Therefore, it is not 
surprising there are very poor overlaps between breast cancer gene signatures 
generated from different studies that used different datasets and analytical 
methods. 
Despite sharing few common genes, most breast cancer prognostic gene 
signatures show quite good concordance in predicting patient outcome [94, 
108, 109] indicating that they capture similar information regarding the 
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underlying biological processes. Indeed, it has been reported that most 
randomly sampled gene lists show significant statistical association with breast 
cancer survival [110]. This is likely due to the pervasive influence of 
proliferation on gene expression such that more than 50% of the breast cancer 
transcriptome is correlated with meta-PCNA, which is a set of genes showing 
strong correlation to the Proliferating Cell Nuclear Antigen (PCNA), a measure 
of proliferation in cells [110]. Therefore, much of the prognostic ability of many 
published breast cancer gene signatures, as well as that of randomly selected 
gene-sets, stems from capturing the effect of proliferation [110-112]. This is 
reflected in the observation that most published breast cancer gene signature 
are good at classifying ER+ breast cancers but perform relatively poorly for ER- 
breast cancer [108] and that proliferation is the strongest parameter predicting 
clinical outcome in ER+ breast cancers [111]. 
 Together these data suggest that there is a need for development of 
prognostic models that are applicable to other breast cancer subgroups outside 
of ER+ breast cancers, as well as signatures that capture other aspects of breast 
cancer biology independent of proliferation. 
1.3.2.4 Gene-based	versus	network-based	approach	for	the	
discovery	of	prognostic	gene	signatures		
There are limitations associated with gene signatures developed using gene-
based methods that do not take into account the context of signalling 
pathways/networks. For example, it has been demonstrated that activation of 
the JNK protein could lead to both apoptosis and proliferation depending on 
the cellular signalling network state at the time of activation [113]. This 
demonstrates that the cellular role of a protein is not static but is dynamic 
depending on the context of the signalling network it operates in. Therefore, it 
might be an over-simplification if only the expression of disparate genes is use 
to predict prognosis without taking into account the signalling network the 
gene is involved in.  
There are several reasons why a network-based approach to identify 
prognostic or therapeutic markers offers advantages over a gene-based 
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approach. Firstly, a complex disease such as cancer is rarely a result of aberrant 
regulation of a single gene but likely reflects perturbations in multiple 
pathways or biological processes. Secondly, recent genomic sequencing studies 
have shown that although cancer somatic mutations are heterogeneous and 
diverse at the gene level, convergence has been observed at the pathway level 
[114, 115]. Thirdly, a property of biological networks is the occurrence of hub 
genes or proteins [116]. These are highly connected nodes whose deletion or 
perturbation is expected to have more widespread effects compared to non-
hub genes. Therefore, studying genes in the network context allows 
identification of these key genes or proteins that potentially have the greatest 
therapeutic impact and/or prognostic power. Finally, a network-based 
approach offers insights into the underlying biological pathways or processes 
that are less evident when genes are studied separately. 
Network-based approaches to prognostic gene signature discovery have been 
successfully applied to various cancer types, including breast cancer. For 
example, Frolich et al. [117] demonstrated that it is possible to derive a 
consensus signature from seemingly different breast cancer prognostic gene 
signatures by mapping them onto protein-protein interaction networks to 
derive common upstream regulators. Their approach yields consensus 
signatures that are more stable and biological meaningful in terms of the 
enriched biological pathways. Wu et al. [118] superimposed gene correlations 
obtained from breast cancer microarray expression data onto a functional 
protein interaction network to discover gene modules associated with the 
disease process. They identified a 31-gene signature that validated across 5 
independent gene expression studies and outperformed 48 other published 
gene signatures.  
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1.3.3 Identifying	biologically	perturbed	NR-regulated	
networks	in	breast	cancer	
1.3.3.1 Goals	of	differential	expression,	co-expression	and	
differential	co-expression	analysis	
There are 3 major approaches for analyzing gene expression data as illustrated 
in Figure 4: 1) Identify genes differentially expressed between experimental 
conditions (differential expression); 2) Identify genes that change in variance 
across experimental conditions (differential variability); and 3) Identify 
patterns and changes in gene-gene correlations (differential co-expression).  
 
Figure 4: Common approaches to studying gene expression data. Re-used from Gaiteri et al. 
[119], with permission from John Wiley and Sons. 
 
In differential expression and differential variability analyses, genes that 
showed different expression levels and differential variance across different 
conditions are identified respectively. The motivation is that the differentially 
expressed genes or genes that show variability may have a role in the 
underlying biological differences between conditions and studying these genes 
will reveal the underlying mechanisms. In the identification of differentially 
expressed or differentially variable genes, each gene expression is considered 
separately and any potential interactions between genes are ignored.  
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In co-expression analysis, the focus is on the correlations in expression 
patterns between genes and the aim is usually to identify groups of genes that 
are expressed in a coordinated fashion. Such coordinated expression patterns 
are considered evidence for potential functional relatedness such as co-
regulation or being part of common biological processes. Studies have shown 
that co-expressed genes tend to be functionally related [120-122]. A gene co-
expression network differs to a gene regulatory network in that a co-
expression network does not attempt to infer the causality relationship 
between genes. The edges or connections in a gene co-expression network 
only represent correlation or dependency relationship without any 
directionality.  
Extending the co-expression concept, differential co-expression (DC) analysis 
focuses on identifying changes in the co-expression patterns between 
conditions, such as disease versus normal [123]. Under the premise that a pair 
of genes that is co-expressed is more likely to be co-regulated, significant 
changes in the co-expression patterns of genes between conditions are 
indications of potential altered regulatory mechanisms, such as perturbation 
or rewiring of regulatory networks as a result of a disease process or 
environmental differences. Differential co-expression may occur in the 
absence of differential expression and therefore not be detectable by standard 
differential expression analysis [124, 125].  
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1.3.3.2 Detection	of	co-expression	and	differential	co-
expression	
This section aims to give an overview of the common methodology used to 
detect co-expression and differential co-expression from expression data 
(Figure 5). 
 
Figure 5: Common steps involved in co-expression and differential co-expression analysis. 
1.3.3.2.1 Co-expression	analysis	
In general, methods for co-expression analysis consist of 2 steps: calculating a 
co-expression measure and selecting a significant threshold (Figure 5A).  
1) Calculating co-expression measures: the input into gene co-
expression analysis is often an n x m matrix of the expression of n genes 
in m samples. First, a co-expression measure is calculated for each gene 
pair from the input expression matrix, resulting in an n x n matrix of 
co-expression values. The most commonly used co-expression measure 
is the Pearson correlation coefficient. But other measures have also 
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been used including: Spearman Rank correlation coefficient, Euclidean 
distance and Mutual Information. 
2) Determining co-expression significance: After calculating a measure 
of co-expression, significant co-expression needs to be identified. 
Several strategies have been used for determining co-expression 
significance, most notably:  
a. Hard thresholding of correlation values: a hard threshold cut-off 
is selected (often arbitrarily or subjectively) and any co-
expression value exceeding this cut-off is deemed significant.  
b. Thresholding based on T-test statistics after application of 
Fisher’s z-transformation:  Fisher’s z-transformation is applied to 
the Pearson correlation coefficients so that the distribution of 
correlation values is approximately normal. This allows 
calculation of a z-score and associated p-value for each 
correlation and a cut-off is set on the p-value [123, 126-128]. 
c. Thresholding based on empirical P-values from permutation tests: 
Permutation-based strategies rely on permutation tests to 
calculate empirical p-values for each correlation and a cut-off is 
set using empirical p-values. In this approach, the expression 
data is randomly permuted and co-expression measure is 
calculated for each randomly permutated gene-pair. This 
random permutation is repeated n times and the empirical p-
value is taken as the number of times out of n permutations 
where a co-expression measure based on the randomly permuted 
data is larger or equal to that observed for the real data [129, 130].  
d. Soft-thresholding: adopted by Weighted Gene Co-expression 
Network Analysis (WGCNA) framework [131]. In this approach, 
all co-expression values are retained but the co-expression value 
is raised to a power ‘beta’ so as to emphasize the high 
correlations at the expense of low correlations. WGCNA relies on 
the scale-free property of biological networks to choose an 
appropriate ‘beta’. Specifically, multiple co-expression networks 
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are constructed for multiple ‘beta’ values and the final ‘beta’ is 
selected based on the scale-free topology of the associated 
network [132, 133].  
The adjacency matrix resulting after application of a co-expression threshold is 
a representation of a co-expression network. This matrix can be either binary 
with 0 and 1 as cell values or continuous if the network is weighted to retain 
information regarding the strength of co-expression. This matrix can be 
transformed into different formats for visualization in network visualization 
software such as Cytoscape (http://www.cytoscape.org/) or Gelphi 
(https://gephi.org/). 
1.3.3.2.2 Identifying	differential	co-expression	
The input into differential co-expression analysis is usually two matrices 
containing pair-wise co-expression measures between genes, one for each 
experimental condition (Figure 5B). Several strategies have been proposed to 
detect differential co-expression. These strategies can be grouped into 3 broad 
groups: 
1) Targeted approach: in this approach, a priori defined gene modules 
are studied to assess whether each show significant difference in co-
expression in one condition compared to another [134, 135]. The main 
drawback of the targeted approach is that it relies on a priori defined 
gene sets and therefore not able to identify novel differentially co-
expressed gene modules.  
2) Semi-targeted approach: this approach identifies significant co-
expressed gene pairs or gene modules in one condition then examines 
whether these are also significantly co-expressed in the other condition 
[136, 137]. If a gene pair or gene module is significantly co-expressed in 
one condition but not the other, then it is considered to be 
differentially co-expressed. The main disadvantage of this approach is 
that it will only detect groups of genes that emerge as significantly co-
expressed modules in at least one condition and therefore may miss 
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more subtle cases, for example those displaying significant changes in 
co-expression across conditions but not strong co-expression in one 
particular condition.  
3) Untargeted approach: More recently, untargeted approaches that 
directly test for differential co-expression across conditions have been 
developed. In this approach, a differential co-expression measure is 
calculated for corresponding co-expression values observed in the two 
different conditions. Then the significance of the differential co-
expression measure is directly assessed. The same approaches used to 
determine co-expression significance described in the previous section 
can be extended to determine differential co-expression significance. 
Examples of untargeted approach to differential co-expression analysis 
include DiffCoEx [133], Differential Coexpression profile (DCp)[138] and 
Differential Correlation in Expression for meta-module recovery 
(DICER) [139].  
1.3.3.2.3 Network	module	detection	and	downstream	analyses	
Clustering of the co-expression or differential co-expression matrix is often 
performed to detect modules of significantly correlated or differentially 
correlated genes respectively. Clustering can be done using standard 
hierarchical clustering. Modules are then extracted from the resulting 
dendrogram using either a fixed cut height or more sophisticated algorithms 
such as dynamicTreeCut [140]. 
The biological significance of co-expressed or differentially co-expressed 
modules can then be inferred by relating genes within each module to external 
annotations such as gene ontologies, pathways, genomic variations or patient 
survival.  
1.3.3.3 Application	of	co-expression	and	differential	co-
expression	to	gain	insights	into	nuclear	receptor	functions	
To date, there have only been a few studies that have systematically 
investigated NR regulatory networks based on expression data. Bookout et al. 
and Yang et al. performed anatomical profiling of the expression patterns of all 
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NRs in mice to infer the potential functions and transcriptional networks of 
NRs [141, 142]. In the context of breast cancer, more recently regulatory 
networks of a number of NRs were constructed from genomic binding profiles 
(ChIP-chip or ChIP-Seq) in breast cancer cell lines [26]. While these are useful 
resources which have brought valuable insights into the complex 
transcriptional network of NRs in breast cancer, technical challenges 
associated with ChIP-chip and ChIP-Seq prevented these methods from being 
routinely applicable to primary breast cancer tissues to truly capture the 
heterogeneity observed in breast cancer. These challenges include: i) the 
requirement for fresh or frozen samples with high quality chromatin, therefore 
difficult to apply to archived formalin-fixed paraffin-embedded clinical 
samples; ii) the requirement for large amounts of starting materials to assay a 
single transcription factor which limits its application to scarce clinical 
samples; iii) the requirement for specific antibodies for each transcription 
factor that are not always available; iv) complicated experimental procedures 
(compared to expression profiling for example), often needing TF-specific 
optimization to generate ChIP-seq sequencing libraries; and v) challenges 
associated with data analysis and interpretation. 
Co-expression and differential co-expression analysis have been successfully 
applied as a complementary approach to differential expression to gain 
insights into the interactions between genes and how these changes in 
response to different conditions. For example, co-expression analyses were 
applied to identify modules of genes with coordinate expression in different 
cancer cell lines [143, 144], to identify prognostic gene signatures [118, 143], to 
infer cancer-associated driver mutations [145]. Differential co-expression has 
also been applied to identify changes in gene interactions in disease versus 
normal tissues [126, 130, 134, 146] and in different cancer types or subtypes [127, 
136, 146]. 
However, to date the only study applying co-expression analysis methods to 
investigate the roles of nuclear receptors in breast cancer was carried out using 
NR expression in the NCI-60 cell lines and a limited number of breast tissue 
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microarrays [144] and no study has been reported in which differential co-
expression has been utilized to examine the change in NR co-expression 
networks in breast cancer compared to the normal breast or between different 
normal breast cell lineages. 
With the advance of high throughput expression profiling technologies, we 
now have genome-wide expression data for a large number of primary breast 
cancer and normal tissues encompassing multiple breast cancer subtypes in 
public data repositories. In addition, we have generated sensitive quantitative 
PCR-based expression profiles of all human NRs and co-regulators in a 
carefully curated cohort of breast cancer and normal breast tissues, as well as 
genome-wide RNA-seq gene expression profiles of normal breast tissues at a 
single cell level. This thesis represents the first systematic investigation into 
NR networks in the normal breast and how they are perturbed in breast cancer 
through co-expression and differential co-expression analysis of primary breast 
tissues. 
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1.4 Hypotheses	and	Aims	
1.4.1 Hypotheses	
1. In addition to ER and PR, other NRs mediate critical aspects of breast 
development and breast cancer biology and are of value as potential 
biomarkers and therapeutic targets for breast cancer. 
2. Applying network-based approaches to the analysis of gene expression 
data will enable identification of key NR and NR-regulated biological 
processes important in normal breast development and/or breast 
cancer biology that are not evident using traditional gene-based 
approaches. 
1.4.2 Aims	of	this	study	
1. Identify NRs and co-regulators that have prognostic and/or therapeutic 
value in breast cancer 
2. Gain insights into the roles of NRs in the normal breast and breast 
cancer through co-expression and differential co-expression network 
analysis using genome-wide expression data from primary breast 
tissues. 
3. Identify NR-regulated pathways or processes that are perturbed in 
breast cancer compared to the normal breast 
4. Identify NR-regulated pathways or processes that are differentially 
regulated in different normal breast cell lineages 
1.5 Thesis	chapters		
As a whole, this thesis explores the expression, co-expression and differential 
co-expression of NRs in the normal breast and breast cancers as a means to 
infer their functional roles and identify NR-related gene signatures with 
prognostic utility. The main focus and contents of each chapter is described 
below.  
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Chapter 1 consists of two sections. The first section provides a detailed review 
of the expression, mechanisms of action and functional roles of NRs in the 
normal breast and breast cancer (published as a review in the Journal of 
Molecular Endocrinology [1], manuscript provided in Appendix A). The second 
section introduces the analytical methodologies of relevance to this thesis. 
Specifically, it provides an overview of the approaches to breast cancer 
prognostication, gene co-expression and differential co-expression analysis. 
Chapter 2 describes in detail the data and methodologies utilized in this 
thesis. 
Chapter 3 examines the changes in expression and correlation between all 
known NRs and 238 coregulators in human breast tissues. The cell- and 
context-specificity of NR action occurs through their interaction with defined 
groups of coregulators, proteins that interact with NRs to either activate or 
repress the transcription of specific genes. The transcriptional outcome 
regulated by NRs is dependent on the complement of coregulators present in 
the target cell. Using highly sensitive quantitative real-time PCR profiles of all 
known NRs and coregulators in human breast specimens (pre- and post-
menopausal normal breast, and ER+ and ER- breast cancers), we identified 
NR-coregulator interactions altered in breast cancer. Based on the change in 
NR-coregulator interactions observed, we developed molecular signatures 
independent of proliferation that outperform existing discriminators, and of 
demonstrated utility in both ER+ and ER- breast cancers. This work has been 
published and is presented in this thesis in the format of a published article. 
Chapter 4 further extends the concepts and analyses described in Chapter 3 in 
both scope and analysis methodologies. In this chapter, more statistically 
rigorous methods were used to identify genes whose expression significantly 
correlated with NRs, and instead of limiting the analysis to interactions 
between NR and coregulators, we surveyed the expression correlations 
between NRs and all other genes in the genome. Although a lot of research 
effort has been put into understanding the roles of specific NRs (such as ER or 
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PGR) in breast cancer, the coordinated behaviours of NRs in the normal breast 
and breast cancer are largely unexplored. This chapter represents the first 
systematic analysis of NR-centered gene co-expression networks as a means of 
inferring NR functional roles as well as identifying NR signatures with 
prognostic value in different breast cancer subtypes. 
Chapter 5 examines the expression, distribution and co-expression networks 
of NRs in different normal breast epithelial cell types at single-cell level. To 
date, very little is known about the expression and distribution of NRs in the 
normal breast epithelium. Here, single cell RNA-seq expression profiles of 126 
normal breast cells were used for un-supervised classification of cells into 
different cell types representative of the normal breast epithelial cell lineages. 
This is then followed by characterization of cell type specific NR expression 
and co-expression networks. 
Chapter 6 investigates the functional roles of the mineralocorticoid receptor 
(MR) and the potential crosstalk between MR and retinoic acid receptor 
signalling in the breast. Taking observations from in silico analysis of NR co-
expression networks in Chapter 4 as the springboard, this chapter 
demonstrates the utility of gene co-expression network analysis for the 
inference of potential NR-NR signalling crosstalk and for generating novel 
hypotheses about their functional roles. Through a combination of in silico 
and in vitro analysis, this chapter provides evidence supporting a role for MR 
in the regulation of breast cancer cell proliferation, and a convergence of MR 
and RAR signalling on the regulation of metabolic response of the normal 
breast and breast cancer cells. 
Finally, Chapter 7 concludes this thesis with a brief discussion of the main 
outcomes and limitations of this work along with future directions for the 
research. 
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2 Materials and Methods 
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2.1 NR	nomenclature	
Throughout this thesis, the official gene symbols associated with the Entrez 
gene identifiers of NRs were used as the NR name. In some cases, this 
corresponds to the common names of NRs while in others, the official gene 
symbol corresponds to the NURSA systematic naming of NRs. The following 
table is provided to help with cross-referencing of NR names. 
Table 3: NR nomenclature 
Entrez	ID	 NURSA	Symbol	 Official	Gene	Symbol	 Common	Name	
367	 NR3C4	 AR	 AR	
9970	 NR1I3	 NR1I3	 CAR	
7025	 NR2F1	 NR2F1	 COUP-TFI	
7026	 NR2F2	 NR2F2	 COUP-TFII	
190	 NR0B1	 NR0B1	 DAX	
9572	 NR1D1	 NR1D1	 REV-ERBa	
9975	 NR1D2	 NR1D2	 REV-ERBb	
2063	 NR2F6	 NR2F6	 EAR2	
2099	 NR3A1	 ESR1	 ERa	
2100	 NR3A2	 ESR2	 ERb	
2101	 NR3B1	 ESRRA	 ERRa	
2103	 NR3B2	 ESRRB	 ERRb	
2104	 NR3B3	 ESRRG	 ERRg	
9971	 NR1H4	 NR1H4	 FXRa	
2649	 NR6A1	 NR6A1	 GCNF	
2908	 NR3C1	 NR3C1	 GR	
3172	 NR2A1	 HNF4A	 HNF4a	
3174	 NR2A2	 HNF4G	 HNF4g	
2494	 NR5A2	 NR5A2	 LRH-1	
10062	 NR1H3	 NR1H3	 LXRa	
7376	 NR1H2	 NR1H2	 LXRb	
4306	 NR3C2	 NR3C2	 MR	
8013	 NR4A3	 NR4A3	 NOR1	
3164	 NR4A1	 NR4A1	 NUR77	
4929	 NR4A2	 NR4A2	 NURR1	
5241	 NR3C3	 PGR	 PR	
10002	 NR2E3	 NR2E3	 PNR	
5465	 NR1C1	 PPARA	 PPARa	
5467	 NR1C2	 PPARD	 PPARd	
5468	 NR1C3	 PPARG	 PPARg	
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8856	 NR1I2	 NR1I2	 PXR	
5914	 NR1B1	 RARA	 RARa	
5915	 NR1B2	 RARB	 RARb	
5916	 NR1B3	 RARG	 RARg	
6095	 NR1F1	 RORA	 RORa	
6096	 NR1F2	 RORB	 RORb	
6097	 NR1F3	 RORC	 RORg	
6256	 NR2B1	 RXRA	 RXRa	
6257	 NR2B2	 RXRB	 RXRb	
6258	 NR2B3	 RXRG	 RXRg	
2516	 NR5A1	 NR5A1	 SF-1	
8431	 NR0B2	 NR0B2	 SHP	
7067	 NR1A1	 THRA	 TRa	
7068	 NR1A2	 THRB	 TRb	
7101	 NR2E1	 NR2E1	 TLX	
7181	 NR2C1	 NR2C1	 TR2	
7182	 NR2C2	 NR2C2	 TR4	
31165	 NR2B4	 USP	 USP	
7421	 NR1I1	 VDR	 VDR	
 
2.2 Datasets	used	in	this	thesis	
2.2.1 Dataset	1:	TLDA	arrays	of	human	primary	breast	
tissues	
Taqman low-density quantitative PCR array data of 66 breast tumours and 50 
normal samples. This dataset was generated in-house as described in Section 
2.3.2 and has been published in [62] and [2]. The characteristics of the cohort 
of samples in this dataset are described in Section 2.3.1. 
2.2.2 Dataset	2:	Microarray	meta-dataset	(Affymetrix	
HG133A)	
To assess the association between gene expression and patient prognosis, we 
compiled a large cohort of breast cancer gene expression microarrays with 
associated clinical and patient survival data from the public data repositories. 
This breast cancer microarray meta-dataset consists of 2227 breast cancer 
cases (of which 2189 were annotated with survival data) from multiple datasets 
profiled on the Affymetrix HG133A platform. Frozen Robust Multiarray 
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Analysis (fRMA) normalization [147] was performed on the Affymetrix 
microarrays to enable combined analysis of the multiple datasets. This 
algorithm utilizes pre-computed estimates of probe-specific effects and 
variances obtained from large publicly available databases. These pre-
computed values are then used in concert with information from new array(s) 
for normalization and summarization, allowing separately processed datasets 
to be compared. fRMA normalized expression values were retrieved from 
inSilicoDb via its Bioconductor package.  
Table 4:  List of microarray breast cancer datasets used in survival analyses 
Study	 GEO	accession	
	Number	
of	samples	 Platform	
Schmidt	et	al.,	2008	[148]	 GSE11121	 200	 Affymetrix	HG133A	
Pawitan	et	al.,	2005	[149]	 GSE1456	 159	 Affymetrix	HG133A	
Symmans	et	al.,	2010	[150]	 GSE17705	 298	 Affymetrix	HG133A	
Wang	et	al.,	2006	[151]	 GSE2034	 286	 Affymetrix	HG133A	
Hatzis	et	al.,	2011	[152]	 GSE25055	 310	 Affymetrix	HG133A	
Hatzis	et	al.,	2011	[152]	 GSE25065	 198	 Affymetrix	HG133A	
Miller	et	al.,	2005	[153]	 GSE3494	 251	 Affymetrix	HG133A	
Loi	et	al.,	2007	[154]	 GSE6532	 327	 Affymetrix	HG133A	
Desmedt	et	al.,	2007	[154]	 GSE7390	 198	 Affymetrix	HG133A	
 
2.2.3 Dataset	3:	Breast	cancer	microarrays	from	the	
METABRIC	study	
This dataset consists of 1992 breast cancer microarrays (of which 1853 were 
annotated with survival data) from the METABRIC study [83] profiled on the 
Illumina HT-12 v3 platform. Illumina HT-12 v3 array data (EGAD00010000210 
and EGAD00010000211) were downloaded from the European Genome 
Phenome Archive and the normalized expression values as published in the 
METABRIC publication were used in all analyses.  
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2.2.4 Dataset	4:	TCGA	Breast	Invasive	Carcinoma	RNA-
Seq	data	
RNA-Seq V2 expression profiles of 988 primary breast tumors and 106 adjacent 
normal breast tissues were 0btained from the Breast Invasive Carcinoma 
dataset of The Cancer Genome Atlas (TCGA). The gene-based “scaled 
estimate” value provided in TCGA’s RNA-SeqV2 data was taken as the 
expression measure for each gene. In all analyses, this value was transformed 
by multiplying by 106 to obtain a measure in term of Transcripts Per Million 
(TPM) followed by a log2 transformation. 
2.2.5 Dataset	5:	Single-cell	RNA-seq	expression	of	
normal	breast	epithelial	cells	
Primary cultured normal breast epithelial cells from two individuals, denoted 
SCA1 and SCA2, were profiled by single-cell RNA-sequencing using the 
methods described in Section 2.4. A total of 126 cells were sequenced at single 
cell level. The originating sample and treatment of these 126 cells are tabulated 
in Table 5. 
Table 5: Treatment and sample information of the 126 cells sequenced by single cell RNA-seq 
 Treatment 
Vehicle Progesterone 
SCA1 sample 22 24 
SCA2 sample 36 44 
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2.3 TLDA	profiling	of	human	breast	tissues		
2.3.1 Human	breast	tissue	cohorts	
The breast tissue cohorts and the TaqMan low-density array (TLDA) 
experimental procedures described in Chapter 3 of this thesis have been 
previously published [62]. Briefly, this cohort consists of 66 individual cases of 
primary invasive ductal carcinoma and 50 normal breast samples with no 
known history of disease. To be included in the cohort, samples were required 
to display a defined level of cellularity, low inflammatory cell content, and low 
fat content. The majority of cancer tissues contained more than 75% tumour, 
and most (68%) of the normal tissues contained 50% normal epithelium. The 
four tissues groups in this cohort were ER+ (n=33, mean age = 58.8 yr, age 
range – 36-90 yr), ER- (n=33, mean age = 53.2, age range = 27-85 yr), 
premenopausal normal (n = 30, mean age = 37.6 yr, age range = 20-46 yr), and 
postmenopausal normal (n=20, mean age = 60.4, age range = 28-78 yr). 
2.3.2 Taqman	low-density	array	expression	profiling	
Chapter 3 employs the same experimental procedures as those described in 
[62] to profile the expression of 238 NR coregulators in the same human breast 
tissue cohorts. Briefly, we custom-designed micro-fluidic cards, TaqMan Low 
Density arrays from ABI (Applied BioSystems), which included 238 
coregulators (as defined by the Nuclear Receptor Signaling Atlas (NURSA: 
www.nursa.org)) and 16 internal controls for normalization (these comprised 
18S-Eukaryotic ribosomal RNA; ACTB - Actin, beta; B2M - Beta-2-
microglobulin; GAPDH - Glyceraldehyde-3-phosphatedehydrogenase; GUSB - 
Glucuronidase, beta; HMBS - Hydroxymethylbilane synthase; HPRT1 - 
Hypoxanthine phosphoribosyltransferase 1; IPO8 - Importin 8; PGK1-
Phosphoglycerate kinase 1; POLR2A - Polymerase (RNA) II (DNA directed) 
polypeptide A, 220kDa; PPIA - Peptidylprolyl isomerase A (cyclophilin A); 
RPLP0 - Ribosomal protein, large, P0; TBP - TATA box binding protein; TFRC - 
Transferrin receptor (p90, CD71); UBC - Ubiquitin C; YWHAZ - tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase activation protein, zeta 
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polypeptide) against which to normalize the expression of the coregulators in 
normal and neoplastic breast tissue. These controls include 18S rRNA, GAPDH 
and RPLP0, validated real-time PCR controls in NURSA-supported nuclear 
receptor profiling studies [155]. The geNorm software embedded within the 
ABI/integromics StatMiner V4.1 software package was used to compute least 
expression variation and select the most appropriate, stable and robust 
combination of internal control genes (MRPL19, PGK1, PPIA, TFRC and UBC) 
against which to normalise the expression data (against the median of the 
most stable controls). 
For each sample, 1.5 µg of total RNA was reverse transcribed with random 
hexamers and SuperScript III reverse transcriptase (Invitrogen) in a total 
volume of 45 µl. A total of 100 µl reaction mixture containing 50 µl cDNA 
template (333 ng) in RNase-free water and an equal volume of TaqMan 
universal master mix (Applied Biosystems, Foster City, CA) was added to each 
TLDA fill reservoir. Four reservoirs per sample were filled. The TLDA includes 
all coregulators and endogenous controls in triplicate. After sealing the plate, 
it was run on an ABI 7900HT Real Time instrument (Applied Biosystems). 
2.3.3 Processing	of	TaqMan	low-density	arrays	
2.3.3.1 Normalization	of	Taqman	low-density	arrays	
TLDAs were analyzed by the relative quantification method of DCt. The 
geNorm algorithm [156] in the Integromics StatMiner software package was 
used to select the most stable house keeping genes to be used as reference for 
normalization. The Ct values of each assayed gene were then normalized 
against the median of the selected house keeping genes to obtain the delta Ct 
(DCt) values for NR coregulators. 
We made use of the DCt values previously obtained for the 48 NR in [62] to 
perform combined analyses of the expression correlation pattern of nuclear 
receptors and coregulators in Chapter 3. 
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2.3.3.2 Filtering	of	outlier	samples	
Ct value measurements above 35 cycles were considered inaccurate. Samples 
for which more than 40% of genes had Ct values above 35 were deemed to be 
outliers and removed from subsequent analyses. Three samples 
(ERneg02TB003, ERneg08RMH456, ERpos07RMH188) were removed from 
both the nuclear receptor and coregulator TLDA data. 
2.4 Single	cell	expression	profiling	of	normal	
breast	cells	
2.4.1 Processing	of	normal	breast	tissue	 
Normal breast tissues were obtained under informed consent from patients 
undergoing reduction mammoplasty procedures. Tissues were minced under 
sterile conditions in serum-free medium, then collagenase digested overnight, 
filtered, washed and organoids were collected as described previously [157] 
Aliquots of primary normal breast organoids were mixed with growth factor 
reduced matrigel matrix and overlaid with MCDB170 medium [158] (Life 
Technologies), then grown at 37°C for 8 days. Organoids formed organized 
structures characterised by a central lumen, lined by cytokeratin 18 positive 
(CK18+) luminal cells, surrounded by p63+ myoepithelial cells. 
Cultures were harvested and dissociated to single cell suspensions, then 
labelled with Sytox Green to differentiate live and dead cells. Single cells were 
captured into 96-well plates using a BD FACS Aria cell sorter, then 
immediately lysed and amplified using the SmartSeq2 protocol [159] and 
sequencing libraries prepared using Nextera XT reagents (Illumina). Samples 
were sequenced on the Illumina HiSeq platform. 
2.4.2 Processing	of	single-cell	sequencing	data	
After quality control of raw sequencing reads using FastQC [160], reads were 
aligned to the Ensembl GRCh37 reference genome using Star aligner [161]. 
Quantitation of the number of reads associated with each gene (read 
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counting) was performed with HTseq [162] using GENCODE v19 gene 
annotations. A mean read count threshold of 1 was used to filter out low 
abundance genes. Low abundance genes do not contain enough information 
for statistical inferences, and the discrete nature of these counts interfere with 
downstream statistical inferences. Figure 6 shows the distribution of the 
average read counts of all genes and the vertical blue dashed line marks the 
low abundance cut-off. Genes with mean read count of at least 1 are retained. 
Applying a mean read count of 1 to filter out low abundance genes also 
resulted in removal of many of the genes that are uniquely expressed in only 1 
cell at low abundance, and which are more likely to represent technical noise. 
The number of uniquely expressed genes dropped from 4,254 genes to 173 
genes after applying the mean read count of 1 cut-off while the number of 
ubiquitously expressed genes (1058 genes) remains the same. Read counts for 
each gene were then normalised by the total number of mapped reads for each 
cell and the normalised count was used in all subsequent analyses. 
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Figure 6: Distribution of the average read counts of genes. Vertical blue dashed line marks the 
cut-off. Genes with mean expression to the right of the cut-off (average read count > 1) are 
retained. 
2.4.3 Cell	type	classification	from	single	cell	RNA-
Sequencing	data	
2.4.3.1 Modelling	technical	noise	and	gene	filtering	
Several factors contribute to the high technical noise observed in single cell 
RNA-seq including: 1) the minute amount of starting mRNA material that is 
obtained from a single cell; 2) different capture efficiencies whereby a large 
fraction of RNA is stochastically lost during the sample preparation steps; and 
3) bias introduced through reverse transcription and amplification. Together, 
these factors contribute to a substantial increase in the level of technical noise 
relative to bulk-level RNA-sequencing [163-166]. 
Kim et al. [163] investigated allelic expression at the single cell level and 
estimated that only 17.8% of stochastic allele-specific gene expression can be 
attributed to biological noise, the rest being due to technical noise. Brennecke 
et al. [166] demonstrated a relationship between technical noise and the 
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amount of starting RNA material through a dilution series of technical 
replicates taken from the same pool of total RNA. They observed that the 
strength of technical noise of a given gene depends mainly on the gene’s 
average expression (read count), with the level of technical noise increasing 
substantially for genes with low read count. They developed a method for 
inferring the dependence between technical noise and gene expression based 
on either the expression of spike-in controls or expression of endogenous 
genes where spike-ins were not available, and for selecting genes with high 
biological variation across the cell population. 
In this thesis, the method proposed by Brennecke et al. was used to test, for 
each gene, the null hypothesis that the biological coefficient of variation (CV2) 
is less than a chosen level (we used CV2 < 0.25) at a false discovery rate (FDR) 
< 10%. All genes are expected to show some expression variation from cell to 
cell, but a high level of variance will indicate that the gene is more likely to be 
important in explaining the heterogeneity within the cell population. The 
genes passing the criteria specified (CV2 < 0.25 and FDR < 10%) were 
considered to be highly variable and the expression of these genes were used 
for cell type classification. 
2.4.3.2 Cell	type	classification	
Principal Component Analysis (PCA) was performed on the expression profiles 
of highly variable genes identified in the previous section (Section 2.4.3.1). The 
top 5% of genes contributing the most to the variability observed in the first 4 
principal components were selected as potential biomarkers. Unsupervised 
hierarchical clustering (HCL) of potential biomarker genes was performed and 
cell types were identified through fixed-height cutting of the hierarchically 
clustered cell. The HCL showed clustering of cells into 3 broad groups that 
displayed differential expression for markers often used to distinguish 
progenitors, luminal and basal epithelial cell types of the normal breast. 
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2.5 Microarray	expression	profiling	of	MR-
inducible	breast	cancer	cells	
MR inducible MCF-7 breast cancer cells (developed in the laboratory of our 
collaborator Peter Fuller, Hudson Institute, Victoria) were treated with 
RPMI+10% charcoal-stripped heat inactivated fetal calf serum FCS +/- Dox (1 
µg/ml) for 48 hours with daily media replacement. Cells were then treated for 
6 hours with aldosterone (10nM), retinoic acid (1µM), 17b-estradiol (10nM) or 
their combinations. The cell experiments were performed in the Fuller 
laboratory. 
Total RNA was isolated using RNAqueous purification columns (Invitrogen). 
Total RNA (500ng) was amplified and biotin labeled using Illumina TotalPrep 
reagents (Invitrogen). The amplified samples (750ng) were hybridized to 
human whole genome HT-12 gene expression bead arrays using the 
recommended Illumina reagents and following the manufacturer’s protocol. 
Raw data was background corrected, variance stabilized and quantile 
normalized using the lumiExpresso function from Bioconductor’s lumi 
package [167] Differential expression analysis was performed using 
Bioconductor’s limma package [168]. Genes with FDR adjusted P-values ≤ 0.05 
and at least 1.5 fold up or down regulated were taken as differentially 
expressed. 
2.6 Prognostication	and	survival	analysis	
2.6.1 Assessing	prognostic	utility	of	a	gene	signature	
To assess the prognostic utility of a gene signature (a set of genes) in a 
particular sample cohort, the following approach was applied. 
1) Each sample in the cohort was assigned a risk score calculated based on 
the weighted linear combination of the expression of the signature 
genes. The “sig.score” function from the genefu R package [169] was 
used to do this. The method applied to calculate the weights for the 
Materials and Methods 
 72 
linear combination of gene expression is described in more detail in the 
sub-section 2.6.1.1 below. 
2) Multivariate Cox Regression was performed (adjusted for ER status, 
node status and grade) to test the association of the calculated risk 
scores with patient survival. The resulting Cox Regression p-value was 
adjusted for multiple testing where applicable, using the Benjamini-
Hochberg multiple testing correction method. A gene signature with 
Benjamini-Hochberg corrected P-value <= 0.01 was considered 
significantly associated with survival or having prognostic value in the 
sample cohort being studied. 
3) The ability of the calculated risk scores to segregate samples into Low 
Risk and High Risk were also assessed through Kaplan Meier analysis. 
In this analysis, samples were assigned into either the Low Risk or High 
Risk group based on the calculated risk score (bottom half of risk scores  
= Low Risk, upper half of risk scores = High Risk). A gene signature 
with a Kaplan Meier Log Rank p-value <= 0.05 was considered to have 
significant ability to separate cohort samples into good or poor 
prognosis groups. 
2.6.1.1 Risk	score	calculation	–	estimating	gene	expression	
weights	
As described above, to assess the prognostic utility of a gene signature, each 
sample was assigned a risk score calculated as the average of the weighted 
expression of genes in the signature. The method used to estimate the 
coefficients that were used to weight the expression of each gene is described 
in the steps below: 
1) Half of the samples were randomly chosen as the training set. 
2) Using the training set, univariate Cox Regression was performed to test 
the association of the expression of each gene with patient survival. 
3) The sign and magnitude of the univariate Cox Regression coefficient for 
each gene obtained from step 2 was then used as the coefficient to 
weight the expression of each gene. 
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2.7 Co-expression	and	differential	co-
expression	analysis	
2.7.1 Co-expression	analysis	
Genes that participate in the same biological pathway or processes are often 
expressed in a similar way across many samples. Therefore, co-expression 
analysis is a powerful tool to identify genes that are potentially functionally 
related. In this thesis, co-expression analysis was applied to two datasets to 
identify NR-centered networks of potentially functionally related genes. The 
first dataset consists of RNA-seq expression profiles of 988 primary breast 
tumors and 106 adjacent normal breast tissues 0btained from the Breast 
Invasive Carcinoma dataset of The Cancer Genome Atlas (TCGA). The second 
dataset consists of single-cell RNA-seq expression profiles of 126 normal breast 
epithelial cells obtained from 2 different individuals. These datasets are 
described in more detail in Section 2.2.4 and Section 2.2.5 respectively. 
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2.7.1.1 Co-expression	measure	
As introduced in Section1.3.3.2, co-expression analysis aims to identify groups 
of genes that are expressed in a coordinated fashion. In order to do this, we 
need to first calculate a measure of co-expression. Here, the Pearson’s product 
moment correlation coefficient was used to measure the linear dependence 
between two genes. Matrices of pair-wise Pearson Correlation Coefficient 
between NRs and other genes (non-NR) were constructed for each sample 
cohort separately. For the TCGA’s RNA-Seq expression dataset, two co-
expression matrices were constructed for normal and cancer samples 
separately. For the single cell RNA-seq data of normal breast epithelial cells, 
two co-expression matrices were also constructed, one for the luminal and 
another for the basal cell type. 
2.7.1.2 Determination	of	co-expression	significance	
A commonly applied method to test for significance of Pearson correlation is 
to perform Fisher’s z’ transformation of Pearson’s r value to obtained the more 
normally distributed Fisher’s z’ values which facilitate the use of t-test based 
methods for significance testing. We investigated the applicability of this 
approach as followed: 
Fisher’s z’ transformation was applied to convert the Pearson’s r to obtain a 
more normally distributed z’ using the fisherz function of the psych package in 
R [170].  
The formula for the transformation is as follows: 𝑧" = 	0.5 ∗ ln 1 + 𝑟 − ln 1 − 𝑟         (1) 
where r is the Pearson’s correlation coefficient. 
Then a standardized score was calculated from the z’ values as followed: 𝑧 = 𝑧" − 𝑢 /𝜎         (2) 
where 𝑢 is the mean and 𝜎 is the standard deviation of the z’ values for each 
sample cohort.  
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The distribution of Pearson’s r values obtained for all NR-nonNR gene pairs in 
the 106 normal and 988 cancer samples of Dataset 4 (described in Section2.2.4) 
was plotted in Figure 7. The distribution of Pearson correlations in cancer 
samples is much narrower and less extreme compared to that observed in 
normal indicating that overall genes are more strongly correlated in normal 
compared to cancer samples. 
 
Figure 7: Distribution of Pearson correlation coefficients in normal and cancer samples. Density 
plot of the distribution of all pair-wise gene correlations observed in Normal versus Cancer 
samples of TCGA's Breast Invasive Carcinoma RNA-Seq data. 
Figure 8 shows the quantile-quantile plots of Pearson’s r, Fisher’s z’ and the 
standardized Fisher’s z’ values (z values) obtained for all NR-nonNR gene pairs 
in the 106 normal and 988 cancer samples of Dataset 4 (Section2.2.4: TCGA 
Breast Invasive Carcinoma RNA-Seq data). It shows that Pearson correlation 
coefficients are not normally distributed, even after Fisher’s z’ transformation, 
especially in Cancer samples. 
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Figure 8: Quantile-quantile plot of pair-wise Pearson's r, z' and standardized z values. A point on 
the plot corresponds to one of the quantiles of the observed data (of in this case Pearson’s r, z’ 
or standardized z values) against the same quantile of a theoretical standard normal 
population. A 45-degree reference line (thin line) is also plotted. The quantile points should fall 
approximately along this reference line if the two sets of data come from a population with the 
same distribution. Hence, strongly non-linear patterns indicate that the observed data is not 
normally distributed 
Given the difference in the distribution of Pearson’s r observed in normal and 
cancer samples, as well as the non-normality of both Pearson’s r and the 
corresponding Fisher’s z’ values, parametric tests such as t-test are not suitable 
to be used for significance testing in this case. This is because the t-test makes 
two important assumptions a) the measurements are independent and b) the 
data are approximately normally distributed. Both of these assumptions are 
not valid because the expression levels of genes are not independent and the 
correlation coefficients are not normally distributed. Therefore, it was decided 
that the use of the non-parametric permutation test is a more suitable method 
of testing for co-expression significance in our dataset. 
The permutation tests were performed in a sample cohort specific manner to 
account for any cohort-specific difference in gene correlations or inter-
dependency. Within each cohort (Normal samples, Cancer samples, Luminal 
cells, Basal cells), genes were randomly permutated (ie. random shuffling of 
gene labels) and the co-expression measure for the randomized data was 
compared to that of the real data. After 10,000 randomizations, empirical p-
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values were calculated as the proportion of randomized tests with greater or 
equal value to that observed with the real data. Gene pairs with empirical p-
values less than or equal to 0.05 were considered significantly co-expressed. 
2.7.2 Differential	co-expression	analysis	
The goal of differential co-expression analysis is to identify significant changes 
in co-expression of genes in different conditions (eg. disease vs. healthy). With 
the purpose of identifying biological processes and pathways potentially 
governed by NRs in the normal breast and breast cancer, as well as identifying 
those that are altered in the disease process, we applied two differential co-
expression analysis approaches to Dataset 4 (Section2.2.4: TCGA Breast 
Invasive Carcinoma RNA-Seq data).  
2.7.2.1 Approach	1	–	Analysis	of	differential	co-expression	
patterns	of	genes	identified	as	significantly	co-expressed	
with	NRs	in	either	normal	breast	or	breast	cancer	
The first approach involves firstly the identification of significant co-
expression within each condition followed by the examination of whether this 
significant co-expression is altered between conditions. For example, the 
CoXpress algorithm considers a gene cluster that has significant average 
correlation in one condition but not the other to be differentially co-expressed 
[136].  
For this approach, we followed the steps outlined in Figure 9 below. 
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Figure 9: First approach to differential co-expression analysis. 
Firstly in Step 1, we performed co-expression analysis as detailed in Section 
2.7.1 to identify genes significantly correlated to NRs in either normal breast of 
breast cancer. The identified genes make up the compendium of genes 
potentially involved in NR-related biological processes in either the normal 
breast or breast cancer. In Step 2, we constructed 2 matrices holding co-
expression measures (as described in Section 2.7.1.1) between NRs and all of 
the “compendium genes”, one constructed from the expression profiles of 
normal samples and the other constructed from the expression profile of 
cancer samples. Then in Step 3, a matrix of differential co-expression was 
calculated from the two co-expression matrices as described in Section 2.7.2.3. 
Finally, the matrix of differential co-expression values was then clustered using 
unsupervised hierarchical clustering and differentially co-expressed modules 
were identified through fixed height cutting of the hierarchical gene trees.  
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2.7.2.2 Approach	2	–	direct	testing	of	differential	co-
expression	significance	
In the second approach, instead of establishing that the co-expression is 
significant in one condition but not the other, all changes in gene correlation 
are directly tested for significance. Variations of this approach have been 
published [126, 129, 130, 133].  We wrote R scripts to perform the steps outlined 
in Figure 10 below to construct the differential co-expression matrix and 
directly test differential co-expression measures for significance. 
 
Figure 10: Second approach to differential co-expression analysis 
Firstly, condition-specific co-expression measures were calculated between 
NRs and all non-NR genes in the genome. Then a matrix of differential co-
expression was constructed as described below in Section 2.7.2.3 Then, all 
differential co-expression measures were directly tested for significance using 
the method described in Section 2.7.2.4. Finally, significantly differentially co-
expressed genes were clustered based on their differential co-expression 
measures to identify significantly differentially co-expressed gene modules. 
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Step	5:	Functional	inference	of	significantly	differentially	co-expressed	gene	modules
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2.7.2.3 Differential	co-expression	measure	
The difference in co-expression of gene u and v between conditions a and b 
was quantified using this formula: 𝐷𝐶4→67,9 = 	𝑍67,9 −	𝑍47,9        (3) 
where 𝑍47,9	and 𝑍67,9	are the standardized correlation values (z values as 
obtained using Equation 2 in Section2.7.1.1) of genes u and v in condition a and 
b respectively.  
2.7.2.4 Determination	of	differential	co-expression	
significance	
The same permutation-based approach used for testing co-expression 
significance was used to directly test differential co-expression measures for 
significance. Within each condition of the two conditions being studied (eg. 
cancer versus normal, luminal versus basal), the matrix of gene expressions is 
randomly permutated and the condition-specific co-expression matrix for the 
randomized data is calculated as described in Section 2.7.1.1. Then a matrix of 
differential co-expression measures is constructed from the two co-expression 
matrices obtained from randomized data as described by Equation 3 
(Section2.7.2.3). The differential co-expression values obtained from the 
randomized data are then compared to those obtained from the real data. 
After 10,000 randomizations, empirical p-values were calculated as the 
proportion of randomized tests with greater or equal value to those observed 
with the real data. Gene pairs with empirical p-values less than or equal to 0.05 
are considered significantly differentially co-expressed. 
2.7.2.5 Identification	of	co-expressed	or	differentially	co-
expressed	gene	modules	
To detect co-expressed or differentially co-expressed gene modules, the matrix 
of co-expression or differential co-expression measures was clustered using 
unsupervised hierarchical clustering and gene modules were identified by 
cutting the hierarchical tree at a fixed height. Modules with at least 50 
members are retained for functional analysis. The similarity/distance measures 
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used for hierarchical clustering depended on the data being clustered. If 
continuous values of co-expression or differential co-expression were being 
clustered, the Pearson correlation was used as the similarity measure to cluster 
columns (NRs) and Euclidean distance was used as the similarity measure to 
cluster rows (non-NR genes). If binary data was being clustered, the Jaccard 
Index was used as the similarity measure for both rows and columns. 
2.8 Ontology	and	gene	set	over-
representation	analysis	
2.8.1 Gene	ontology	(GO)	over-representation	analysis	
Gene ontology enrichment analyses were performed using the Functional 
Classification Tools of the DAVID Bioinformatics Resource 6.8 [171, 172]. 
Biological Process GO terms with at least four genes from the input gene list 
associated with an enrichment P-value < 0.005 and FDR < 10% were retained. 
The GO terms were then sorted by the number of genes associated with each 
term and the top 10 GO terms are presented. 
2.8.2 Gene	set	enrichment	analysis	(GSEA)	
Gene Set Enrichment Analysis (GSEA) [173, 174] is a computational method 
that determines whether an a priori defined set of genes shows statistically 
significant, concordant differences between two biological states. In this 
thesis, PreRankedGSEA was used to identify MSigDB [174] hallmark gene sets 
(v5.1) [175] enriched in gene lists that have been pre-ranked by either 
differential expression fold changes or co-expression measures. Hallmark gene 
sets significant at an FDR q-value < 10% were retained. 
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A B S T R A C T
Although molecular signatures based on transcript expression in breast cancer samples
have provided new insights into breast cancer classification and prognosis, there are
acknowledged limitations in current signatures. To provide rational, pathway-based signa-
tures of disrupted physiology in cancer tissues that may be relevant to prognosis, this
study has directly quantitated changed gene expression, between normal breast and can-
cer tissue, as a basis for signature development. The nuclear receptor (NR) family of tran-
scription factors, and their coregulators, are fundamental regulators of every aspect of
metazoan life, and were rigorously quantified in normal breast tissues and ERa positive
and ERa negative breast cancers. Coregulator expression was highly correlated with that
of selected NR in normal breast, particularly from postmenopausal women. These associ-
ations were markedly decreased in breast cancer, and the expression of the majority of cor-
egulators was down-regulated in cancer tissues compared with normal. While in cancer
the loss of NR-coregulator associations observed in normal breast was common, a small
number of NR (Rev-ERBb, GR, NOR1, LRH-1 and PGR) acquired new associations with core-
gulators in cancer tissues. Elevated expression of these NR in cancers was associated with
poorer outcome in large clinical cohorts, as well as suggesting the activation of ERa
-related, but ERa-independent, pathways in ERa negative cancers. In addition, the com-
bined expression of small numbers of NR and coregulators in breast cancer was identified
as a signature predicting outcome in ERa negative breast cancer patients, not linked to pro-
liferation and with predictive power superior to existing signatures containing many more
genes. These findings highlight the power of predictive signatures derived from the quan-
titative determination of altered gene expression between normal breast and breast can-
cers. Taken together, the findings of this study identify networks of NR-coregulator
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associations active in normal breast but disrupted in breast cancer, and moreover provide
evidence that signatures based on NR networks disrupted in cancer can provide important
prognostic information in breast cancer patients.
ª 2014 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
1. Introduction
Breast cancer is one of themost commonmalignancies world-
wide, affecting millions of women annually in developed and
developing communities. Its prevalence and increasing inci-
dence has galvanized significant advances in the treatment
options available, and continued advances in understanding
of its biological underpinnings have revealed that breast can-
cer is both clinically and biologically heterogeneous. Consid-
erable effort has been expended to identify tumor features
that are prognostic of patient outcome, and/or predictive of
responsiveness to particular treatment regimens. In this re-
gard, a defining feature of breast cancers is the presence of es-
trogen receptor alpha (ERa), where ERa positive and ERa
negative cancers are characterized by major differences in
biology, sensitivity and response to treatment, and patient
outcome.
While ERa, progesterone receptor (PR) and epidermal
growth factor receptor 2 (HER 2) are the histopathological
markers that underpin current clinical management of breast
cancer (Weigel and Dowsett, 2010), the imperative for increas-
ingly refined and personalized predictive tools has driven the
inclusion of molecular profiling in breast cancer prognostica-
tion, and there is now a significant body of evidence that mo-
lecular profiling of transcripts expressed in breast cancer
samples can contribute to classification of breast cancers
and to prognostic signatures (Weigelt et al., 2010a), now being
tested in clinical trials (www.agendia.com/pages/mindact;
Zujewski and Kamin, 2008). Although molecular-based signa-
tures have revealed a range of breast cancer subtypes with
distinct responses to treatment and outcome, and can identify
patients at higher risk of early recurrence, there are acknowl-
edged limitations in the current signatures (Geyer et al., 2012).
These include the striking lack of overlap between signatures
derived from different sample sets; their primary utility in ERa
positive breast cancers and the lack of signatures that are pre-
dictive in both ERa positive and ERa negative cancers; the
contribution of proliferation-related genes to signature per-
formance (Venet et al., 2011); and the complicating influence
of transcripts present in the variable proportion of normal tis-
sue admixed with the cancer component of samples used in
signature discovery (Weigelt et al., 2010b). In addition, signa-
tures based on the combined complement of genes expressed
in cancer tissue at the time of sampling fail to provide insight
into biological pathways or processes involved in
carcinogenesis.
The emerging evidence for increased immune response ac-
tivity as a predictor of improved prognosis has prompted a
focus on signatures that incorporate immune pathways.
These are proving to be useful in ERa negative breast cancers
(Nagalla et al., 2013), but identification of proliferation-
independent signatures for ERa positive breast cancers, or
signatures predictive in both ERa positive and ERa negative
cancers, remains challenging. To overcome some of these lim-
itations, and also to provide rational, pathway-based signa-
tures of disrupted physiology in cancer tissues that may be
relevant to prognosis, this study has directly quantitated
changed gene expression between normal breast, and cancer
tissue, as a basis for signature development. Our emphasis
was two-fold: first, to base the discovery on accurately quan-
titated differences between normal and cancer tissue, and
second, to focus on components of a gene family that serves
as fundamental regulators of metazoan biology and are there-
fore active in every aspect of human physiology. The nuclear
receptor (NR) superfamily of transcription factors are crucial
in reproduction, development, growth, metabolism and ho-
meostasis. In terms of pathophysiology, they play key roles
in the cardiovascular and immune systems, the central ner-
vous system and the musculoskeletal system, and in the gen-
esis and progression of cancer (Conzen, 2008). The NR family
are expressed in the normal breast, and pan-repression of
the majority of NR is associated with carcinogenesis (Muscat
et al., 2013), highlighting the rationale for a role for NR in
development and progression of the disease.
The cell- and context-specificity of NR action occurs
through their interaction with defined groups of coregulators,
proteins that interact with NR to either activate or repress the
transcription of specific genes (Lanz et al., 2007; McKenna and
O’Malley, 2010). The transcriptional outcome regulated by NR
is dependent on the complement of coregulators present in
the target cell. Using human breast specimens (pre-and
post-menopausal normal breast, and ERa positive and ERa
negative breast cancers), we have quantitated all known NR
coregulators in the human breast, and identified NR-
coregulator interactions altered in cancer. We have developed
molecular signatures independent of proliferation that
outperform existing discriminators, and of demonstrated util-
ity in both ERa positive and ERa negative breast cancers.
2. Materials and Methods
2.1. Human breast tissue cohorts and mRNA profiling
by TaqMan low-density array (TLDA)
The breast tissue cohorts profiled in this study and the TLDA
experimental procedures have been previously published
(Muscat et al., 2013). Thepresent study employs the sameexper-
imental procedures to profile the expression of 238 coregulators
(listed inSupplementary Figure 1) in the samehumanbreast tis-
sue cohorts. Briefly, we custom-designed micro-fluidic cards,
TaqMan Low Density arrays from ABI (Applied BioSystems),
which included 238 coregulators (as defined by the Nuclear Re-
ceptor SignalingAtlas (NURSA:www.nursa.org)) and 16 internal
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controls for normalization (these comprised 18S-Eukaryotic ri-
bosomal RNA; ACTB e Actin, beta; 2M e Beta-2-microglobulin;
GAPDH e Glyceraldehyde-3-phosphatedehydrogenase; GUSB e
Glucuronidase, beta; HMBS e Hydroxymethylbilane synthase;
HPRT1 e Hypoxanthine phosphoribosyltransferase 1; IPO8 e
Importin 8; PGK1-Phosphoglycerate kinase 1; POLR2A e Poly-
merase (RNA) II (DNA directed) polypeptide A, 220 kDa; PPIA e
Peptidylprolyl isomerase A (cyclophilin A); RPLP0 e Ribosomal
protein, large, P0; TBP e TATA box binding protein; TFRC e
Transferrin receptor (p90, CD71); UBC e Ubiquitin C; YWHAZ e
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase acti-
vation protein, zeta polypeptide) against which to normalize
the expression of the coregulators in normal and neoplastic
breast tissue. These controls include 18S rRNA, GAPDH and
RPLP0,validatedreal-timePCRcontrols inNURSA-supportednu-
clear receptorprofilingstudies (Holbecketal., 2010).ThegeNorm
software embeddedwithin the ABI/intergromics StatMiner V4.1
software package was used to compute least expression varia-
tionandselect themostappropriate, stableandrobust combina-
tion of internal control genes (MRPL19, PGK1, PPIA, TFRC and
UBC) against which to normalise the expression data (against
the median of themost stable controls).
For each sample, 1.5 mg of total RNA was reverse tran-
scribed with random hexamers and SuperScript III reverse
transcriptase (Invitrogen) in a total volume of 45 ml. A total
of 100 ml reaction mixture containing 50 ml cDNA template
(333 ng) in RNase-free water and an equal volume of TaqMan!
universal master mix (Applied Biosystems, Foster City, CA)
was added to each TLDAfill reservoir. Four reservoirs per sam-
ple were filled. The TLDA includes all coregulators and endog-
enous controls in triplicate. After sealing the plate, it was run
on an ABI 7900HT Real Time instrument (Applied Biosystems).
We made use of the delta Ct (DCt) values previously ob-
tained for the 48 NR in (Muscat et al., 2013) to perform com-
bined analyses of the expression correlation pattern of
nuclear receptors and coregulators in this study.
2.2. Normalization of TaqMan low density arrays
TLDAs were analyzed by the relative quantification method of
DCt. The geNorm (Vandesompele et al., 2002) algorithm in the
Integromics StatMiner software package was used to select
the most stable house keeping genes to be used as reference
for normalization. The Ct values (Supplementary Table 1) of
each assayed genes were then normalized against themedian
of the selected house keeping genes to obtain the DCt values.
Supplementary Figure 1 shows a boxplot of the DCt values of
all coregulators in each of the 4 cohorts.
2.3. Filtering of outlier samples
Ct valuemeasurements above 35 cycles were considered inac-
curate. Samples for which more than 40% of genes had Ct
values above 35 were deemed to be outliers and removed
from subsequent analyses. Three samples (ERneg02TB003,
ERneg08RMH456, ERpos07RMH188) were removed from both
the nuclear receptor and coregulator TLDA data.
2.4. Principal Component Analysis
Principal component analysis of coregulator DCt values was
performed in R with genes as variables to investigate the cor-
egulators that best characterize the different patient cohorts.
Three dimensional scatter plots of samples against the first
3 principal components were generated by the Scatterplot3d
(Ligges and Machler, 2003) package.
2.5. Detection of differentially expressed genes
A moderated t-statistic test based on the limma framework
implemented in the HTqPCR (Dvinge and Bertone, 2009) soft-
warepackagewasused todetect differentially expressedgenes.
Genes having a Benjamini and Hochberg adjusted P-value less
than0.05andat least1.5 foldupordown-regulatedwere termed
differentially expressed (Supplementary Table 2A).
2.6. Validation of combining NR and coregulator data by
investigation of TLDA cross-card batch effect
As NR and coregulator data were derived from distinct TLDA
cards, we determined the validity of a combined analysis of
NR and coregulator data by comparing expression of the
house keeping control genes on both the NR and coregulator
TLDAs. In addition, unsupervised hierarchical clustering of
samples based on raw Ct values of all NR and coregulator
genes was performed to determine if samples clustered in a
batch (array) specific manner. We found expression of the
control genes to be highly consistent between arrays (r2 value
0.98) with no evidence of cross-card batch effects in clustering
of samples (results not shown).
2.7. Correlation-based analysis of nuclear receptors and
coregulators interactions
Pairwise Spearman Rank Correlation coefficients were calcu-
lated for all possible pairs of nuclear receptors and coregula-
tors in a cohort-specific manner. Two genes were considered
highly correlated if the Spearman Rank Correlation coefficient
was !0.7 or "#0.7.
2.8. Pathways and functional analysis
Differentially expressed coregulators were separated into two
groups based on the direction of change in expression (up- or
down-regulated). The Ingenuity Pathways Analysis (IPA) Pack-
age was used to detect over-represented functional annota-
tions and canonical pathways associated with up-regulated
or down-regulated coregulators. Given the very small number
of genes that were up-regulated, we assessed only enriched
functional annotations for this group and retained annota-
tions with enrichment P-value of less than 0.05. For down-
regulated coregulators, over-represented canonical pathways
with Bonferroni adjusted P-values of less than 0.05 were
retained.
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2.9. Breast cancer microarray datasets
In order to establish nuclear receptors and coregulators asso-
ciated with prognosis, we compiled a large cohort of breast
cancer gene expression microarrays with associated clinical
data from previously published work. In total, we compiled
2227 breast cancer cases (of which 2189 were annotated with
survival data) from multiple datasets profiled on the Affyme-
trix Hg133A platform and an additional 1992 breast cancer
cases (of which 1853 were annotated with survival data)
from the METABRIC study (Curtis et al., 2012) profiled on the
Illumina HT-12 v3 platform. Supplementary Table 3 lists the
microarrays datasets included in our analysis.
fRMA (Frozen Robust Multiarray Analysis) normalization
(McCall et al., 2010) was performed on the Affymetrixmicroar-
rays to enable combined analysis of the multiple datasets.
This algorithm utilizes pre-computed estimates of probe-
specific effects and variances obtained from large publicly
available databases. These pre-computed values are then
used in concert with information from new array(s) for
normalization and summarization, allowing separately pro-
cessed datasets to be compared. fRMA normalized expression
values were retrieved from inSilicoDb via its Bioconductor
package. Illumina HT-12 v3 array data (EGAD00010000210
and EGAD00010000211) were downloaded from the European
Genome Phenome Archive and the normalized expression
values as published in the METABRIC publication were used.
To identify genes correlated with ERa expression, breast
cancermicroarrays profiled on Affymetrix Human HG133A ar-
rays (listed in Supplementary Table 3) were divided into ERa
positive and ERa e subsets based on the associated IHC ERa
status. Pairwise Spearman Rank Correlation coefficients
were calculated for each gene profiled on the array with
each of the nuclear receptors: ESR1, REV-ERa Bb, GR, NOR1,
LRH-1 and PR. Spearman Rank Correlation coefficient !0.7 or
"#0.7 were used to filter for genes showing high expression
correlation with these nuclear receptors in either ERa positive
or ERa negative breast cancers.
2.10. Identification of nuclear receptors and coregulators
associated with prognosis
We employed the process outlined in Supplementary Figure 2
to identify nuclear receptors and coregulators, expression of
which associates with patient survival. In this process, sam-
ples from each of the microarray platforms were randomly
divided into two groups, one used for training and the other
for validation. The Training and Validation sets were of com-
parable size, as was the ratio of patients with events to those
without events. A bootstrap approach was employed to iden-
tify genes significantly associated with breast cancer survival
in the Training Set. Specifically, we randomly sampled with
replacement from the Training Sets and performedUnivariate
Cox Regression on the randomly selected subgroup. This pro-
cess (sampling with replacement followed by Univariate Cox
Regression) was repeated 1000 times.We then defined an r-in-
dex for each gene as the ratio of times out of the 1000 analyses
that the gene showed significant association with survival
(Adjusted Cox Regression P-value " 0.05). We used distant
metastasis free survival (DMFS) for samples where that
information is available. For samples without associated
DMFS information, the following survival measures in order
of decreasing preference were used: relapse free survival
(RFS), disease free survival (DFS) and disease specific survival
(DSS).
For the Affymetrix Training samples, we identified 80 cor-
egulators and 23 nuclear receptors with an r-index !0.75; 43
coregulators and 5 nuclear receptors were identified in the
Illumina Training Set. Genes with an r-index of at least 0.75
on both Affymetrix and Illumina platformswere then selected
for Multivariate Cox Regression adjusting for ERa status and
node status. This process identified 3 nuclear receptors and
16 coregulators, expression of which significantly associates
with patient survival independent of ERa status and node sta-
tus on both microarray platforms (Supplementary Table 4).
2.11. Validation of NR and coregulator centered gene
signature
Breast cancer microarray samples from the Validation Sets
were used to assess whether the nuclear receptors and core-
gulators identified can predict patient survival. We assessed
the performance of 3 gene signatures: (i) 19-gene signature
(19 nuclear receptors and coregulators listed in
Supplementary Table 4); (ii) 3-NR signature (PPARd, PGR and
GR); and (iii) 3 NR plus cytoskeletal gene signature (PPARd,
PGR, GR, CFL1 and GSN).
For each signature, samples from the Validation Sets were
assigned risk scores calculated on the signed average of the
signature genes expression (by the “sig.score” function from
the genefu R package (Haibe-Kains et al., 2011)). In this method,
thesample risk score iscalculatedastheaverageof theweighted
expression of the genes in each signature.We used the sign and
magnitude of the Univariate Cox Regression coefficient of
expressionofeachgeneobtainedfromall samplesof theDiscov-
ery Sets as the input coefficients into sig.score. Samples were
then classified into 3 different risk groups based on the assigned
risk scores: low(bottomtertile), intermediate (middle tertile)and
high (top tertile). The performance of each gene signature was
then assessed on Kaplan Meier and a Concordance Index [as
detailed in (Harrell et al., 1996)]. The Concordance Index repre-
sents the probability that, for a pair of randomly chosen compa-
rable patients, the patient with the higher risk prediction will
experience an event before the lower risk patient.
Further, using the Validation samples (Supplementary
Figure 2) of METABRIC dataset, we tested the prognostic power
of the 3NR, 3NRþcytoskeletal genes and the 19 genes in breast
cancer subgroups identified by immunohistochemical marker
staining. Subtype classification as assigned in the METABRIC
dataset was used to categorize samples into subgroups
(Normal-like, Basal, Luminal A, Luminal B, HERa 2). Then the
risk prediction method as described above is used to test the
prognostic power of the signatures in each of the subtypes. In
this analysis, we estimated input coefficients into sig.score in a
subtype specificmanner instead of using all Discovery samples.
Prognostic performance of the NR and coregulator based
signatures identified was assessed in comparison to 48 other
published signatures (Venet et al., 2011) with the same sample
cohorts and outcome association method detailed above.
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3. Results
3.1. Expression of coregulators differs between normal
and breast cancer tissues
Supervised hierarchical cluster analysis demonstrates that a
majority of coregulators were expressed differently in breast
cancers compared with normal breast and that the expression
of many coregulators also differs between ERa positive and
ERa negative cancers (Figure 1A).
This observation is supported by unsupervised Principal
Component Analysis (PCA), with normal and cancer samples
clustering into two relatively well-defined subgroups reflect-
ing the change in coregulator expression in cancer samples
compared with normal tissue (Figure 1B). Expression levels
of coregulators showed greater variation among cancer sam-
ples, evidenced by the greater spread observed on the PCA
plot. In addition, expression profiles of coregulators also differ
between ERa positive and ERa negative breast cancers. This
difference is more evident when PCA was performed on the
cancer samples independently of the normal samples
(Figure 1C).
The changed expression of themajority of coregulators be-
tween normal and cancer cohorts supports the view that the
separation of cohorts based on coregulator expression reflects
Figure 1 e Expression profile of coregulators in different sample cohorts. A) Clustered heatmap of coregulator delta Ct values supervised by cohort
illustrating that a majority of coregulators expression differs between Normal and Cancer and also between ERa positive and ERa negative
cancers. B) is a 3D plot of samples against the first 3 PCA components (unsupervised PCA analysis) illustrating the separation between Cancer and
Normal samples. C) shows a similar plot of a PCA analysis of Cancer samples independently of Normal samples reflecting the difference in
coregulator expression in ERa negative compared to ERa positive breast cancers. Samples are colored based on cohort: light blue (Premenopausal
Normal), dark blue (Postmenopausal Normal), orange (ERa positive cancers) and red (ERa negative cancers).
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multiple coregulator changes, each with an individually small
contribution to the phenotype, rather than a few coregulators
with a large effect on the phenotype. This is reflected in the
small proportion of variance of each gene captured by each
principal component in the PCA analysis (Supplementary
Figure 3A). The first principal component only accounted for
w55% of the total variance in the dataset with each subse-
quent principal components capturing small increases in cu-
mulative variance (Supplementary Figure 3B).
3.2. Pan-repression of coregulators in neoplastic breast
tissues
The majority of coregulators showed decreased expression in
cancer comparedwith normal tissue, with coregulator repres-
sion more pronounced in ERa negative than ERa positive can-
cers (Figures 1A and 2).
Overall, ERa negative breast cancers are associated with
more extensive disruptions in the coregulator transcriptome,
Figure 2 e Differentially expressed coregulators Clustered heatmap of the log2 (Fold change) of significantly differentially expressed coregulators
(adj. P-value £ 0.05 and at least 1.5 fold up or down regulated) illustrating that coregulator repression is more pronounced in ERa negative
compared to ERa positive cancers. Panel A highlights a cluster of coregulators that are down regulated in both ERa positive and ERa negative
breast cancers compared to normal breast. Panel B shows a cluster of coregulators with increased expression in either ERa positive or ERa
negative cancers. Panel C highlights a subset of coregulators whose expression differs between ERa negative and ERa positive tumors.
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with an increased number of genes differentially expressed
plus an increase in the magnitude of the change in expres-
sion (Figure 2, Supplementary Table 2A). Cluster A in
Figure 2 highlights coregulators that are down-regulated in
both ERa positive and ERa negative breast cancers compared
with normal breast. Cluster B in Figure 2 shows coregulators
with increased expression in either ERa positive or ERa nega-
tive cancers; cluster C in Figure 2 highlights coregulator
expression that differs between ERa positive and ERa nega-
tive tumors.
Using a moderated t-test implemented in the HTqPCR
package, we identified differentially expressed coregulators.
On the criterion of at least 1.5 fold up or down-regulation
and Benjamini Hochberg adjusted P-value !0.05, we found
101 (42%) of the 238 coregulators profiled in ERa positive can-
cer samples are differentially expressed compared with
normal, of which 11 genes are up-regulated and 90 down-
regulated. In ERa negative cancers compared with normal,
203 (85%) of the 238 coregulators are differentially expressed,
of which only 3 coregulators are up-regulated and the other
200 down-regulated (Figure 2, Supplementary Table 2).
Although a minority of coregulators are up-regulated in
either ERa positive or ERa negative breast cancers compared
with normal breast, most (10/12, 83%) of these are associated
with Cellular Growth and Proliferation, and predicted to be acti-
vated, according to functional annotation on IPA (Fisher Exact
P-value ¼ 1.03E-05, activation z-score ¼ 2.307, Supplementary
Table 5A). Of the up-regulated coregulators, only CNNE1 is
specifically up-regulated in ERa negative breast cancers while
CNNA2 and TRIP13 are up-regulated in both ERa positive and
ERa negative cancers; the other 9 coregulators are up-
regulated specifically in ERa positive cancers (Figure 2B,
Supplementary Table 2B).
In contrast with the specific association of coregulators
up-regulated in breast cancer with NR pathways involved
in proliferation and disease progression, coregulators that
were down-regulated in either ERa positive or ERa negative
breast cancers compared with normal were associated
with a large range of NR pathways (Supplementary Table
5B). Among the most significantly down-regulated pathways
in breast cancer are Estrogen Receptor Signaling; RAR activa-
tion; Glucocorticoid Receptor Signaling, Aryl Hydrocarbon Recep-
tor Signaling; TR-RXR Activation; and PPAR signaling. As
noted above, the numbers of down-regulated pathways in
cancer compared with normal was greater for ERa negative
than for ERa positive breast cancers (Supplementary
Table 5B).
3.3. Relationships between expression of NR and
coregulators in normal breast and breast cancer
To explore the potential functional parallels between NR and
coregulators, we determined the correlation between NR and
coregulator expression in each of the four breast cohorts
(ERa positive, ERa negative, premenopausal normal, postmen-
opausal normal). This was done by combining the coregulator
expression data of this study with previously published
expression data for NR (Muscat et al., 2013) measured in the
same cohort of samples. We first examined the pairwise
expression correlation between each nuclear receptor and
coregulator. Figure 3A shows the numbers of coregulators
with expression highly correlated (Spearman Rank Correla-
tion #0.7 or !$0.7) with that of each nuclear receptor, with
NR ranked by decreasing NR-coregulator associations in
normal postmenopausal breast samples, where the most
abundant NR-coregulator associations are observed. Tran-
script levels of NR such as RARg, RORg, VDR, RARb, HNF4g,
RXRb, COUP-TF1/2, MR and PPARg are correlated with the
largest number of coregulators in these tissues. Although
fewer associations are evident in normal premenopausal
samples, and in either ERa positive or ERa negative breast can-
cers, cancer-related gains and losses in NR-coregulator associ-
ation are observed (Figure 3A). For example, expression of
RARb correlates strongly with 97 coregulators specifically in
postmenopausal normal but not in any of the other three sam-
ple cohorts. Likewise, expression of RXRa shows strong inter-
correlation with multiple coregulators specifically in ERa pos-
itive cancer samples. In contrast, AR expression correlates
with fewer coregulators and the correlation is only observed
in ERa positive cancer samples. All nuclear receptors display
positive correlation with coregulators except for PPARg,
expression of which strongly and negatively correlates with
more than 30 coregulators only in normal breast tissues
(Supplementary Table 6).
A major cancer-associated shift in the expression correla-
tion patterns of nuclear receptors and coregulators is sup-
ported by Figure 3B, which illustrates the proportion of
strongly correlated NR-coregulator pairs that are observed
only in normal breast, ERa positive or ERa negative samples
as well as those commonly observed in multiple cohorts.
Only 36% of all highly correlated NR-coregulator pairs are
common to both normal and cancer samples (Figure 3B: ERa
positive and Normal; ERa negative and Normal; ERa positive
and ERa negative and Normal) while 31% are observed only
in normal samples (Figure 3B: Normal only) and 32% are ac-
quired correlations observed only in cancer samples
(Figure 3B: ERa positive only; ERa negative only; ERa positive
and ERa negative).
The proportion of highly correlated NR-coregulator pairs in
ERa negative cancer samples not observed in normal samples
is much higher (Figure 3B: ERa negative only, 26%) compared to
that observed inERapositive cancer samples (Figure 3B: ERapos-
itive only, 3%). This suggests that overall, ERa negative breast
cancers are associated with increased dysregulation of the NR-
coregulator interaction network compared with ERa positive
cancers.
Several nuclear receptors displayed pan-ERa status
changes in expression correlation with coregulators. Of
particular interest are the nuclear receptors ERb, LXRa and
PPARg which show either no or negative correlation with
most coregulators in normal breast samples but strong posi-
tive correlation with coregulators in cancer (Figure 3C). Other
nuclear receptors display ERa status-specific shifts in expres-
sion correlation with coregulators (Figure 3D). AR, ESRRg,
RORg, RXRa and RXRg are highly correlated with multiple cor-
egulators in ERa positive cancers and these correlations are
disrupted in ERa negative cancers. In contrast, REV-ERBb, GR,
NOR1, LRH-1 and PGR displayed the opposite pattern and ac-
quire strong correlations with multiple coregulators specif-
ically in ERa negative cancers.
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A B
C D
Figure 3 e Expression correlation patterns of nuclear receptors and coregulators. A) Bar plot of the numbers of coregulators highly correlated
(Spearman Rank Correlation ‡ 0.7) with each nuclear receptor in each of the 4 cohorts, ranked by NR with greatest numbers of associations in
post-menopausal normal samples. B) Pie chart showing the proportions of highly correlated NR-coregulator gene pairs that are observed uniquely
or in multiple cohorts as a fraction of all highly correlated gene pairs observed. C) lists nuclear receptors displaying pan-cancer changes in
correlation pattern with coregulators. D) lists coregulators showing ERa status specific correlation pattern with coregulators. For each panel of C)
and D), cohorts are listed in rows and all coregulators are tiled across columns. Heatmap cells are colored according to the Spearman Rank
Correlation coefficients of each NR-coregulator pair.
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3.4. NR-coregulator interactions acquired in cancer have
stronger prognostic power than NR-coregulator interactions
disrupted between normal and cancer
To determinewhether nuclear receptors that become strongly
correlated with coregulators in ERa negative breast cancer
(Figure 3D panel 1) are associated with DMFS, we made use
of published microarray datasets with associated clinical in-
formation (Validation samples, refer to Supplementary
Figure 2 and Materials and Methods). The prognostic value
of those nuclear receptors with disrupted correlations with
multiple coregulators in ERa negative cancers (Figure 3D
panel 2) was also explored.
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Figure 4 e Prognostic value of NR displaying ERa -status specific expression correlations with coregulators. Kaplan Meier plots of the probability
of survival for samples classified into Low, Intermediate and High risk groups based on the expression profile two different groups of nuclear
receptors: Group 1 (Rev-erbb, GR, NOR1, LRH-1 and PR) and Group 2 (AR, ERRU, RORg, RXRa, RXRg). Samples from the Validation Sets
(Supplementary Figure 2) were used for this analysis (927 samples profiled on Illumina HT12v3 arrays). Log rank Pval represent the log rank P-
value for the Kaplan Meier curves. Cox.Reg.Pval is the univariate Cox Regression P-value for the association of sample risk scores with patient
survival. C-index represents the Concordance Index calculated as detailed in Harrell et al. (1996).
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Breast cancer cases were classified into low, intermediate
and high risk-groups based on risk scores calculated from
the expression of the nuclear receptors in each of Panel 1
and Panel 2 in Figure 3D. Kaplan Meier plots of the probability
of DMFS of the risk-groups for ERa positive and ERa negative
breast cancers show that the expression of nuclear receptors
displaying acquired correlations with multiple coregulators
in ERa negative cancers (Group 1: Rev-ERBb, GR, NOR1, LRH-1
and PGR) significantly segregates patients at low from those
at high risk (Figure 4), and this is confirmed in an independent
dataset (Supplementary Figure 4). The expression of nuclear
receptors showing disrupted interactions (Group 2: AR, ESRRg,
RORg, RXRa and RXRg) has no predictive power for patient
survival in ERa negative cancers while having modest predic-
tive power in ERa positive cancers (Figure 4 and
Supplementary Figure 4).
Given that Group 1 (Rev-ERa Bb, GR, NOR1, LRH-1 and PGR)
included NR linked with ERa expression and/or function, we
asked whether the genes that acquired correlations with
Group 1 NR in ERa negative cancers were ERa-associated,
perhaps reflecting ERa-independent signaling in these can-
cers. Genes most strongly correlated with ERa were identified
in the Affymetrix datasets (921 genes; Pearson correlation co-
efficient !0.7 or "#0.7), and their correlation with the Group 1
NR determined. While GR and LRH-1 were correlated with
few/no ERa-correlated genes in ERa positive cancers, they ac-
quired such correlations in ERa negative cancers (Figure 5),
supporting the possibility that these NR may be involved in
ERa-associated but ERa-independent pathways. Although cor-
relations were detected between PGR and these genes in ERa
negative cancers, the significance level did not pass the cut-
off threshold of 0.7 (not shown).
3.5. Prognostic value of nuclear receptors and
coregulators in breast cancer
The prognostic power of the small number of nuclear recep-
tors that acquired correlation with multiple coregulators in
breast cancers (Figure 4) raised the question of whether cor-
egulators, alone or in combination with nuclear receptors,
were associated with breast cancer outcome. To address
this question, we performed a comprehensive survey of
the association of all nuclear receptor and coregulator
expression levels with patient survival in large cohort of
publicly available breast cancer microarray datasets. In to-
tal, we compiled gene expression data from over 4000 breast
cancer tissue microarrays profiled on two microarray plat-
forms: Affymetrix Hg133A (2189 samples) and Illumina HT-
12 v3 (1853 samples) (Supplementary Table 3). Given the
multiplicity of markers already linked to clinical outcome
in breast cancer, and the challenges in identifying prog-
nostic gene signatures that perform better than chance
alone (Venet et al., 2011), we employed the rigorous analyt-
ical approach outlined in Supplementary Figure 2 (Materials
& Methods). Using the Affymetrix Training samples, as pre-
viously noted, we identified 80 coregulators and 23 NR hav-
ing r-index ! 0.750, and 43 coregulators and 5 NR for the
Illumina Training Set.
Therewere 3 nuclear receptors (GR, PGR, PPARd) and 16 cor-
egulators with expression profiles robustly associated with
patient survival, independent of ERa status or node status
on both microarray platforms (listed in Supplementary Table
4). These genes have functional roles relevant to cancer
biology including: cell cycle regulation (CDKN1C, CCNA2,
CCNE1, PA2G4), cytoskeletal organisation (CLF1, GSN), chro-
matin modifiers (SMARCA2, HMGB2), known oncogenes or
cancer-related genes (RPL7A, NSD1, PRAME, FUS), and also
include 4 (33%) of the 12 genes that are increased in cancer
compared with normal breast (Figure 2: TRIP13, CCNE3,
CCNA2, PRAME). Figure 6A represents a heatmap of the r-in-
dex of each of the 19 genes which represent the number of
times out of 1000 bootstrap Cox regression analyses of
different sample subgroups in which the expression of the
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but ERa-independent pathways. Expression correlation profiles in ERa
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Figure 6 e Nuclear receptors and coregulators with prognostic values. A) Heatmap of r-index values of the 19-gene signature. The r-index is a
measure of the robustness of a gene’s association with survival and represents the number of analyses out of 1000 Cox Regression analyses of
randomly sampled subgroups of samples in which the gene is found to be significantly associated with patient survival. B) Kaplan Meier plot
showing significant segregation of samples (1094 validation samples profiled on Affymetrix Hg133a arrays) classified into Low, Intermediate and
High risk-groups based on the expression of the 19 genes. C) Similar to B) but using a second set of 927 validation samples profiled on Illumina
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gene is found to be associated with survival. The r-index thus
represents the robustness of a gene’s association with patient
survival.
The combined expression of the 19 genes identified can
segregate low-risk from high-risk breast cancers. Samples
from the Validation Sets (1094 samples profiled on Affymetrix
Hg133A and 927 samples profiled on Illumina HT-12 v3) were
classified into 3 different risk groups based on risk scores
calculated from the expression of the 19 genes: low (bottom
tertile), intermediate (middle tertile) and high (top tertile).
Kaplan Meier analysis showed significant segregation of the
three risk-groups (Figures 6B and C). Furthermore, classifica-
tion of samples into low, intermediate and high risk-groups
on expression profiles of just the 3 nuclear receptors (GR,
PGR, PPARd) also results in significant segregation of low, in-
termediate and high-risk samples (Figure 6D). We also
observed that addition of the two genes known to be involved
in cytoskeletal organization (CFL1 and GSN) into the survival
model together with the 3 NR resulted in further separation
of the risk groups (Figure 6E).
We also tested the prognostic power of the 3NR, 3NRþcy-
toskeletal genes and the 19-gene signature in breast cancer
subgroups identified by immunohistochemical marker stain-
ing. The signatures had little or no predictive power in Basal
and HERa 2 subtypes, but identified subgroups of patients
with different prognosis in the Luminal A, Luminal B and
Normal-like subtypes (not shown).
3.6. Performance comparison
A limitation of current breast cancer signatures is that most
have been shown to be no more strongly associated with
outcome than random sets of genes, although signatures con-
taining over 100 genes are more significant (Venet et al., 2011).
We compared the performanceofNR and coregulator centered
gene signatures with 48 other published breast cancer signa-
tures (compiled from Venet et al. (2011)). Using samples from
our Validation Sets, we calculated sample risk scores based
on the expression of the genes in each signature. The associa-
tionof the calculated risk scoreswithpatient survivalwas then
tested by Univariate Cox Regression and Concordance Index.
Figure 7 shows the Concordance Index for each gene signa-
ture calculated for (i) all samples in the Validation Sets
(Figure 7A) and (ii) ERa negative samples of the Validation
Sets (Figure 7B). The 19-gene signature performance is compa-
rable to signatures of larger sizes, in all cases (Figure 7A) and
more particularly in ERa negative cases (Figure 7B). The signa-
tures for the 5 NR that acquired correlations in ERa negative
cancer (from Figure 4); and the 3 NR Plus Cytoskeletal gene sig-
natures do not rank well when all samples of the Validation
Sets are used (Figure 7A), they are, however, able to predict pa-
tient survival for ERa negative samples better than signatures
with larger gene numbers (Figure 7B). We also observed that
prediction accuracy of gene signatures varies, depending on
the microarray platform used, with some signatures
performing better on one microarray platform than the other.
In ERa negative breast cancers, there are two published signa-
tures thathavecomparableor fewernumbersof genes than the
NR-coregulator signatures identified in this study, namely the
Yu et al. (2007) (14 genes) and Buffa et al. (2010) (3 genes) signa-
tures (Figure 7B). There was no overlap between the 19-gene
NR-coregulator signature identified in this study,and thegenes
contained within either the Yu or Buffa signatures, nor did
functional analysis reveal any overlap, with the Yu signature
being associatedwith cell surface receptor linked signal trans-
duction, immune response and cell motility (not shown).
It isknownthatmostof thegenes inbreastcancersignatures
are correlatedwithproliferation, and this is amajor confounder
in outcome prediction (Venet et al., 2011). To assess the impact
of proliferation on the prognostic power of the NR-coregulator
gene signatures that we identified, we adjusted for the effect
of proliferation by adjusting for the expression of the meta-
PCNA signature, which comprises the genes most strongly
correlated with Proliferating Cell Nuclear Antigen (PCNA) gene
expression (Venet et al., 2011).We found thatwhile for ERa pos-
itive cancers, meta-PCNA adjustment reduced the prognostic
power ofmost of the gene signatureswe examined, it hadmin-
imal impact for ERanegativecancersand the19-genesignature;
the 5 NR that acquired correlations in cancer signature (from
Figure 4); and the 3 NR plus cytoskeletal gene signature
remained predictive of outcome in this cohort
(Supplementary Figure 5).
4. Discussion
This study comprises the first combined profiling of nuclear
receptors and coregulators in the human breast. Notable
strengths include the robust quantitation of coregulator tran-
scripts in cohorts of curated human breast tissues, both
normal and cancer, plus validation cohorts comprising of all
publicly available breast cancer microarray datasets across
all platforms. In this regard the study provides significant
pathophysiologically relevant insights to supplement studies
based on cell line models (Kittler et al., 2013). Our findings
reveal an almost pan-repression of coregulator expression in
neoplastic breast tissue and show that ERa negative cancers
are associated with more widespread disruptions of the core-
gulator transcriptome. In addition, the study highlights
important cancer-associated shifts in nuclear receptor and
coregulator expression patterns. We then complemented the
expression profiling of nuclear receptors and coregulators
with a comprehensive survey of the prognostic value of NR
and coregulators in published breast cancer microarrays to
identify nuclear receptors and coregulators with high prog-
nostic significance.
The coregulator transcriptome was strikingly disrupted in
cancer compared with normal breast, with a small number of
coregulators up-regulated and the majority repressed. Up-
regulation was overwhelmingly associated with proliferation,
HT12v3 arrays. D) and E) Kaplan Meier plot showing significant segregation of 1094 validation samples profiled on Affymetrix Hg133a arrays
classified into Low and High risk-groups based on the expression of (D) the 3 nuclear receptors GR, PGR and PPARd; and (E) the 3 nuclear
receptors and two cytoskeletal genes CFL1 and GSN.
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consistent with different regulatory networks being operative
in both ERa positive and ERa negative breast cancers; differ-
ential expression of the two cyclins CCND1 and CCNE1 in
ERa positive and ERa negative cancers suggest different
mechanisms for controlling progression of G1 to S phase of
the cell cycle in these two subgroups. CCND1 is up-
regulated in ERa positive and down-regulated in ERa negative
cancers, consistent with published reports that ERa can
induce CCND1 expression (Cicatiello et al., 2010). It is possible
that in ERa negative cancers progression from G1 to S phase
is mediated through CCNE1, which is specifically up-
regulated in ERa negative cancers in contrast with the
decreased level of CCND1. In addition, the coregulators
VAV3, a Rho GTPase guanine nucleotide exchange factor,
and SPDEF, the SAM pointed domain containing ETS tran-
scription factor, are up-regulated specifically in ERa positive
breast cancers and down-regulated in ERa negative breast
cancers, consistent with previously published reports that
VAV3 overexpression enhances ERa-mediated signaling
(Doolan et al., 2008), and that SPDEF is associated with pa-
tient survival in ERa positive breast cancers (Sood et al.,
2009). Up-regulation of both RARa and CRABP2 (cellular
B
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Figure 7 e Comparison of NR/coregulator based gene signature with other published signatures. A) Concordance indices of 48 published
signatures and 3 NR/coregulator based signatures computed using 1094 samples profiled on Affymetrix Hg133a arrays (blue) and 927 samples
profiled on Illumina HT12v3 arrays (red). Both ERa positive and ERa negative samples were included in the analysis. B) Similar to A) but
concordance indices were calculated using only ERa negative samples.
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retinoic binding protein 2) specifically in ERa positive cancers
is further evidence for differential regulation, in the case of
retinoic acid signaling, in ERa positive and ERa negative
breast cancer subgroups.
Pan-repression of coregulator expression in neoplastic
breast tissues was not unexpected given our earlier observa-
tion that breast cancer is associated with a pan-repression
of nuclear receptors except for EAR2, AR, RARa and the
NR4A subgroup (Muscat et al., 2013). The specific mechanisms
whereby repression of nuclear receptors and coregulators is
involved in breast cancer pathogenesis are unclear. In cancers
multiple NR-mediated pathways associated with cell differen-
tiation were repressed, eg Retinoic Acid Activation and Glucocor-
ticoid Receptor Signaling pathways; with up-regulation of cell
cycle related genes this would have a net effect of increased
cell growth and proliferation.
In the absence of detailed genomic localization maps and
proteineprotein interaction data for most nuclear receptors
and coregulators in breast cancer tissues, and the impossi-
bility of experimentally deriving functional data from human
tissue cohorts, we determined the correlation betweenNR and
coregulator expression as a measure of functional related-
ness. While setting very strong correlation thresholds for sig-
nificance, we acknowledge that correlated expression
indicates, but does not prove, functional co-operation. Never-
theless, this approach has revealed interesting insights into
the complex regulatory networks of nuclear receptors in the
human breast.
First, most of the strong NR-coregulator correlations
occurred in the normal postmenopausal breast, with NR
including RARg, RORg, VDR, RARb, HNF4g, RXRb, COUP-TF1/
2, MR and PPARg associating with the largest number of core-
gulators, and pointing to the potential for active signaling net-
works around these receptors in normal breast. TheseNRwere
also associated with coregulators in pre-menopausal breast,
but less frequently. Many if not all of these associations were
lost in cancer, consistent with the overall down-regulation
both of NR (Muscat et al., 2013) and coregulators (this study)
in cancer compared with normal tissue. NR that acquired
expression correlations (Rev-ERBb, GR, NOR1, LRH-1, PR) spe-
cifically in ERa negative breast cancers predicted poorer
outcome for those patients, suggesting the potential for clini-
cally significant activation of new signaling networks associ-
ated with unrestrained cancer biology involving these NR
specifically in ERa negative breast cancers. Interestingly, NR
whose associations with coregulators are disrupted in ERa
negative breast cancers are not as strongly associatedwith pa-
tient outcome. This finding is particularly interesting in the
context of regulatory networks, given that cancer is not simply
a disease with a genetic basis but is ultimately driven by per-
turbations at the network level (Creixell et al., 2012). During
cancer development, it is likely that signaling processes are
not simply disrupted but are also re-wired resulting in new
signaling landscapes favorable to the development of the can-
cer cells. It is therefore perhaps logical that those re-wired
signaling processes favoring maintenance and progression of
cancer will have a stronger impact on patient outcome.
Secondly, we observed a positive correlation between the
expression of most nuclear receptors and coregulators, with
the exception of PPARg, ERb and RXRg, expression of which
inversely correlates with multiple coregulators specifically in
normal but not cancer tissues. It is arguably more logical for
the expression of nuclear receptors to be positively correlated
with that of coregulators for co-operational control of gene
regulation. It is more unexpected to observe patterns of wide-
spread inverse correlations, as in the case of PPARg; PPARg
and its coregulator PPARgC1A are both strongly down-
regulated in both ERa positive and ERa negative cancers,
consistent with reports that the presence of PPARg is associ-
ated with an anti-tumorigenic effect (Bonofiglio et al., 2006;
Lu et al., 2005; Suzuki et al., 2006). PPARg positively correlates
with very few genes, among which are the tumor suppressor
CAV1, the testosterone 17-beta-dehydrogenase gene
HSD17B13 and the aldo-keto reductase AKR1C1/AKR1C2
gene. HSD17B13 is involved in estrogen biosynthesis and
responsible for converting estrone to estradiol-17-beta while
AKR1C1/AKR1C2 catalyses the reduction of progesterone to
the inactive 20a-hydroxy-progesterone. Both HSD17B13 and
AKR1C1/AKR1C2 are strongly down-regulated, consistent
with attenuated steroid metabolism, in both ERa positive
and ERa negative cancer samples. The strong positive correla-
tion of PPARg with HSD17B13 and AKR1C1/AKR1C2 in normal
breast only, its repression in cancer and the striking inverse
correlation pattern between PPARg and multiple coregulators
suggest that dysregulation of this NR might contribute to
altered steroid metabolism and thereby to aberrant control
of estrogen and progesterone mediated signaling in breast
cancer.
The demonstration that NR-coregulator associations in
normal breast are disrupted in cancer, and the acquisition of
associations unique to cancer tissues, signal the potential
for NR-coregulator networks not only to be implicated in the
biology of breast cancer but also relevant to clinical outcome.
Testing of such possibilities, in order to discover meaningful
associations between gene signatures and clinical outcome,
is fraught with pitfalls in that most current breast cancer sig-
natures are not robust across datasets and microarray plat-
forms, and moreover are no more strongly associated with
outcome than random sets of genes (Venet et al., 2011). This
is probably due to the extremely high individual variability
of sampled tumor expression profiles resulting in passenger
signals overwhelming the real cancer signature. To circum-
vent this limitation, we employed a bootstrap resampling
approach on 2 different microarray platforms. There were
only 19 genes (3 nuclear receptors (GR, PGR, PPARd) and 16 cor-
egulators) with expression profiles robustly associated with
patient survival, independent of ERa or node status on both
microarray platforms. Low levels of expression of the signa-
ture genes identify patients with a significantly lower proba-
bility of distant metastases, across both the microarray
platforms, whereas high expression is associated with poorer
prognosis. Low expression of the 3 NR alone, or of the 3 NR
with the cytoskeletal genes, also stratified patients with better
prognosis. Two of the 3 NR in the 19-gene signature (GR,
PPARd) have been identified by ChIP-chip to be central nodes
in a regulatory network of NR and associated transcription
factors in MCF-7 cells (Kittler et al., 2013), and their robust as-
sociation with clinical outcome identified in this study high-
lights the importance of signaling networks specifically
associated with these 3 NR in breast cancer.
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To evaluate how well NR-coregulator-based signatures
performed in comparison to other published breast cancer sig-
natures, and mindful of the weak predictive power of pub-
lished signatures containing fewer than 100 genes, the
performance of the NR-coregulator-based signatures was
compared to that of all published breast cancer signatures.
The performance of the 19-gene NR-coregulator-based signa-
ture is comparable to many other signatures of much larger
sizes in predicting outcome for all breast cancer samples
(both ERa positive and ERa negative), highlighting the power
of predictive signatures derived from the quantitative deter-
mination of altered gene expression between normal breast
and breast cancers.
This study highlights major differences in coregulator
expression and NR-coregulator interaction between ERa posi-
tive and ERa negative breast cancers that reflects divergent
regulatory controls in these two breast cancer subtypes. Spe-
cifically, a majority of the profiled coregulators (81%) are
differentially expressed between ERa positive and ERa nega-
tive breast cancers, with ERa negative cancers being associ-
ated with an increase in both the number of coregulators
being repressed as well as an increase in the magnitude of
the repression. The change in coregulator expression is asso-
ciated with ERa-specific perturbations in NR-coregulator
expression. Specifically, RXRa, TRa, COUP-TF2, RORg showed
strong associations of with multiple coregulators in ERa posi-
tive breast cancers suggesting the increased importance of
retinoic acid signaling in this subtype and consistentwith pro-
liferation being a major influence on patient outcome in ERa
positive cancers. ERa negative cancers, on the other hand,
are associated with acquired interactions between REV-
ERBb, TR4, GR, PPARa, NOR1, LRH-1 and a large number of cor-
egulators. NR-coregulator interactions acquired specifically in
ERa negative cancers have the potential to impact a wide
range of cellular pathways and processes including chromatin
remodeling, glucocorticoid receptor signaling and cell cycle
regulation. Overall, our results suggest that ERa negative
breast cancer is associated with increased severity in pertur-
bation of normal NR-coregulator interactions and that there
exists significant differences in theway normal gene regulato-
ry networks are altered in these breast cancers. As a conse-
quence, some NR and coregulators have stronger influence
on patient outcome in ERa negative or positive breast cancer
compared to the other. We observed that the 3NR plus cyto-
skeletal genes obtained the highest Concordance Index for
ERa negative cancer, with its performance in predicting
outcome for ERa positive cancer less robust. In addition,
PCNA-adjustment has minimal influence on the prognostic
power of most gene signatures in ERa negative cancers. It is
thus possible that while proliferation is a major influence on
outcome association in ERa positive cancers, it is not the prin-
cipal factor that influences outcome for ERa negative breast
cancers. ERa negative breast cancer outcomesmight be driven
by factors including cell movement and metastasis, as sug-
gested by the strong influence of cytoskeletal genes in predict-
ing patient outcome for this subgroup. In addition, we
demonstrated that NR showing acquired correlations with
multiple coregulators specifically in ERa negative cancers
have stronger influence on patient outcome in these cancers.
This observation emphasizes the importance of examining
not only “loss-of-function” disruptions but also “gain-of-func-
tion” perturbations in the search for therapeutic and prog-
nostic markers for breast cancer.
In conclusion, this study has identified networks of nuclear
receptor-coregulator interactions active in normal breast but
disrupted in breast cancer, and moreover provides evidence
that signatures based on NR networks disrupted in cancer
can provide important prognostic information in breast can-
cer patients, including ERa negative patients, for whom exist-
ing prognostic measures are limited.
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Overview	
Studies have shown that cancer evolves dynamically with waves of clonal 
expansion driven by selective pressure, and that the accumulation of somatic 
mutations in cancerous and precancerous cells is a complex and dynamic 
process [176]. Therefore, the development and progression of breast cancer is 
rarely the result of an abnormality in a single gene and more often the result of 
perturbations in the complex networks of inter-connected biological processes 
that govern intra and inter-cellular interactions. 
With the ability to encapsulate the activities of multiple regulatory processes 
simultaneously, gene co-expression and differential co-expression analyses are 
powerful tools to study complex diseases. Co-expression network analysis has 
been successfully applied to the study of many complex diseases including 
diabetes [177], schizophrenia [178], autism spectrum disorders [179] as well as 
many cancers [134, 143, 180-183].  
In the context of breast cancer, co-expression network analyses have been 
applied to identify genes associated with prognosis [118, 183-185], study 
changes in stromal-epithelial gene regulation [181] and to identify relationships 
between transcription factors [144].  
However, to date the only study applying co-expression analysis methods to 
investigate the roles of nuclear receptors in breast cancer was carried out using 
NR expression in NCI-60 cell lines and a limited numbers of breast tissue 
microarrays [144] and no study has been reported in which differential co-
expression has been utilized to examine the change in NR co-expression 
networks in breast cancer compared to the normal breast. 
There is a wealth of literature on the functional roles and prognostic value of 
individual NRs in breast cancer. As reviewed in Section 1.2, the majority of NRs 
are expressed in the breast and several NRs have functional roles in the 
development and progression of breast cancer. However, the coordinated 
behaviour of the family of human NRs in the breast and breast cancer are 
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largely unexplored. In this chapter, we utilize gene expression datasets to 
investigate the networks of NRs in the normal breast and breast cancer via co-
expression and differential co-expression analyses. 
4.1 Chapter	hypothesis	and	aims	
Hypothesis 1: Co-expression analysis can help identify critical biological 
processes regulated by nuclear receptors in normal breast development and 
breast cancer biology 
Aims 1: To identify genes co-expressed with individual or groups of NRs in the 
normal breast or breast cancer 
This aim is explored in Section 4.2. In this section, genes significantly co-
expressed with NRs in adjacent normal breast tissues or breast cancer tissues 
were identified. Unsupervised clustering of NR co-expressed genes was 
performed to identify co-expressed gene modules followed by gene ontology 
enrichment analysis to infer the functional significance of each co-expressed 
gene module. 
Aims 2: To identify changes in the co-expression networks of NRs in breast 
cancer compared to the normal breast 
This aim is explored in Section 4.3. In this section, two different approaches 
were used to identify genes differentially co-expressed with NRs in breast 
cancer compared to the normal breast. Unsupervised clustering of NR 
differentially co-expressed genes was performed to identify differentially co-
expressed gene modules followed by gene ontology enrichment analysis for 
module functional inference. 
4.2 NR	co-expression	networks	in	the	
normal	breast	and	breast	cancer	
This section focuses on the analysis of NR-centered co-expression networks 
using expression profiles of normal breast as well as breast cancer tissues to 
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identify biological process potentially governed by NRs and to infer potential 
functional relationships between NRs.  
The method described in Section 2.7.1 was used to identify significantly co-
expressed NR-nonNR gene pairs based on the RNA-seq expression profiles of 
106 adjacent normal breast tissues and 988 breast cancer tissues obtained from 
the TCGA (Dataset 4, described in Section2.2.4). A total of 5941 and 8424 genes 
were identified as significantly co-expressed with at least one NR in the normal 
breast and breast cancer respectively. Figure 11 summarizes the number of 
genes identified to be significantly co-expressed with each NR in the two 
cohorts. 
 
 
Figure 11: Numbers of NR co-expressed genes in normal and cancer. Number of genes 
significantly co-expressed with each NR in the normal breast and breast cancer. 
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Although simplistic in its measure, Figure 11 suggests that there is major 
disruption or re-wiring of the NR regulatory networks in breast cancer 
compared to the normal breast as judged by the change in the number of 
genes co-expressed with each NR. If the number of genes significantly co-
expressed with an NR can be taken as an indirect measure of its influence - 
which may not be true because correlation does not imply a cause-effect or 
regulatory relationship – then this figure suggests that different groups of NRs 
are active or influential in the biology of normal breast and breast cancer. 
4.2.1 NR	co-expression	networks	in	the	normal	breast	
The 5941 genes found to be co-expressed with at least one NR in normal breast 
tissues were clustered based on their co-expression profiles. Figure 12 shows 
the heatmap of the clustered NR-centered co-expression matrix and the 10 co-
expressed gene modules identified. 
A number of observations can be made from Figure 12: 
1) The majority of genes found to be significantly co-expressed with NRs 
are not specifically co-expressed with only one NR. Instead, they are 
often co-expressed with multiple NRs. For example, genes in co-
expressed module 1 showed significant co-expression with the NR4A 
sub-family of NRs and genes in co-expressed module 9 showed positive 
co-expression with multiple NRs including RARB, HNF4G, ESRGG and 
negative co-expression with PPARG and RXRG. This observation is in 
agreement with published literature using ChIP-chip and ChIP-seq data 
to infer regulatory networks of a number of NRs in breast cancer, in 
which it was observed that NR regulatory networks are tightly 
interconnected, with extensive crosstalk between NRs and “hot spots”, 
genes transcriptionally regulated by multiple transcription factors, are 
quite common [26]. 
2) Positive correlations are more common than negative correlations. This 
was also observed in a large-scale co-expression analysis of nearly 4000 
microarrays by Lee et al. [122] and no published literature exploring 
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explanations for this observation has been found. It is not certain if this 
observation reflects technical limitations in detecting real biological 
negative correlations or whether it is biologically true that 
transcriptional repression or a repressive relationship between genes is 
a less common regulatory mechanism.  
 
Figure 12: NR co-expression networks in the normal breast. Clustered heatmap of the Pearson 
correlation coefficients of genes co-expressed with NRs in normal breast tissues. NRs are listed 
across the columns with identifiers in the format of  “Gene symbol | Entrez Gene ID”. NR co-
expressed genes are in rows. Only NRs with at least 20 significantly co-expressed genes are 
included in this heatmap. Cell values are the Pearson correlation of each NR-nonNR gene pair 
that is significantly co-expressed. Grey indicates absence of significant co-expression. Gene 
modules were identified through fixed-height cutting of the hierarchical gene tree guided by 
visual inspection of the differential expression profile.  
To infer the potential functional roles of the different groups of NRs in the 
normal breast, GO enrichment analysis was performed using the DAVID 
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bioinformatics tools to identify biological processes over-represented in each 
of the co-expressed gene modules. Biological Processes Ontology annotations 
significantly over-represented (p-value <= 0.005 and FDR < 10% with at least 4 
module genes associated) are then sorted by the number of module genes 
associated and the top 10 annotations for each gene module are shown in 
Table 6. 
Table 6: Top 10 GO terms enriched in NR co-expressed gene modules identified in normal breast 
(Figure 12). Only modules with significantly over-represented functional ontologies are included 
in this table (modules 2,4,5 and 6 are not included because of the absence of significantly over-
represented functional ontologies). Count = numbers of co-expressed genes annotated with the 
term. % = proportion of NR co-expressed genes. P-value = modified Fisher Exact P-value, also 
called the EASE score. FE = fold enrichment. FDR = P-value adjusted for false discovery by the 
Benjamini-Hochberg procedure. 
		 Term	 Count	 %	 P-value	 FE	 FDR	
1	
GO:0045944~positive	regulation	of	
transcription	from	RNA	polymerase	II	
promoter	 15	 26.32	 9.10E-07	 4.90	 1.38E-03	
GO:0006366~transcription	from	RNA	
polymerase	II	promoter	 10	 17.54	 2.23E-05	 6.24	 3.38E-02	
GO:0008285~negative	regulation	of	cell	
proliferation	 9	 15.79	 2.95E-05	 7.10	 4.46E-02	
GO:0042493~response	to	drug	 8	 14.04	 8.79E-05	 7.34	 1.33E-01	
GO:0043066~negative	regulation	of	apoptotic	
process	 8	 14.04	 4.89E-04	 5.54	 7.36E-01	
GO:0032496~response	to	lipopolysaccharide	 7	 12.28	 1.97E-05	 12.22	 2.98E-02	
GO:0008284~positive	regulation	of	cell	
proliferation	 7	 12.28	 3.24E-03	 4.70	 4.79E+00	
GO:0032570~response	to	progesterone	 5	 8.77	 1.57E-05	 32.28	 2.37E-02	
GO:0034097~response	to	cytokine	 5	 8.77	 2.65E-05	 28.32	 4.01E-02	
GO:0009612~response	to	mechanical	stimulus	 5	 8.77	 4.20E-05	 25.22	 6.34E-02	
3	
GO:0043547~positive	regulation	of	GTPase	
activity	 33	 5.78	 4.30E-04	 1.95	 7.53E-01	
GO:0006468~protein	phosphorylation	 29	 5.08	 2.92E-04	 2.11	 5.12E-01	
GO:0001525~angiogenesis	 19	 3.33	 1.55E-04	 2.81	 2.72E-01	
GO:0016477~cell	migration	 17	 2.98	 5.76E-05	 3.31	 1.01E-01	
GO:0030198~extracellular	matrix	organization	 16	 2.80	 8.52E-04	 2.72	 1.49E+00	
GO:0008152~metabolic	process	 15	 2.63	 8.16E-04	 2.85	 1.43E+00	
GO:0032869~cellular	response	to	insulin	
stimulus	 12	 2.10	 6.25E-05	 4.54	 1.10E-01	
GO:0035335~peptidyl-tyrosine	
dephosphorylation	 12	 2.10	 1.83E-04	 4.04	 3.22E-01	
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GO:0006470~protein	dephosphorylation	 12	 2.10	 1.34E-03	 3.20	 2.34E+00	
GO:0030036~actin	cytoskeleton	organization	 12	 2.10	 1.84E-03	 3.07	 3.19E+00	
4	 GO:0006400~tRNA	modification	 4	 1.69	 3.73E-03	 12.63	 5.57	
7	
GO:0006351~transcription,	DNA-templated	 119	 14.71	 3.89E-06	 1.51	 6.78E-03	
GO:0043547~positive	regulation	of	GTPase	
activity	 41	 5.07	 4.19E-04	 1.80	 7.26E-01	
GO:0006281~DNA	repair	 27	 3.34	 3.28E-06	 2.84	 5.71E-03	
GO:0000398~mRNA	splicing,	via	spliceosome	 23	 2.84	 9.86E-05	 2.56	 1.71E-01	
GO:0006260~DNA	replication	 16	 1.98	 1.87E-03	 2.50	 3.20E+00	
GO:0016568~chromatin	modification	 13	 1.61	 5.78E-04	 3.28	 1.00E+00	
GO:0006406~mRNA	export	from	nucleus	 12	 1.48	 2.33E-03	 2.97	 3.98E+00	
GO:0006342~chromatin	silencing	 8	 0.99	 2.31E-03	 4.30	 3.94E+00	
8	
GO:0034097~response	to	cytokine	 4	 4.35	 2.03E-03	 15.71	 2.97E+00	
GO:0007249~I-kappaB	kinase/NF-kappaB	
signaling	 4	 4.35	 2.35E-03	 14.92	 3.43E+00	
9	
GO:0006355~regulation	of	transcription,	DNA-
templated	 493	 16.81	 1.36E-74	 2.19	 2.58E-71	
GO:0051301~cell	division	 83	 2.83	 8.85E-06	 1.61	 1.68E-02	
GO:0016567~protein	ubiquitination	 76	 2.59	 1.28E-03	 1.42	 2.41E+00	
GO:0006281~DNA	repair	 74	 2.52	 2.24E-10	 2.11	 4.24E-07	
GO:0000398~mRNA	splicing,	via	spliceosome	 68	 2.32	 4.58E-09	 2.05	 8.69E-06	
GO:0006397~mRNA	processing	 58	 1.98	 9.54E-09	 2.16	 1.81E-05	
GO:0006974~cellular	response	to	DNA	
damage	stimulus	 57	 1.94	 6.42E-06	 1.82	 1.22E-02	
GO:0007067~mitotic	nuclear	division	 57	 1.94	 9.66E-04	 1.53	 1.82E+00	
GO:0006260~DNA	replication	 56	 1.91	 3.58E-10	 2.38	 6.78E-07	
GO:0008380~RNA	splicing	 51	 1.74	 5.24E-07	 2.05	 9.93E-04	
10	
GO:0006355~regulation	of	transcription,	DNA-
templated	 128	 13.96	 1.88E-11	 1.82	 3.33E-08	
GO:0006468~protein	phosphorylation	 38	 4.14	 7.54E-04	 1.79	 1.33E+00	
GO:0016567~protein	ubiquitination	 36	 3.93	 2.86E-05	 2.16	 5.07E-02	
GO:0016032~viral	process	 35	 3.82	 1.11E-05	 2.29	 1.96E-02	
GO:0006974~cellular	response	to	DNA	
damage	stimulus	 32	 3.49	 1.09E-08	 3.28	 1.93E-05	
GO:0006511~ubiquitin-dependent	protein	
catabolic	process	 29	 3.16	 2.24E-08	 3.43	 3.97E-05	
GO:0006886~intracellular	protein	transport	 25	 2.73	 2.68E-04	 2.28	 4.74E-01	
GO:0006281~DNA	repair	 23	 2.51	 1.43E-03	 2.11	 2.50E+00	
GO:0043161~proteasome-mediated	ubiquitin-
dependent	protein	catabolic	process	 21	 2.29	 1.10E-03	 2.25	 1.94E+00	
GO:0042787~protein	ubiquitination	involved	
in	ubiquitin-dependent	protein	catabolic	
process	 20	 2.18	 8.78E-05	 2.81	 1.56E-01	
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Four out of the 10 co-expression modules identified (modules 2, 4, 5 and 6) did 
not have any associated significant biological functions.  Modules 2 (55 genes), 
5 (71 genes) and 6 (66 genes) contain small numbers of genes, which are not 
optimal for gene set or functional ontology enrichment analysis. With 
enrichment analysis in general, and the DAVID tool in particular, larger gene 
lists give more statistical power and higher sensitivity (stronger enrichment p-
values).  
From Table 6, possible functional roles of a number of NRs in the normal 
breast are summarized below: 
Module Positively 
correlated NRs 
Negatively 
correlated NRs 
Possible functions 
1 NR4A1/2/3  • regulation of cell 
proliferation and 
apoptosis 
3 NR3C1, ESR2, 
PPARG, PPARA 
VDR, RORC • cell adhesion 
• cell migration 
• angiogenesis 
• metabolic response 
7  RXRB, PPARD, 
VDR 
PPARG, RXRG • transcriptional control 
• GTPase activity 
• DNA replication 
• DNA repair 
• chromatin 
modification 
9 HNF4G, ESRRG, 
RARB, NR6A1, 
NR2C2, NR2C1, 
NR3C2 
PPARG, ESR2, 
NR1H3 
• transcriptional 
regulation 
• cell cycle control 
• DNA repair 
• Protein ubiquination 
• mRNA processing 
10 NR2C1, NR2C2  • protein ubiquination 
• protein 
phosphorylation 
• DNA damage response 
 
4.2.2 NR	co-expression	network	in	breast	cancer	
The same methodology that was used to identify genes significantly co-
expressed with NRs in normal breast tissues was applied to the 988 breast 
Identification of co-expressed and differentially co-expressed NR networks in the 
normal breast and breast cancer 
 108 
cancer tissues. The 8424 genes found to be co-expressed with at least one NR 
in breast cancers were then clustered based on their co-expression profiles. 
Figure 13 shows the heatmap of the clustered NR-centered co-expression 
matrix and the 16 co-expressed gene modules identified in breast cancer and 
Table 7 lists the top 10 Biological Processes Gene Ontology terms significantly 
enriched in each of the 16 gene modules. 
A number of observations can be made from Figure 13 and Table 7 
1) Similar to what has been observed in the normal tissues, NR-centered 
co-expression networks in breast cancer are also highly inter-connected 
and positive correlations are more commonly observed than negative 
correlations.  
2) Major changes in the NR co-expression network are observed. Most 
notable are:  
a. The loss of co-expression between the nuclear receptors HNF4G, 
ESRRG, RARB, NR6A1 with genes involved in cell cycle and 
transcriptional control. Another group of NRs (NR1D2, NR2C2, 
NR2C1, NR3C1, RORA, AR) was observed to gain co-expression 
with genes involved in these biological processes in cancer. 
b. The gain of co-expression between the nuclear receptors ESR1, 
PGR, NR2E3, RARA and genes in Module 8 of Figure 13. Gene 
ontology analysis showed that Module 8 is enriched with genes 
involved in cilium assembly and movement. Furthermore, 
analysis using the Enrichr geneset enrichment analysis tool [186] 
showed that Module 8 genes are strongly enriched (adjusted 
enrichment P-values = 2.42E-07) with genes that are bound by 
ESR1 in ChIP-chip and ChIP-Seq experiments in breast cancer 
cell lines (MCF-7 and T47D), providing further evidence 
supporting the regulatory relationship between ESR1 and genes 
in Module 8 in breast cancer. 
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 Figure 13: NR co-expression network in breast cancer. NRs are listed across the columns with 
identifiers in the format of  “Gene symbol | Entrez Gene ID”. NR co-expressed genes are in rows. 
Cell values are the Pearson correlation of each NR-nonNR gene pair that is significantly co-
expressed. Only NRs with at least 20 significantly co-expressed genes are included in this 
heatmap. Grey indicates absence of significant co-expression. Gene modules were identified 
through fixed-height cutting of the hierarchical gene tree guided by visual inspection of the 
differential expression profile.  
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Table 7: Top 10 GO terms enriched in NR co-expression gene modules of breast cancers (Figure 
13). Only modules with significantly over-represented functional ontologies are included in this 
table (modules 6, 7, and 9 are not included because of the absence of significantly over-
represented functional ontologies). Count = numbers of co-expressed genes annotated with the 
term. % = proportion of NR co-expressed genes. P-value = modified Fisher Exact P-value, also 
called the EASE score. FE = fold enrichment. FDR = P-value adjusted for false discovery by the 
Benjamini-Hochberg procedure. 
		 Term	 Count	 %	 PValue	 FE	 FDR	
1	
GO:0006955~immune	response	 66	 18.44	 4.57E-40	 8.08	 7.64E-37	
GO:0007165~signal	transduction	 65	 18.16	 1.55E-14	 2.88	 2.60E-11	
GO:0006954~inflammatory	response	 48	 13.41	 1.10E-24	 6.52	 1.83E-21	
GO:0045087~innate	immune	response	 45	 12.57	 8.07E-20	 5.39	 1.35E-16	
GO:0050776~regulation	of	immune	
response	 42	 11.73	 1.53E-32	12.15	 2.55E-29	
GO:0002250~adaptive	immune	response	 38	 10.61	 7.71E-31	13.23	 1.29E-27	
GO:0007155~cell	adhesion	 32	 8.94	 1.59E-09	 3.59	 2.66E-06	
GO:0031295~T	cell	costimulation	 26	 7.26	 3.82E-24	17.17	 6.39E-21	
GO:0007166~cell	surface	receptor	signaling	
pathway	 25	 6.98	 7.62E-10	 4.70	 1.27E-06	
GO:0043547~positive	regulation	of	GTPase	
activity	 24	 6.70	 6.73E-04	 2.19	 1.12E+00	
GO:0006915~apoptotic	process	 24	 6.70	 7.06E-04	 2.18	 1.17E+00	
2	 GO:0006955~immune	response	 6	 11.76	 3.09E-03	 5.84	 4.01E+00	
3	
GO:0006954~inflammatory	response	 11	 7.86	 3.91E-04	 4.03	 6.13E-01	
GO:0007166~cell	surface	receptor	signaling	
pathway	 9	 6.43	 7.89E-04	 4.56	 1.23E+00	
4	
GO:0055114~oxidation-reduction	process	 10	 12.50	 3.43E-04	 4.43	 5.00E-01	
GO:0071356~cellular	response	to	tumor	
necrosis	factor	 8	 10.00	 1.75E-07	19.08	 2.56E-04	
GO:0001523~retinoid	metabolic	process	 6	 7.50	 3.20E-06	25.81	 4.68E-03	
GO:0071347~cellular	response	to	
interleukin-1	 5	 6.25	 1.45E-04	18.48	 2.12E-01	
GO:0042593~glucose	homeostasis	 5	 6.25	 5.59E-04	12.99	 8.15E-01	
GO:0042572~retinol	metabolic	process	 4	 5.00	 1.90E-04	34.98	 2.78E-01	
GO:0002548~monocyte	chemotaxis	 4	 5.00	 5.21E-04	24.99	 7.59E-01	
5	
GO:0007155~cell	adhesion	 45	 8.21	 1.48E-12	 3.45	 2.60E-09	
GO:0001525~angiogenesis	 34	 6.20	 5.94E-15	 5.37	 1.04E-11	
GO:0006508~proteolysis	 30	 5.47	 2.28E-04	 2.11	 4.01E-01	
GO:0008285~negative	regulation	of	cell	
proliferation	 25	 4.56	 4.16E-04	 2.22	 7.30E-01	
GO:0007267~cell-cell	signaling	 20	 3.65	 1.21E-04	 2.77	 2.13E-01	
GO:0045766~positive	regulation	of	 17	 3.10	 1.54E-07	 5.20	 2.71E-04	
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angiogenesis	
GO:0070374~positive	regulation	of	ERK1	
and	ERK2	cascade	 16	 2.92	 1.41E-04	 3.22	 2.49E-01	
GO:0016055~Wnt	signaling	pathway	 16	 2.92	 2.93E-04	 3.01	 5.15E-01	
GO:0016525~negative	regulation	of	
angiogenesis	 15	 2.74	 1.50E-09	 8.52	 2.64E-06	
GO:0030335~positive	regulation	of	cell	
migration	 15	 2.74	 7.81E-04	 2.87	 1.37E+00	
8	
GO:0015031~protein	transport	 33	 3.16	 2.13E-03	 1.77	 3.74E+00	
GO:0042384~cilium	assembly	 22	 2.11	 3.28E-07	 3.75	 5.86E-04	
GO:0060271~cilium	morphogenesis	 21	 2.01	 5.99E-06	 3.27	 1.07E-02	
GO:0003341~cilium	movement	 9	 0.86	 2.38E-05	 7.05	 4.24E-02	
GO:0048791~calcium	ion-regulated	
exocytosis	of	neurotransmitter	 8	 0.77	 2.09E-03	 4.34	 3.66E+00	
GO:0036159~inner	dynein	arm	assembly	 7	 0.67	 1.40E-05	11.39	 2.50E-02	
GO:0036158~outer	dynein	arm	assembly	 7	 0.67	 3.77E-05	 9.87	 6.73E-02	
GO:0044458~motile	cilium	assembly	 6	 0.57	 4.69E-04	 8.46	 8.32E-01	
GO:0010039~response	to	iron	ion	 6	 0.57	 1.19E-03	 7.05	 2.10E+00	
10	
GO:0007067~mitotic	nuclear	division	 6	 8.22	 2.53E-03	 6.25	 3.41E+00	
GO:0042787~protein	ubiquitination	
involved	in	ubiquitin-dependent	protein	
catabolic	process	 5	 6.85	 2.76E-03	 8.44	 3.70E+00	
11	
GO:0016032~viral	process	 21	 3.15	 2.25E-03	 2.13	 3.81E+00	
GO:0006397~mRNA	processing	 16	 2.40	 8.73E-04	 2.71	 1.49E+00	
GO:0008380~RNA	splicing	 15	 2.25	 1.21E-03	 2.74	 2.05E+00	
GO:0042787~protein	ubiquitination	
involved	in	ubiquitin-dependent	protein	
catabolic	process	 14	 2.10	 1.66E-03	 2.77	 2.83E+00	
GO:0006461~protein	complex	assembly	 12	 1.80	 1.55E-03	 3.14	 2.64E+00	
12	
GO:0016024~CDP-diacylglycerol	
biosynthetic	process	 5	 0.75	 6.56E-04	11.66	 1.12E+00	
GO:0007165~signal	transduction	 119	 10.36	 2.59E-09	 1.74	 4.77E-06	
GO:0045944~positive	regulation	of	
transcription	from	RNA	polymerase	II	
promoter	 84	 7.31	 5.16E-04	 1.45	 9.45E-01	
GO:0007155~cell	adhesion	 75	 6.53	 1.78E-15	 2.77	 3.26E-12	
GO:0043547~positive	regulation	of	GTPase	
activity	 70	 6.09	 6.27E-09	 2.10	 1.15E-05	
GO:0006468~protein	phosphorylation	 45	 3.92	 8.92E-04	 1.67	 1.63E+00	
GO:0006954~inflammatory	response	 43	 3.74	 6.19E-05	 1.92	 1.14E-01	
GO:0030198~extracellular	matrix	
organization	 42	 3.66	 8.20E-13	 3.63	 1.51E-09	
GO:0006955~immune	response	 42	 3.66	 1.11E-03	 1.69	 2.03E+00	
GO:0001525~angiogenesis	 40	 3.48	 8.41E-10	 3.04	 1.55E-06	
GO:0007156~homophilic	cell	adhesion	via	
plasma	membrane	adhesion	molecules	 34	 2.96	 1.47E-10	 3.65	 2.70E-07	
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13	
GO:0006355~regulation	of	transcription,	
DNA-templated	 458	 16.47	 1.06E-61	 2.09	 2.00E-58	
GO:0000122~negative	regulation	of	
transcription	from	RNA	polymerase	II	
promoter	 148	 5.32	 8.50E-06	 1.41	 1.61E-02	
GO:0045893~positive	regulation	of	
transcription,	DNA-templated	 120	 4.31	 1.10E-07	 1.60	 2.09E-04	
GO:0016567~protein	ubiquitination	 108	 3.88	 6.56E-14	 2.06	 1.24E-10	
GO:0006468~protein	phosphorylation	 101	 3.63	 1.24E-05	 1.52	 2.35E-02	
GO:0015031~protein	transport	 100	 3.60	 2.06E-08	 1.74	 3.88E-05	
GO:0045892~negative	regulation	of	
transcription,	DNA-templated	 97	 3.49	 2.24E-03	 1.33	 4.15E+00	
GO:0016032~viral	process	 83	 2.98	 4.62E-09	 1.90	 8.73E-06	
GO:0051301~cell	division	 80	 2.88	 3.55E-05	 1.57	 6.71E-02	
GO:0006974~cellular	response	to	DNA	
damage	stimulus	 72	 2.59	 9.91E-13	 2.37	 1.87E-09	
14	
GO:0006351~transcription,	DNA-templated	 62	 18.84	 8.35E-07	 1.90	 1.35E-03	
GO:0098609~cell-cell	adhesion	 13	 3.95	 2.05E-03	 2.87	 3.25E+00	
GO:0007254~JNK	cascade	 7	 2.13	 1.56E-04	 8.54	 2.51E-01	
15	
GO:0043547~positive	regulation	of	GTPase	
activity	 16	 7.08	 2.40E-03	 2.44	 3.68E+00	
GO:0006366~transcription	from	RNA	
polymerase	II	promoter	 15	 6.64	 2.60E-03	 2.52	 3.98E+00	
GO:0090630~activation	of	GTPase	activity	 7	 3.10	 3.04E-04	 7.63	 4.73E-01	
GO:1902017~regulation	of	cilium	assembly	 6	 2.65	 6.31E-05	13.96	 9.85E-02	
GO:0031338~regulation	of	vesicle	fusion	 6	 2.65	 1.32E-04	12.02	 2.05E-01	
16	
GO:0006351~transcription,	DNA-templated	 46	 22.44	 4.42E-07	 2.18	 6.80E-04	
GO:0006355~regulation	of	transcription,	
DNA-templated	 30	 14.63	 1.37E-03	 1.85	 2.09E+00	
GO:0035329~hippo	signaling	 4	 1.95	 2.93E-03	13.74	 4.42E+00	
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Gene ontology analysis of NR-centered co-expression gene modules in breast 
cancer showed strong enrichment of functionally coherent ontologies. Possible 
functional roles of NRs in breast cancer based on gene ontology analysis of NR 
co-expressed gene modules are summarized below: 
Module	 Positively	correlated	NRs	
Negatively	
correlated	
NRs	
Functions	
1,2,3	 NR1H3,	ESR2,	NR4A3	 ESR1	 Immune	response	
4	 	PPARG	 		 Oxidation	reduction,	glucose	homeostatis	
5	 NR2F1,	NR5A2,	PPARG	 		
Cell	adhesion,	angiogenesis,	proteolysis,	
cell	proliferation	and	migration	
8	
ESR1,	PGR,	
RARA,	NR2E3,	
AR	
	NR2E1	
cilium	assembly,	morphogenesis	and	
movement	
protein	transport	
10	 NR2C1	 		 mitotic	nuclear	division,	protein	ubiquitination	
11	 NR2C2,	PPARA	 		 mRNA	processing,	RNA	splicing,	protein	ubiquitination	
12	
NR3C1,	RORA,	
NR2F1,	NR5A2,	
NR3C2	
		
Multiple	processes:	signal	transduction,	
cell	adhesion,	angiogenesis,	immune	
response	
13	
NR1D2,	NR2C2,	
NR3C1,	RORA,	
AR,	THRB,	ESR1,	
PGR	
	ESRRA	
Regulation	of	transcription,	protein	
ubiquitination,	cell	division,	cell	cycle,	
DNA	repair,	chromatin	modification	
14	 NR1H2	 		 Transcription,	cell	adhesion,	JNK	cascade	
15	 RXRA	 		 Transcription,	activation	of	GTPase,	cilium	assembly	
16	 RXRB	 		 Transcription,	hippo	signaling	
 
4.2.3 NR-NR	interactions	inferred	through	co-
expression	analysis	
In addition to informing on the possible functions of NRs in the normal breast 
and breast cancer, examining the co-expression profiles of NRs with other 
genes in the genome may help with the identification of relationships or 
crosstalk in the signalling pathways of different NRs. Based on the premise 
that if two NRs are significantly co-expressed with the same set of genes, then 
they are more likely to be functionally related, a simple plot of the percentage 
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of significantly co-expressed genes shared between an NR and other NRs can 
help identify potential functional crosstalk in NR signalling.  
For example, Figure 14 below shows plots of the percentage of genes co-
expressed with ESR1 and PGR respectively that overlap with co-expressed 
genes for other NRs. From these plots it can immediately be seen that 
approximately 50% of ESR1 co-expressed genes are also co-expressed with AR, 
RARA and PGR in breast cancer. Several studies have reported the crosstalk 
between ESR1 and RARA in breast cancer [15, 16]. Likewise, there have been 
studies reporting the inhibitory effect of AR on ESR1 signalling in ER+ breast 
cancer [70, 71]. Figure 14 also suggests that functional crosstalk between PGR 
and ESR1 is much stronger in breast cancer compared to the normal breast as 
evident by the higher percentage of co-expressed genes shared by these two 
nuclear receptors in breast cancer. Our group has recently published data, 
obtained from different datasets independent from the dataset examined here, 
showing that convergence of PGR and ESR1 signalling is only observed in 
breast cancer and that the two receptors are quite functionally distinct in the 
normal breast [187]. The functional distinction of ESR1 and PGR in the normal 
breast is also supported by analysis of the normal breast epithelial cells at 
single cell level, showing that ESR1 is more often expressed in the Luminal cell 
lineage while PGR is observed expressed in the Basal lineage (Section 5.3.3). 
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Figure 14: Co-expression based identification potential functional crosstalk between NRs. Plots 
of the percentage of genes significantly co-expressed with ESR1 and PGR that overlap with co-
expressed genes identified for other NRs in the normal breast and breast cancer. For clarity, 
only NRs sharing more than 25% of ESR1 or PGR co-expressed genes are labelled on these plots. 
 
Similar plots were also obtained for the other NRs (data not shown) as we 
think such a catalogue may be useful in generating novel hypotheses for 
exploring potential functional NR-NR crosstalk in the normal breast and 
breast cancer. 
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4.2.4 Section	summary	
In this section, NR centered co-expression networks were constructed using 
the RNA-seq expression profiles of 106 normal breast and 988 breast cancer 
tissues obtained from the TCGA breast cancer dataset. The aims were to 
identify biological processes potentially governed by NRs in the normal breast 
and breast cancer and to identify potential functional relationships between 
NRs. 
The main observations and findings of this section are summarized below. 
1) NR co-expression networks constructed from bulk expression profiles 
are highly inter-connected in both the normal breast and breast cancer. 
2) Co-expressed gene modules identified from the normal and cancer NR-
centered co-expression networks showed enrichment of functionally 
coherent GO terms. In the cancer NR-centered co-expression network 
in particular, the gene modules identified showed strong enrichment 
for genes involved in the various cancer hallmarks including immune 
response, metabolic processes, cell adhesion and angiogenesis, cell 
cycle and transcriptional control. This result suggests that co-
expression analysis was able to identify NR-associated biological 
processes relevant to breast cancer biology and also provide insights 
into the different groups of NRs that are potentially involved in the 
regulation of these processes. 
3) The NR co-expression networks in breast cancer and normal breast are 
very different, both in terms of the number of genes co-expressed with 
each NR as well as the pattern of shared co-expressed genes between 
NRs. This suggests that there are major re-wirings of the NR regulatory 
networks in breast cancer compared to the normal breast. 
4) Examination of the fraction of shared co-expressed genes between 
different NRs may help in identifying potential functional relationships 
between NRs, as exemplified through the profile generated for ESR1 in 
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Figure 14. Examination of catalogues of profiles generated for other NRs 
may help guide future explorations of novel NR-NR signalling crosstalk.  
4.3 Identification	of	NR	networks	altered	in	
breast	cancer	
The aim of this section is to identify biological processes or pathways 
potentially governed by NRs that are altered during the development and 
progression of breast cancer compared to the normal breast. Towards this aim, 
we applied two differential co-expression analysis approaches as detailed in 
Section 2.7.2. The first approach looks at the compendium of genes that are 
co-expressed with NRs in either the normal breast or breast cancer and 
examines the change in their co-expression with NRs to identify patterns of 
cancer-associated changes in the NR gene networks. The second approach 
focuses on the identification and characterization of gene clusters significantly 
differentially co-expressed with NRs. The subtle difference between the two 
approaches is that the second approach focuses on characterizing gene 
clusters with significant differential co-expression to NRs between normal and 
cancer while the first approach provides an overview of the changes in co-
expression for the compendium of genes co-expressed with NRs. 
4.3.1 Approach	1	
In the first approach, genes significantly co-expressed with at least one NR 
were first detected (Section 4.2.1 and Section 4.2.2) within each sample cohort 
(Normal or Cancer). The list of genes that were identified was combined into a 
compendium of genes potentially involved in NR-related biological processes 
in either the normal breast or breast cancer. The differential co-expression 
profile of these genes to NRs was then analysed with the aims to: 
1) Identify gene modules with coordinated change in co-expression to one
or a group of NRs in breast cancer compared to the normal breast, and
the biological processes associated with these gene modules.
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2) Identify breast cancer associated functional grouping of NRs based on 
the similarity of their differential co-expression profiles with other 
genes in the genome. 
3) Examine the prognostic value of NRs grouped based on differential co-
expression profiles to other genes in the genome (identified in 2) 
4.3.1.1 Identification	and	functional	characterization	of	
gene	modules	based	on	their	differential	co-expression	to	
NRs	in	breast	cancer	compared	to	the	normal	breast.	
A total of 5941 and 8424 genes were identified significantly co-expressed with 
at least one NR in the normal breast and breast cancer respectively. There was 
a total of 9,867 genes in the combined compendium of genes co-expressed 
with NRs in either normal or cancer. Figure 15 shows a clustered heatmap of 
the change in differential co-expression with NRs between normal and cancer 
for these genes. It can be observed that there are very distinct patterns of 
coordinated changes in co-expression with clusters of genes displaying strong 
increases in co-expression with some NRs while having decreased co-
expression with others. For example, genes in gene cluster 1 showed strong 
increases in co-expression (differential co-expression) with the NRs in groups 
2 and 6, and decreased co-expression with NRs in group 7 and PPARA. 
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Figure 15: Cancer associated changes in NR co-expression networks identified by Approach 1. 
Clustered heatmap of differential co-expression profiles of genes co-expressed with NRs in 
either normal breast or breast cancer. NRs are listed across the columns with identifiers in the 
format of  “Gene symbol | Entrez Gene ID”. NR co-expressed genes are in rows. Cell values are 
the differential co-expression measure for each NR-nonNR gene pairs (Cancer versus Normal). 
This differential co-expression matrix was clustered using unsupervised hierarchical clustering 
with Pearson correlation distance measure for the columns and Euclidian distance measure for 
the rows. Gene modules were identified through fixed-height cutting of the hierarchical gene 
tree guided by visual inspection of the differential co-expression profile. Co-expressed gene 
clusters are numbered from 1 – 7 (black numbering next to cluster). NR groups with more than 1 
Identification of co-expressed and differentially co-expressed NR networks in the 
normal breast and breast cancer 
 120 
member are numbered from 1-7 in green. There are 3 NR groups with only 1 member and these 
are referred to using the NR names (HNF4A, NR1D1, PPARA). 
 
To investigate whether genes clustered based on change in co-expression 
profiles to NRs are functionally related, we performed gene ontology over-
representation analysis using DAVID Bioinformatics Resources as described in 
Section 2.8.1.  
Table 8 shows the top 10 biological process gene ontology terms associated 
with each of the 7 gene clusters. It can be observed that the 7 gene clusters 
identified based on patterns of change in co-expression to NRs have quite 
distinct biological functions. Cluster 1 showed enrichment of genes involved in 
oxidation-reduction processes. Cluster 2 showed enrichment of genes involved 
in angiogenesis, cell adhesion and signal transduction and immune response. 
Cluster 3 is enriched with genes involved in various metabolic processes. 
Cluster 4 contains genes involved in mitochondrial electron transport chain. 
Cluster 5 contains genes involved in gene transcription and cell cycle genes. 
Cluster 6 is enriched with genes involved in regulation of transcription, 
protein transport and DNA damage response. Finally, Cluster 7 contains genes 
involved in intracellular protein transport. 
Table 8: Top 10 GO terms associated with each gene cluster in Figure 15. Only modules with 
significantly over-represented functional ontologies are included in this table. Count = numbers 
of co-expressed genes annotated with the term. % = proportion of NR co-expressed genes. P-
value = modified Fisher Exact P-value, also called the EASE score. FE = fold enrichment. FDR = P-
value adjusted for false discovery by the Benjamini-Hochberg procedure. 
		 Term	
Coun
t	 %	 PValue	 FE	 FDR	
1	
GO:0055114~oxidation-reduction	process	 13	 10.48	 6.89E-04	 3.21	 1.02E+00	
GO:0032981~mitochondrial	respiratory	chain	
complex	I	assembly	 5	 4.03	 8.82E-04	 11.59	 1.30E+00	
GO:0006361~transcription	initiation	from	RNA	
polymerase	I	promoter	 4	 3.23	 1.43E-03	 17.70	 2.10E+00	
GO:0035338~long-chain	fatty-acyl-CoA	biosynthetic	
process	 4	 3.23	 2.89E-03	 13.91	 4.19E+00	
2	GO:0007165~signal	transduction	 102	 8.64	 2.71E-04	 1.42	 5.00E-01	GO:0007155~cell	adhesion	 66	 5.59	 2.87E-10	 2.32	 5.32E-07	
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GO:0043547~positive	regulation	of	GTPase	activity	 64	 5.42	 3.86E-06	 1.83	 7.15E-03	
GO:0001525~angiogenesis	 50	 4.23	 3.98E-15	 3.62	 7.41E-12	
GO:0006954~inflammatory	response	 42	 3.56	 3.56E-04	 1.79	 6.57E-01	
GO:0030198~extracellular	matrix	organization	 38	 3.22	 9.43E-10	 3.13	 1.75E-06	
GO:0010628~positive	regulation	of	gene	expression	 31	 2.62	 8.37E-04	 1.91	 1.54E+00	
GO:0007596~blood	coagulation	 24	 2.03	 1.02E-03	 2.11	 1.87E+00	
GO:0006898~receptor-mediated	endocytosis	 24	 2.03	 1.18E-03	 2.08	 2.16E+00	
GO:0002576~platelet	degranulation	 23	 1.95	 2.56E-07	 3.61	 4.74E-04	
3	
GO:0055114~oxidation-reduction	process	 45	 7.17	 1.87E-07	 2.37	 3.27E-04	
GO:0001523~retinoid	metabolic	process	 11	 1.75	 2.14E-05	 5.63	 3.73E-02	
GO:1902600~hydrogen	ion	transmembrane	
transport	 10	 1.59	 1.29E-04	 5.12	 2.25E-01	
GO:0006099~tricarboxylic	acid	cycle	 9	 1.43	 2.46E-06	 9.69	 4.30E-03	
GO:0007584~response	to	nutrient	 9	 1.43	 2.45E-03	 3.80	 4.20E+00	
GO:0042572~retinol	metabolic	process	 8	 1.27	 3.53E-05	 8.32	 6.16E-02	
GO:0006635~fatty	acid	beta-oxidation	 8	 1.27	 4.51E-04	 5.67	 7.84E-01	
GO:0006094~gluconeogenesis	 8	 1.27	 4.51E-04	 5.67	 7.84E-01	
GO:0006120~mitochondrial	electron	transport,	
NADH	to	ubiquinone	 8	 1.27	 8.81E-04	 5.10	 1.53E+00	
GO:0006090~pyruvate	metabolic	process	 7	 1.11	 5.01E-05	 9.93	 8.74E-02	
4	
GO:0006120~mitochondrial	electron	transport,	
NADH	to	ubiquinone	 10	 6.45	 2.04E-10	 24.65	 3.14E-07	
GO:0032981~mitochondrial	respiratory	chain	
complex	I	assembly	 10	 6.45	 2.14E-09	 19.18	 3.28E-06	
GO:0070125~mitochondrial	translational	
elongation	 8	 5.16	 6.29E-06	 11.37	 9.67E-03	
GO:0070126~mitochondrial	translational	
termination	 8	 5.16	 6.80E-06	 11.24	 1.05E-02	
5	
GO:0006351~transcription,	DNA-templated	 484	 12.02	 1.21E-07	 1.23	 2.34E-04	
GO:0006355~regulation	of	transcription,	DNA-
templated	 357	 8.87	 3.02E-04	 1.18	 5.83E-01	
GO:0006364~rRNA	processing	 147	 3.65	 7.58E-53	 3.40	 1.47E-49	
GO:0051301~cell	division	 132	 3.28	 3.91E-14	 1.87	 7.56E-11	
GO:0006412~translation	 120	 2.98	 2.95E-22	 2.35	 5.70E-19	
GO:0000398~mRNA	splicing,	via	spliceosome	 114	 2.83	 9.07E-25	 2.54	 1.75E-21	
GO:0006281~DNA	repair	 107	 2.66	 2.47E-18	 2.26	 4.78E-15	
GO:0007067~mitotic	nuclear	division	 90	 2.24	 5.41E-09	 1.80	 1.05E-05	
GO:0098609~cell-cell	adhesion	 90	 2.24	 5.62E-07	 1.65	 1.09E-03	
GO:0016032~viral	process	 89	 2.21	 7.80E-05	 1.47	 1.51E-01	
6	
GO:0006351~transcription,	DNA-templated	 595	 17.24	 1.58E-54	 1.78	 3.02E-51	
GO:0006355~regulation	of	transcription,	DNA-
templated	 508	 14.72	 2.56E-61	 1.97	 4.89E-58	
GO:0000122~negative	regulation	of	transcription	
from	RNA	polymerase	II	promoter	 158	 4.58	 5.18E-04	 1.28	 9.85E-01	
GO:0045892~negative	regulation	of	transcription,	
DNA-templated	 122	 3.54	 2.42E-05	 1.43	 4.62E-02	
GO:0006357~regulation	of	transcription	from	RNA	
polymerase	II	promoter	 107	 3.10	 1.09E-04	 1.42	 2.08E-01	
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GO:0015031~protein	transport	 104	 3.01	 3.77E-06	 1.54	 7.20E-03	
GO:0016567~protein	ubiquitination	 94	 2.72	 1.45E-05	 1.53	 2.77E-02	
GO:0006974~cellular	response	to	DNA	damage	
stimulus	 60	 1.74	 3.38E-05	 1.69	 6.46E-02	
GO:0060271~cilium	morphogenesis	 57	 1.65	 2.80E-11	 2.45	 5.36E-08	
GO:0042384~cilium	assembly	 56	 1.62	 1.17E-12	 2.64	 2.24E-09	
7	GO:0006886~intracellular	protein	transport	 11	 4.07	 2.16E-03	 3.25	 3.48E+00	
 
The fact that genes clustered based on differential co-expression profiles with 
NRs showed enrichment of relatively distinct biological functions suggests that 
1) There is major re-wiring of the NR gene regulatory network associated 
with the development and progression of breast cancer. 
2) As part of the cancer-associated alterations in the NR gene regulatory 
network, specific biological processes regulated by certain NRs in the 
normal breast become regulated by other NRs in breast cancer. For 
example, the differential co-expression profiles of genes in Cluster 2 
suggest that genes involved in cell adhesion, angiogenesis and immune 
response are likely associated with the NRs of Group 7 in the normal 
breast. However this regulation is disrupted in breast cancer as these 
genes showed a strong decrease in co-expression to NRs of Group 7 
while displaying a strong increase in co-expression with NRs in Group 6 
and 2.  
Furthermore, enrichment of biological functions in the gene clusters of Figure 
15 gives functional significance to the grouping of NRs identified in this figure. 
Here, NRs are grouped based on the coordinated change in their co-expression 
with other genes in the genome. Compared to simply clustering NRs based on 
their expression in breast cancer, this is perhaps a better and more 
functionally relevant grouping of NRs with respect to breast cancer biology. 
4.3.1.2 Prognostic	value	of	network-based	NR	groups	in	
different	breast	cancer	subtypes	
We investigated the usefulness of the netw0rk-based NR groups identified in 
Figure 15 of the previous section (Section 4.3.1.1) as prognostic markers in 
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different breast cancer subtypes. To do this, we treated each NR group as a 
prognostic gene signature and tested their prognostic utility in the breast 
cancer microarray dataset from the METABRIC study [83] (Dataset 3, 
described in Section 2.2.3), which has associated subtype and patient survival 
information.  
The utility of each NR group in predicting patient survival was investigated as 
detailed in Section 2.6.1. Briefly, samples from the METABRIC study were first 
separated into the following cohorts: ER+, ER-, Luminal A, Luminal B, HER2, 
and Basal. Within each cohort, each sample was assigned a risk score 
calculated based on the weighted expressions of the signature genes in that 
sample cohort. The association of the calculated risk score with survival was 
then tested in two ways: 1) Multivariate Cox Regression analysis, adjusting for 
ER status, node status and grade; and 2) Kaplan Meier analysis in which the 
cohort samples were categorized into Low Risk or High Risk groups based on 
the calculated risk scores. 
 
Figure 16: Prognostic value of NR groups identified based on differential co-expression. 
Prognostic value of NR groups identified in Figure 15 in different breast cancer subtypes. 
Heatmap values represent the P-values (adjusted for multiple testing with Benjamini Hochberg) 
of the Cox regression analyses testing of the association of the expression of the NRs in each 
group with disease-specific survival (DSS). The Cox regression analysis was adjusted for node 
status, ER status and grade. Only NR groups with significant association with DSS in at least one 
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breast cancer subtype were included in this heatmap. Grey represents no significant association 
with DSS. 
Figure 16 summarize the result of the Cox regression analyses testing the 
prognostic utility of each NR signature in different breast cancer subgroups. 
The majority of NR groups showed a significant association with DSS in ER+ 
breast cancers. However, only NR group 6 showed significant association with 
DSS in ER- breast cancer. NR group 6 also stands out because it showed 
stronger association with DSS in ER-, HER2 and Basal subgroups compared to 
ER+ or Luminal A subgroups of breast cancer.  Kaplan Meier analysis also 
showed that expression of the NRs in group 6 can better segregate samples 
into Low Risk and High Risk in ER-, Her2 and Basal breast cancers compared 
to ER+, Luminal A or Luminal B cancers (Figure 17).  
 
Figure 17: Kaplan Meier analysis of Group 6 NRs. Kaplan Meier plots of the prognostic value of 
Group 6 NRs in different breast cancer subtypes 
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As mentioned in Section 1.3.2.3, it has been reported that the majority of 
published breast cancer gene signatures have good prognostic utility in ER+ 
breast cancer but perform poorly in ER- breast cancers [108]. Due to the 
pervasive influence of proliferation on gene expression, it is believed that the 
majority of current breast cancer prognostic gene signature mainly reflect the 
effect of proliferation, which is known to be the strongest predictor of 
outcome in ER+ breast cancers [111].  
In that context, the identification of a subgroup of NRs that has better 
prognostic utility in ER- compared to ER+ breast cancer is encouraging and 
provides support for the network approach of prognostic gene identification.  
Here, in addition to helping identifying NRs with prognostic value in ER-, 
HER2 and Basal breast cancers, differential co-expression analysis can also 
help with inferring the potential biological processes that these NRs may be 
involved in. For example, it can be inferred from Figure 15 that NRs in Group 6 
are less likely to regulate proliferation and more likely to be involved in other 
aspects of breast cancer biology. This is because NRs in Group 6 showed 
decreased co-expression with genes involved in cell cycle regulation (Figure 15, 
gene module 5) and increased co-expression with genes involved in metabolic 
processes, cell adhesion and angiogenesis (Figure 15, gene modules 1, 2 and 3).  
4.3.2 Approach	2	
In this approach, instead of establishing that co-expression is significant in one 
condition but not the other, the method described in Section 2.7.2.2 was 
applied to directly test for significant changes in pairwise gene correlations 
between cancer and normal. This process identified 6590 genes that showed 
significant differential co-expression with NRs. All of these 6590 genes are 
among the compendium of genes identified as co-expressed with NRs in either 
the normal breast or breast cancer using Approach 1 (Section 4.3.1), i.e. these 
6590 genes are part of the 9,867 genes in the heatmap of Figure 15. 
Examination of the distribution of differential co-expression measures for the 
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significant vs non-significant gene-pairs (Figure 18) showed that the 
differential co-expression values of significantly co-expressed gene pairs (blue 
line) are distributed at the two extreme ends of the range. In other words, 
genes identified as significantly differentially co-expressed by Approach 2 are 
genes that have the strongest change in co-expression to NRs between Cancer 
and Normal. 
 
Figure 18: Distribution of differential co-expression values for significant (blue) and non-
significant (red) differentially co-expressed gene pairs identified in Approach 2. 
Significantly differentially co-expressed gene modules were identified through 
hierarchical clustering of the differential co-expression profiles of these genes 
with NRs and cutting of the clustered gene tree at a fixed height guided by 
visual inspection of the differential expression profiles (Figure 19).  
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Figure 19: Cancer associated changes in NR co-expression network identified by Approach 2. 
Clustered heatmap of significantly differentially co-expressed NR-nonNR gene pairs. NRs are 
listed across the columns with identifiers in the format of  “Gene symbol | Entrez Gene ID”. 
Genes significantly differentially co-expressed with NRs are in rows. Cell values are the 
differential co-expression value for each NR-nonNR gene pairs that are significantly co-
expressed. Only NRs with at least 20 significantly co-expressed genes are included in this 
heatmap. Grey indicates absence of significant co-expression. Gene modules were identified 
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through fixed-height cutting of the hierarchical gene tree guided by visual inspection of the 
differential expression profile.  
Table 9 shows the top ten Biological Processes GO terms associated with each 
of the identified differentially co-expressed gene modules. 
Table 9: Top 10 GO terms enriched in gene clusters identified in Figure 19. Only modules with 
significantly over-represented functional ontologies are included in this table. Count = numbers 
of co-expressed genes annotated with the term. % = proportion of NR co-expressed genes. P-
value = modified Fisher Exact P-value, also called the EASE score. FE = fold enrichment. FDR = P-
value adjusted for false discovery by the Benjamini-Hochberg procedure. 
		 Term	 Count	 %	 PValue	 FE	 FDR	
1	
GO:0007155~cell	adhesion	 60	 7.72	 6.51E-15	 3.16	 1.19E-11	
GO:0043547~positive	regulation	of	GTPase	
activity	 42	 5.41	 3.13E-04	 1.81	 5.64E-01	
GO:0030198~extracellular	matrix	
organization	 38	 4.89	 5.59E-15	 4.70	 1.00E-11	
GO:0001525~angiogenesis	 38	 4.89	 4.85E-13	 4.10	 8.78E-10	
GO:0008285~negative	regulation	of	cell	
proliferation	 35	 4.50	 8.39E-05	 2.08	 1.52E-01	
GO:0008284~positive	regulation	of	cell	
proliferation	 35	 4.50	 1.60E-03	 1.77	 2.85E+00	
GO:0001666~response	to	hypoxia	 24	 3.09	 5.62E-06	 2.99	 1.02E-02	
GO:0007507~heart	development	 21	 2.70	 1.06E-04	 2.70	 1.92E-01	
GO:0022617~extracellular	matrix	
disassembly	 19	 2.45	 1.23E-09	 6.06	 2.23E-06	
GO:0030335~positive	regulation	of	cell	
migration	 19	 2.45	 7.77E-04	 2.45	 1.40E+00	
2	
GO:0006955~immune	response	 35	 13.57	 2.39E-17	 6.19	 3.99E-14	
GO:0006954~inflammatory	response	 31	 12.02	 5.80E-15	 6.01	 9.66E-12	
GO:0043547~positive	regulation	of	GTPase	
activity	 25	 9.69	 6.17E-07	 3.29	 1.03E-03	
GO:0045087~innate	immune	response	 24	 9.30	 2.06E-08	 4.12	 3.44E-05	
GO:0007155~cell	adhesion	 16	 6.20	 1.40E-03	 2.58	 2.32E+00	
GO:0008285~negative	regulation	of	cell	
proliferation	 15	 5.81	 1.28E-03	 2.72	 2.12E+00	
GO:0007166~cell	surface	receptor	signaling	
pathway	 14	 5.43	 9.32E-05	 3.77	 1.56E-01	
GO:0002250~adaptive	immune	response	 13	 5.04	 5.91E-07	 6.66	 9.88E-04	
GO:0050776~regulation	of	immune	response	 13	 5.04	 1.59E-06	 6.07	 2.65E-03	
GO:0018108~peptidyl-tyrosine	
phosphorylation	 12	 4.65	 7.36E-06	 5.79	 1.23E-02	
3	
GO:0007165~signal	transduction	 51	 10.30	 2.44E-04	 1.70	 4.22E-01	
GO:0006954~inflammatory	response	 23	 4.65	 4.02E-04	 2.33	 6.95E-01	
GO:0050900~leukocyte	migration	 15	 3.03	 3.40E-06	 4.73	 5.89E-03	
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GO:0007200~phospholipase	C-activating	G-
protein	coupled	receptor	signaling	pathway	 12	 2.42	 1.18E-06	 6.84	 2.05E-03	
GO:0008360~regulation	of	cell	shape	 12	 2.42	 9.43E-04	 3.35	 1.62E+00	
GO:0019886~antigen	processing	and	
presentation	of	exogenous	peptide	antigen	
via	MHC	class	II	 9	 1.82	 2.55E-03	 3.79	 4.32E+00	
4	
GO:0007155~cell	adhesion	 16	 11.85	 3.18E-07	 5.26	 4.97E-04	
GO:0006508~proteolysis	 13	 9.63	 7.52E-05	 4.08	 1.17E-01	
GO:0001525~angiogenesis	 11	 8.15	 2.23E-06	 7.39	 3.49E-03	
GO:0007229~integrin-mediated	signaling	
pathway	 10	 7.41	 1.69E-08	 15.28	 2.65E-05	
GO:0030198~extracellular	matrix	
organization	 10	 7.41	 5.64E-06	 7.72	 8.81E-03	
GO:0002576~platelet	degranulation	 8	 5.93	 5.05E-06	 11.75	 7.90E-03	
GO:0032355~response	to	estradiol	 8	 5.93	 1.72E-05	 9.76	 2.68E-02	
GO:0007156~homophilic	cell	adhesion	via	
plasma	membrane	adhesion	molecules	 7	 5.19	 6.05E-04	 6.70	 9.41E-01	
GO:0001666~response	to	hypoxia	 7	 5.19	 1.79E-03	 5.43	 2.76E+00	
GO:0045766~positive	regulation	of	
angiogenesis	 6	 4.44	 9.93E-04	 7.82	 1.54E+00	
6	
GO:0055114~oxidation-reduction	process	 30	 6.29	 1.71E-04	 2.14	 2.92E-01	
GO:0016567~protein	ubiquitination	 20	 4.19	 9.53E-04	 2.35	 1.62E+00	
GO:0006886~intracellular	protein	transport	 16	 3.35	 5.17E-04	 2.86	 8.79E-01	
GO:0006635~fatty	acid	beta-oxidation	 8	 1.68	 7.07E-05	 7.67	 1.21E-01	
GO:0042594~response	to	starvation	 7	 1.47	 4.90E-04	 6.87	 8.33E-01	
GO:0019915~lipid	storage	 5	 1.05	 2.25E-03	 8.79	 3.77E+00	
GO:0008593~regulation	of	Notch	signaling	
pathway	 4	 0.84	 1.39E-03	 16.87	 2.35E+00	
8	
GO:0048010~vascular	endothelial	growth	
factor	receptor	signaling	pathway	 8	 3.70	 1.57E-05	 9.87	 2.51E-02	
GO:2000114~regulation	of	establishment	of	
cell	polarity	 4	 1.85	 8.37E-04	 20.90	 1.33E+00	
GO:0051893~regulation	of	focal	adhesion	
assembly	 4	 1.85	 8.37E-04	 20.90	 1.33E+00	
9	
GO:0006355~regulation	of	transcription,	
DNA-templated	 46	 21.20	 2.66E-09	 2.61	 4.16E-06	
GO:0006351~transcription,	DNA-templated	 44	 20.28	 2.37E-05	 1.93	 3.70E-02	
GO:0006468~protein	phosphorylation	 18	 8.29	 2.52E-05	 3.37	 3.93E-02	
GO:0006366~transcription	from	RNA	
polymerase	II	promoter	 15	 6.91	 2.93E-03	 2.48	 4.48E+00	
GO:0016567~protein	ubiquitination	 13	 5.99	 1.04E-03	 3.10	 1.61E+00	
GO:0006886~intracellular	protein	transport	 10	 4.61	 1.79E-03	 3.63	 2.76E+00	
GO:0042787~protein	ubiquitination	involved	
in	ubiquitin-dependent	protein	catabolic	
process	 8	 3.69	 2.09E-03	 4.48	 3.21E+00	
GO:0006661~phosphatidylinositol	
biosynthetic	process	 6	 2.76	 5.59E-04	 8.86	 8.69E-01	
GO:1990090~cellular	response	to	nerve	
growth	factor	stimulus	 5	 2.30	 6.23E-04	 12.60	 9.69E-01	
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GO:0030574~collagen	catabolic	process	 4	 8.00	 4.38E-04	 26.23	 5.93E-01	
GO:0022617~extracellular	matrix	
disassembly	 4	 8.00	 7.25E-04	 22.09	 9.80E-01	
11	
GO:0007165~signal	transduction	 21	 16.15	 5.28E-05	 2.76	 8.07E-02	
GO:0006955~immune	response	 16	 12.31	 8.72E-08	 5.81	 1.33E-04	
GO:0050852~T	cell	receptor	signaling	
pathway	 11	 8.46	 4.51E-08	 11.27	 6.90E-05	
GO:0006954~inflammatory	response	 11	 8.46	 1.95E-04	 4.38	 2.98E-01	
GO:0045087~innate	immune	response	 11	 8.46	 5.15E-04	 3.88	 7.85E-01	
GO:0060333~interferon-gamma-mediated	
signaling	pathway	 9	 6.92	 1.85E-08	 19.34	 2.82E-05	
GO:0051092~positive	regulation	of	NF-
kappaB	transcription	factor	activity	 9	 6.92	 2.58E-06	 10.25	 3.95E-03	
GO:0043123~positive	regulation	of	I-kappaB	
kinase/NF-kappaB	signaling	 9	 6.92	 1.01E-05	 8.53	 1.54E-02	
GO:0051607~defense	response	to	virus	 9	 6.92	 1.20E-05	 8.32	 1.84E-02	
GO:0051056~regulation	of	small	GTPase	
mediated	signal	transduction	 6	 4.62	 1.81E-03	 6.83	 2.73E+00	
12	
GO:0007165~signal	transduction	 63	 13.88	 4.79E-10	 2.34	 8.14E-07	
GO:0006955~immune	response	 48	 10.57	 1.64E-19	 4.93	 2.79E-16	
GO:0002250~adaptive	immune	response	 37	 8.15	 3.59E-27	 11.01	 6.10E-24	
GO:0006954~inflammatory	response	 33	 7.27	 3.59E-10	 3.72	 6.10E-07	
GO:0045087~innate	immune	response	 33	 7.27	 7.49E-09	 3.29	 1.27E-05	
GO:0043547~positive	regulation	of	GTPase	
activity	 29	 6.39	 1.28E-04	 2.22	 2.17E-01	
GO:0007166~cell	surface	receptor	signaling	
pathway	 27	 5.95	 1.37E-09	 4.22	 2.34E-06	
GO:0050776~regulation	of	immune	response	 25	 5.51	 2.72E-13	 6.79	 4.62E-10	
GO:0007155~cell	adhesion	 24	 5.29	 4.62E-04	 2.25	 7.83E-01	
GO:0035556~intracellular	signal	transduction	 23	 5.07	 2.22E-04	 2.43	 3.77E-01	
13	
GO:0006974~cellular	response	to	DNA	
damage	stimulus	 9	 4.92	 1.27E-03	 4.26	 2.00E+00	
GO:0034162~toll-like	receptor	9	signaling	
pathway	 4	 2.19	 4.10E-04	 26.49	 6.48E-01	
14	
GO:0006406~mRNA	export	from	nucleus	 8	 2.75	 9.49E-04	 5.13	 1.56E+00	
GO:0016925~protein	sumoylation	 8	 2.75	 2.24E-03	 4.42	 3.65E+00	
GO:0006950~response	to	stress	 6	 2.06	 2.75E-03	 6.20	 4.46E+00	
16	
GO:0007156~homophilic	cell	adhesion	via	
plasma	membrane	adhesion	molecules	 8	 3.81	 1.45E-03	 4.78	 2.22E+00	
GO:0060078~regulation	of	postsynaptic	
membrane	potential	 4	 1.90	 1.53E-03	 17.15	 2.35E+00	
GO:0009954~proximal/distal	pattern	
formation	 4	 1.90	 1.98E-03	 15.72	 3.03E+00	
GO:0019228~neuronal	action	potential	 4	 1.90	 3.11E-03	 13.47	 4.72E+00	
18	
GO:0006351~transcription,	DNA-templated	 221	 18.13	 1.09E-21	 1.88	 1.97E-18	
GO:0006355~regulation	of	transcription,	
DNA-templated	 185	 15.18	 1.17E-21	 2.03	 2.12E-18	
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GO:0045892~negative	regulation	of	
transcription,	DNA-templated	 54	 4.43	 4.09E-05	 1.80	 7.40E-02	
GO:0000398~mRNA	splicing,	via	spliceosome	 28	 2.30	 3.96E-04	 2.09	 7.14E-01	
GO:0042384~cilium	assembly	 19	 1.56	 8.68E-04	 2.41	 1.56E+00	
GO:0006396~RNA	processing	 15	 1.23	 2.38E-03	 2.51	 4.23E+00	
GO:0090503~RNA	phosphodiester	bond	
hydrolysis,	exonucleolytic	 11	 0.90	 1.97E-06	 6.76	 3.58E-03	
19	
GO:0006351~transcription,	DNA-templated	 157	 20.00	 1.55E-19	 2.06	 2.68E-16	
GO:0006355~regulation	of	transcription,	
DNA-templated	 133	 16.94	 1.22E-19	 2.26	 2.12E-16	
GO:0016567~protein	ubiquitination	 28	 3.57	 8.63E-04	 2.00	 1.48E+00	
GO:0009791~post-embryonic	development	 10	 1.27	 2.23E-03	 3.47	 3.80E+00	
GO:0031297~replication	fork	processing	 6	 0.76	 2.92E-03	 5.92	 4.94E+00	
It can be observed from Table 9 that several of the significantly differentially 
co-expressed gene modules identified using Approach 2 showed strong 
enrichment for cell adhesion, immune response and transcriptional regulation. 
Genes involved in metabolic processes and cell cycle regulation are not as 
strongly enriched as observed in Approach 1. This suggests that co-expression 
between NRs and cell adhesion and immune-related genes are the most 
strongly changed in breast cancer while genes regulating metabolic processes 
showed moderate changes in co-expression to NRs.  
4.3.3 Section	summary	
This section uses two different approaches to investigate NR co-expression 
networks that are altered in breast cancer compared to the normal breast.  
NR-coexpressed genes can be clustered into different gene modules enriched 
with coherent GO terms based on the change in their co-expression with NRs. 
This suggests that 1) there exists functional compartmentalization of the NR 
regulatory network where specific groups of NRs are responsible for regulating 
specific biological processes; and 2) there are coordinated changes in the NR 
regulatory network associated with breast cancer in which genes involved in 
specific biological processes lose co-expression with a group of NRs and gain 
co-expression with another group of NRs. 
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The identification of a subgroup of NRs that have better prognostic utility in 
ER- compared to ER+ breast cancer highlights the utility of differential co-
expression analysis in the identification of prognostic gene signatures that 
capture aspects of breast cancer biology other than proliferation. The 
advantage of this approach is that in addition to identifying prognostic NR 
gene signatures, it also allows investigators to generate new hypotheses about 
the biological processes that these NRs might be involved in. 
The results obtained for the 2 different approaches to differential co-
expression analysis suggest that the 2 approaches are complementary. While 
Approach 1 captures the overall changes to the NR co-expression networks in 
cancer and give insights into the different biological processes associated with 
NR biology that are rewired in breast cancer, Approach 2 helps identify the 
genes and biological processes that showed the strongest change in co-
expression with NRs. 
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5.1 Overview	
The normal breast epithelium is composed of ducts and lobules, lined by 
secretory luminal cells and surrounded by contractile myoepithelial cells 
(Figure 20A). The exact hierarchy of human breast epithelial cell 
differentiation is not known but the commonly accepted model is that both 
luminal and myoepithelial cells arise from a common stem cell, which gives 
rise to bipotent progenitors that differentiate into committed progenitor cells 
for either the luminal or myoepithelial lineages [188] (Figure 20B). It is 
thought that these distinct types of breast epithelial cells may possibly serve as 
the different cell of origin for different breast cancer subtypes [189]. Therefore, 
an understanding of the normal breast epithelial cell populations and the 
pathways involved in defining cell lineages are not only important for 
understanding normal breast development but may also help in the 
identification of biomarkers and therapeutic targets for breast cancer. 
However, much of the current understanding of the mammary epithelial 
hierarchy is derived from mouse models. Furthermore, many cell types have 
few if any reliable markers that can be used to select for purified cell 
populations to be studied, hence much of the current data are based on 
measurements in bulk cell populations that may not be pure. To date, the 
exact number of intermediate cell types is not known and there is limited 
knowledge regarding the pathways that regulate self-renewal and 
differentiation.  
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Figure 20:  Normal breast epithelial cell lineages. (A) Schematic representations of cells of a 
human duct. (B) Schematic model of the human breast epithelial hierarchy and potential 
relationships with breast tumour subtypes. Source: Jane E. Visvader Genes Dev. 2009;23:2563-2577 
[188]. 
Single cell RNA-sequencing allows the profiling of every gene in the genome 
across a large number of individual cells in a single experiment. Single cell 
profiling experiments can be performed on a mixed population of cells without 
having to experimentally separate cell types based on markers. As such, single 
cell profiling allows unbiased identification and classification of cell types and 
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states. Furthermore, single cell measurements preserve information that is lost 
in bulk measurements, as discussed and illustrated in a review by Trapnell 
[190]. Briefly, one of the undesired effects of bulk measurement can be 
described by Simpson’s paradox, in which a trend might be observed in 
different groups of data but disappear or be reversed when these groups are 
combined (Figure 21A). Another undesired effect of bulk measurements is that 
they confound changes due to gene regulation with those due to shifts in cell 
type composition (Figure 21B). Finally, most cell populations are not 
synchronized, therefore sampling of a cell population at any given time will 
often result in a mixture of cells in different states of the cell cycle or 
differentiation stage. Bulk measurement averaging of these cell populations 
through time-series experiments might yield a qualitatively misleading picture 
(Figure 21C). Single cell profiling allows us to overcome these constraints, 
allowing more accurate identification of cell types and states and paving the 
way for the elucidation of cellular intermediates in the mammary epithelial 
cell hierarchy and the molecular pathways that characterize and govern self-
renewal and differentiation of these cell types. 
 
Figure 21: Comparison of single-cell and bulk measurements. Single-cell measurements preserve 
crucial information that is lost by bulk genomics assays. (A) Simpson's Paradox describes the 
misleading effects that arise when averaging signals from multiple individuals. (B) Bulk 
measurements cannot distinguish changes due to gene regulation from those that arise due to 
shifts in the ratio of different cell types in a mixed sample. (C) Time series experiments are 
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affected by averaging when cells proceed through a biological process in an unsynchronized 
manner. A single time point may contain cells from different stages in the process, obscuring 
the dynamics of relevant genes. Image from [190]. 
In this section, expression profiles of 126 epithelial breast cells from 3D 
cultures of two individual primary normal breast tissues were obtained 
through single-cell RNA-sequencing. Cells are classified into different lineages 
and the expression and co-expression networks of NRs in the different cell 
lineages are characterized.  
5.2 Aims	
Aim 1: To characterize cell types from primary normal breast and classify the 
cell pool into different populations representing the distinct lineage groups of 
the normal breast epithelium. 
Aim 2: To characterize nuclear receptor expression in different breast cell 
lineages at single cell level. 
Aim 3: To identify genes co-expressed with individual or groups of NRs in the 
different normal breast cell lineages. 
5.3 Results	
Single cells obtained from primary culture of epithelial organoids from two 
individual normal breast samples, namely SCA1 and SCA2, were profiled by 
single-cell RNA-sequencing using the methods described in Section 2.4. A 
total of 126 cells were sequenced at single cell level. The originating sample 
and treatment of these 126 cells are tabulated in Table 5. Bioinformatics 
processing of single-cell RNA-sequencing data were performed as described in 
Section 2.4.2. 
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5.3.1 Descriptive	analysis	of	the	single	cell	population	
under	studied	
The following figures describe the number and expression levels of genes 
expressed in the 126 cells.  
After filtering out genes with mean expression less than 1 as described in 
Section 2.4.2, a total of 16,788 genes were expressed in this population of cells 
at a mean expression greater than or equal to 1. These genes were used in 
subsequent analyses. The number of genes observed expressed in a given cell 
ranges between ~6,000 and ~10,000 genes (Figure 22). 
 
Figure 22: Number of genes expressed in each of the 126 cells. The number of genes expressed in 
individual cell vary and ranges between ~6,000 and ~10,000 genes. 
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Figure 23 show a plot of the number of genes expressed against the number of 
cells. Of the 16,788 expressed genes, ~ 3000 were expressed in 10 cells or less 
and 173 genes were expressed in only 1 cell. 1058 genes were ubiquitously 
expressed in all 126 cells. Figure 24 shows the same data plotted cumulatively. 
 
Figure 23: Number of genes expressed plotted against the number of cells. 173 genes are uniquely 
expressed in only 1 cell and 1058 genes are ubiquitously expressed in all 126 cells. 
 
Figure 24: Decremental number of genes against number of cells plot. 
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Figure 25 plots the fraction of total genes that are expressed against the 
number of cells and shows that a large fraction of genes are expressed in small 
numbers of cells (40% of genes are expressed in 50% cells or less). Figure 26 
shows that in general, genes expressed in a small number of cells are expressed 
at a lower level in those cells compared to genes that are expressed more 
widely. 
 
Figure 25: Quantiles of the number of cells genes are expressed in showing that 40% of genes are 
expressed in ~50% of cells or less. 
 
Figure 26:  Boxplot of expression level of genes categorized by the number of cells in which 
genes are expressed. The boxes mark the inter-quartile range (IQR), Black dots represent 
outliers (defined as those less than Q1 – 1.5*IQR or greater than Q3 + 1.5IQR, where Q1 and Q3 are 
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the first and third quartile respectively). Lines extend to the first data point before the outlier 
cut-offs. 
5.3.2 Classification	of	cell	types	
We applied the method described in Section 2.4 to identify and classify cells 
into different lineages. Briefly, the method described in [166] was applied to 
account for technical noise and select genes most likely to have true biological 
variability across the cell population. This process resulted in 6,432 genes. The 
expression levels of these 6,432 genes were used in a Principal Component 
Analysis and the top 5% of genes contributing the most to the variability 
observed in each of the first four principal components (total of 1,114 genes) 
were selected as potential biomarkers. Unsupervised hierarchical clustering of 
these 1,114 genes showed clustering of cells into 3 broad groups that displayed 
differential expression for markers often used to distinguish progenitor, 
luminal and basal epithelial cell types of the breast (Figure 27). The first cell 
type (Group P), consists of 14 cells characterized by the high expression of 
genes in Cluster C4 that are involved in epithelial to mesenchymal transition, 
cell adhesion, angiogenesis and negative regulation of apoptosis based on gene 
set enrichment and DAVID ontology over-representation analysis. These cells 
also show strong expression of PROCR, VIM and NOTCH2 genes. Based on 
their gene expression profile, this group of cells is consistent with a 
stem/progenitor group. The second cell type (refered to as Basal in Figure 27) 
consists of 56 cells with high expression of genes in the C6 gene cluster - which 
includes basal markers such as KRT14, TP63 and CD10. However, these cells 
also show high expression of PROCR which has been associated with 
progenitor cells [191]. These cells are possibly a mix of basal and progenitor 
cells. Finally, the third cell type (referred to as Luminal in Figure 27), consists 
of 56 cells characterized by low/absent expression of basal markers while 
having high expression of genes in cluster C3 which contains known luminal 
markers including KRT18, KRT19, MUC1 and CD24. Furthermore, within each 
of the luminal and basal groups, cells showed further clustering into separate 
sub-groups based on the expression of genes in cluster C1, which 
predominantly contains genes that are involved in cell cycle and DNA repair.  
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Figure 27: Classification of breast epithelial cells into different cell lineages. 
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Table 10 shows the top biological processes over-represented in each of the 
gene clusters C1-C6 (P-value < 0.05 and FDR < 5%). 
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Table 10: Top 5 biological processes over-represented in gene cluster C1-C6. Count = numbers of 
co-expressed genes annotated with the term. % = proportion of NR co-expressed genes. P-value 
= modified Fisher Exact P-value, also called the EASE score. FE = fold enrichment. FDR = P-value 
adjusted for false discovery by the Benjamini-Hochberg procedure. 
Gene	
Cluster	 GO	Term	(Biological	process)	 Count	 %	 PValue	
Fold	
Enrich
-ment	
FDR	
C1	
GO:0051301~cell	division	 49	 11.53	 3.28E-23	 5.88	 5.60E-20	
GO:0007067~mitotic	nuclear	
division	 40	 9.41	 7.10E-21	 6.65	 1.21E-17	
GO:0006260~DNA	replication	 32	 7.53	 8.30E-20	 8.42	 1.42E-16	
GO:0007062~sister	chromatid	
cohesion	 26	 6.12	 1.13E-18	 10.59	 1.92E-15	
GO:0000082~G1/S	transition	of	
mitotic	cell	cycle	 25	 5.88	 1.55E-17	 10.18	 2.65E-14	
C2	 GO:0008543~fibroblast	growth	factor	receptor	signaling	pathway	 5	 3.62	 3.28E-03	 8.12	 4.86E+00	
C3	
GO:0016266~O-glycan	processing	 6	 3.13	 3.40E-04	 9.87	 5.39E-01	
GO:0016338~calcium-
independent	cell-cell	adhesion	via	
plasma	membrane	cell-adhesion	
molecules	
4	 2.08	 1.17E-03	 18.81	 1.84E+00	
GO:0007157~heterophilic	cell-cell	
adhesion	via	plasma	membrane	
cell	adhesion	molecules	
5	 2.60	 1.71E-03	 9.68	 2.69E+00	
GO:0050715~positive	regulation	
of	cytokine	secretion	 4	 2.08	 1.96E-03	 15.80	 3.07E+00	
GO:0007605~sensory	perception	
of	sound	 7	 3.65	 2.37E-03	 5.16	 3.69E+00	
C4	
GO:0030198~extracellular	matrix	
organization	 10	 10.87	 8.65E-07	 9.62	 1.34E-03	
GO:0043066~negative	regulation	
of	apoptotic	process	 12	 13.04	 3.13E-05	 4.86	 4.82E-02	
GO:0007596~blood	coagulation	 8	 8.70	 5.27E-05	 8.16	 8.13E-02	
GO:0071230~cellular	response	to	
amino	acid	stimulus	 5	 5.43	 1.46E-04	 18.49	 2.25E-01	
GO:0001525~angiogenesis	 8	 8.70	 1.79E-04	 6.71	 2.76E-01	
C5	 GO:0016236~macroautophagy	 4	 7.02	 1.50E-03	 17.32	 2.11E+00	
C6	
GO:0030198~extracellular	matrix	
organization	 18	 9.14	 4.04E-11	 8.47	 6.62E-08	
GO:0007155~cell	adhesion	 24	 12.18	 9.46E-10	 4.81	 1.55E-06	
GO:0007160~cell-matrix	adhesion	 9	 4.57	 6.73E-06	 9.02	 1.10E-02	
GO:0010951~negative	regulation	
of	endopeptidase	activity	 9	 4.57	 4.99E-05	 6.86	 8.17E-02	
GO:0030574~collagen	catabolic	
process	 7	 3.55	 6.46E-05	 10.09	 1.06E-01	
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5.3.3 Characterization	of	NR	expression	in	normal	
breast	cell	lineages	
Of the 48 human NRs, 34 were expressed in this population of breast epithelial 
cells at a mean read count of 1 or more. Table 11 lists the mean expression and 
distribution (as fraction of cells with expression) of the 34 NRs found to be 
expressed. 
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Table 11: Expression of 34 NRs in breast epithelial cells. 
 
The number of NRs expressed in a cell ranged from 8 to 23 NRs (Figure 28) 
and there was no significant difference in the number of NRs expressed per 
cell in each of the three cell lineages (Figure 29) as determined by TukeyHSD 
test. 
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7376	 NR1H2	 120	 5.35	 5.43	 5.26	 5.38	 0.95	 0.96	 0.96	 0.86	
2908	 NR3C1	 113	 4.34	 3.46	 5	 5.22	 0.9	 0.91	 0.89	 0.86	
5916	 RARG	 108	 4.43	 4.96	 4.64	 1.41	 0.86	 0.84	 0.91	 0.71	
7421	 VDR	 104	 3.89	 3.83	 4.08	 3.35	 0.83	 0.82	 0.86	 0.71	
5914	 RARA	 90	 2.82	 2.91	 2.66	 3.07	 0.71	 0.75	 0.71	 0.57	
7181	 NR2C1	 89	 2.92	 2.78	 3.38	 1.67	 0.71	 0.66	 0.77	 0.64	
2063	 NR2F6	 84	 2.93	 3.25	 2.28	 4.24	 0.67	 0.7	 0.63	 0.71	
6257	 RXRB	 79	 2.06	 2.02	 2.09	 2.12	 0.63	 0.64	 0.63	 0.57	
7068	 THRB	 78	 2.24	 1.71	 2.92	 1.68	 0.62	 0.5	 0.75	 0.57	
7026	 NR2F2	 75	 2.29	 2.69	 1.31	 4.55	 0.6	 0.71	 0.41	 0.86	
5467	 PPARD	 74	 2.24	 2.06	 2.39	 2.31	 0.59	 0.57	 0.59	 0.64	
3164	 NR4A1	 65	 1.69	 2.64	 0.32	 3.39	 0.52	 0.71	 0.27	 0.71	
9572	 NR1D1	 60	 1.8	 1.35	 2.21	 1.93	 0.48	 0.39	 0.55	 0.5	
4929	 NR4A2	 60	 1.74	 1.85	 1.1	 3.86	 0.48	 0.45	 0.41	 0.86	
6095	 RORA	 59	 1.81	 1.5	 1.22	 5.39	 0.47	 0.41	 0.41	 0.93	
2099	 ESR1	 52	 1.37	 2.7	 0.34	 0.15	 0.41	 0.63	 0.27	 0.14	
2101	 ESRRA	 52	 1.58	 1.54	 1.85	 0.67	 0.41	 0.43	 0.46	 0.14	
9975	 NR1D2	 50	 1.47	 1.82	 1.27	 0.85	 0.4	 0.5	 0.36	 0.14	
5465	 PPARA	 47	 1.23	 1.65	 0.91	 0.84	 0.37	 0.45	 0.29	 0.43	
5915	 RARB	 46	 1.29	 0.2	 2.35	 1.38	 0.37	 0.18	 0.54	 0.43	
6256	 RXRA	 45	 0.99	 0.45	 1.62	 0.63	 0.36	 0.18	 0.57	 0.21	
10062	 NR1H3	 41	 1.04	 1.24	 1.01	 0.4	 0.33	 0.38	 0.34	 0.07	
7182	 NR2C2	 41	 0.9	 0.99	 1.02	 0.07	 0.33	 0.36	 0.36	 0.07	
5241	 PGR	 38	 0.97	 0.27	 1.63	 1.17	 0.3	 0.18	 0.45	 0.21	
2649	 NR6A1	 34	 0.93	 1.1	 0.76	 0.92	 0.27	 0.29	 0.25	 0.29	
2104	 ESRRG	 33	 0.93	 1.74	 0.35	 0.02	 0.26	 0.38	 0.2	 0.07	
7067	 THRA	 31	 0.74	 0.46	 0.64	 2.26	 0.25	 0.14	 0.29	 0.5	
6097	 RORC	 29	 0.83	 1.52	 0.31	 0.16	 0.23	 0.34	 0.09	 0.36	
5468	 PPARG	 27	 0.6	 0.21	 0.08	 4.27	 0.21	 0.21	 0.11	 0.64	
367	 AR	 11	 0.32	 0.17	 0.08	 1.88	 0.09	 0.05	 0.04	 0.43	
4306	 NR3C2	 9	 0.19	 0.16	 0.26	 0	 0.07	 0.07	 0.09	 0	
7025	 NR2F1	 6	 0.13	 0	 0.02	 1.05	 0.05	 0	 0.05	 0.21	
8013	 NR4A3	 3	 0.1	 0	 0.11	 0.45	 0.02	 0	 0.04	 0.07	
3174	 HNF4G	 2	 0.1	 0.22	 0	 0	 0.02	 0.04	 0	 0	
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Figure 28: Numbers of NRs expressed in each single cell. 
 
Figure 29: Boxplot of the number of NRs expressed in each cell categorized by cell lineage. Dots 
represent individual cells. 
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Figure 30: Heatmap of NR expression across the studied population of single cells. 
With the exception of a few NRs that showed almost ubiquitous expression 
(NR1H2, NR3C1, RARG, VDR), the presence and level of expression of most 
NRs were quite variable across the population of single cells, as can be seen in 
Figure 30. Of the almost ubiquitously expressed NRs, NR3C1/GR can bind to 
commonly used progestins and anti-progestins, and also binds the same DNA 
motif as PR hence its expression wide expression in normal cells may have 
implications for women taking endocrine treatments. It is also interesting that 
NR1H2/LXRb has been associated with breast cancer outcome/grade yet in 
normal cells it is not associated with a specific cell population.  
We calculated the pair-wise Pearson correlation coefficient between NRs as a 
simple co-expression measure (Figure 31) and found that the pair-wise Pearson 
correlations between different NRs ranged from -0.27 to 0.4 (Figure 31), which 
suggests that overall there is high variability in NR expression at the single cell 
level.  
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Figure 31: Pairwise correlations of NRs at single cell level. Clustered heatmap of the matrix of 
pair-wise Pearson correlation in expression between NRs. 
Next, we examined the distribution and expression level of NRs in the three 
different cell lineages to see whether certain NRs displayed lineage-specific 
expression. Figure 32 and Figure 33 show the level of expression and fraction of 
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cells expressing each NR respectively for each of the three cell lineages.
 
Figure 32: NR expression in different cell types of the normal breast. Boxplot of the expression of 
individual NR categorized by cell lineage. 
 
Figure 33: Distribution of NRs in different cell types of the normal breast epithelium. Plotted as 
a fraction of the total number of cells in each lineage with expression of individual NRs. 
From these two descriptive plots, it can be seen that a number of NRs display 
preferential expression in specific cell populations. PGR, RXRA, RARB, THRB, 
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NR2C1 are expressed more frequently in the Basal cells compared to the other 
two cell types (Figure 33). On the other hand, ESR1, ESRRG, NR1D2 are 
expressed more often in Luminal cells. AR, NR4A2, PPARG, RORA and THRA 
appear to be expressed both more frequently and at higher level in progenitor 
cells.  
To better understand the relationship between the level of expression and the 
distribution of NR expression in the different cell populations, we plotted the 
fold change in mean expression against the fold change in fraction of cells 
expressing each NR for the Luminal versus Basal cell types (Figure 34) and the 
Progenitor versus Non-progenitor (Luminal and Basal) cell types (Figure 35). 
From these plots, certain NRs stand out as potential markers for the different 
breast epithelial lineages. Specifically: 
1) Potential NR markers for the Luminal lineage: RORC, NR4A1, ESR1, 
ESRRG. 
2) Potential NR markers for the Basal lineage: RARB, PGR, RXRA. 
3) Potential NR markers for progenitor cells: AR, NR2F1, PPARG, NR4A3 
Single-cell analysis of NR expression and co-expression networks in normal 
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Figure 34: Differences in the distribution and expression of NRs between Basal and Luminal 
cells. Fold change in lineage-specific distribution and mean expression of NRs for the Luminal 
versus Basal cell types. 
 
 
Figure 35: Distribution and expression of NRs in progenitor and differentiated cells. Fold change 
in lineage-specific distribution and mean expression of NRs for the Progenitor versus Non-
progenitor (Luminal+Basal) cell types. 
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
NR1H3
RORA
RARB
PGR
ESR1
VDRPPARD
NR3C1
NR4A3
NR2C1
NR4A1
THRA
NR1D1
NR1H2RARA
PPARG
RORC
NR6A1
THRB
NR3C2
NR4A2NR2F6
AR
RARGESRRA
NR1D2
2F1
NR2C2
NR2F2
RXRA
PPARA
ESRRG
RXRB
−2
−1
0
1
2
−5.0 −2.5 0.0 2.5 5.0
Expression fold change 
(Luminal/Basal), log2
Fo
ld
 c
ha
ng
e 
in
 fr
ac
tio
n 
of
 c
el
l e
xp
re
ss
in
g 
NR
 
 (L
um
in
al
/B
as
al
), 
lo
g2
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
NR1H3
RORA
RARB
PGR
ESR1
VDR
PPARD
NR3C1
NR4A3
NR2C1
NR4A1
THRA
NR1D1
NR1H2
RARA
PPARG
RORC
NR6A1
THRB
NR3C2
NR4A2
NR2F6
AR
RARG
ESRRANR1D2
NR2F1
NR2C2
NR2F2
RXRA
PPARA
ESRRG
RXRB
−2
0
2
−6 −3 0 3 6
Expression fold change 
Progenitor/(Luminal+Basal), log2
Fo
ld
 c
ha
ng
e 
in
 fr
ac
tio
n 
of
 c
el
l e
xp
re
ss
in
g 
NR
 
 P
ro
ge
ni
to
r/(
Lu
m
in
al
+B
as
al
), 
lo
g2
Single-cell analysis of NR expression and co-expression networks in normal 
breast epithelial cells. 
 153 
To test statistically the significance in differential expression of NRs in the 
different normal epithelial breast cell lineages, The Marker Selection tool of 
the GENE-E software (https://www.broadinstitute.org/cancer/software/GENE-
E/) from the Broad Institute was also used. In this analysis, a test statistic 
(Signal To Noise Ratio method [192]) was used to calculate the difference in 
expression of genes between the two classes being compared, and estimate a 
significance of the test score, which is then corrected for multiple testing. The 
significantly differentially expressed NRs (FDR-BH <= 0.005) identified by this 
analysis are listed in Table 12. The result confirms observations from earlier 
descriptive plots. Additionally, RARG was identified as differentially expressed 
in the combined Luminal+Basal group of cells compared to that of progenitor 
cells. Other potential markers for non-progenitor cell types suggested by 
Figure 35 (NR2C2, ESR1, ESRRG) were not significantly differentially expressed 
in the combined Luminal+Basal cell types compared to the progenitor cell 
type, although ESR1 and ESRRG are significantly differentially expressed 
specifically in the Luminal cells. 
Table 12: NR significantly differentially expressed in different normal breast cell types. (LvsB = 
Luminal versus Basal, PvsD = Progenitor versus Luminal+Basal, FDR–BH = False discovery rate 
estimated using the Benjamini and Hochberg procedure, Bonferroni = False discovery rate 
estimated using the Bonferroni procedure, FWER = family-wise error rate) 
NR	 EntrezID	 Num.	Cells	
SignalTo	
Noise	 P-value	 FDR-BH	 Bonferroni	 FWER	
Fold	
Change	
Biomarker	
Lineage	
Comp-
arision	
NR4A1	 3164	 65	 0.6761	 2.00E-05	 1.14E-04	 8.00E-04	 0.00E+00	 6.31	 Luminal	 LvsB	
ESR1	 2099	 52	 0.5973	 2.00E-05	 1.14E-04	 8.00E-04	 0.00E+00	 6.07	 Luminal	 LvsB	
ESRRG	 2104	 33	 0.3593	 3.20E-04	 1.28E-03	 1.28E-02	 1.16E-02	 4.07	 Luminal	 LvsB	
RORC	 6097	 29	 0.326	 1.22E-03	 4.07E-03	 4.88E-02	 3.66E-02	 4.77	 Luminal	 LvsB	
PGR	 5241	 38	 -0.4102	 1.00E-04	 4.45E-04	 4.00E-03	 1.47E-03	 -5.34	 Basal	 LvsB	
RXRA	 6256	 45	 -0.4292	 4.01E-05	 2.00E-04	 1.60E-03	 7.10E-04	 -3.8	 Basal	 LvsB	
RARB	 5915	 46	 -0.6038	 2.00E-05	 1.14E-04	 8.01E-04	 0.00E+00	 -8.11	 Basal	 LvsB	
PPARG	 5468	 27	 0.8415	 2.00E-05	 1.14E-04	 8.00E-04	 5.20E-04	 17.29	 Progenitor	 PvsD	
RORA	 6095	 59	 0.6719	 2.00E-05	 1.14E-04	 8.00E-04	 7.28E-03	 3.38	 Progenitor	 PvsD	
AR	 367	 11	 0.5054	 2.00E-04	 8.89E-04	 8.00E-03	 1.26E-01	 12.7	 Progenitor	 PvsD	
NR2F1	 7025	 6	 0.4624	 8.60E-04	 3.44E-03	 3.44E-02	 2.10E-01	 52.26	 Progenitor	 PvsD	
RARG	 5916	 108	 -0.691	 4.01E-05	 2.00E-04	 1.60E-03	 5.81E-03	 -3.26	 Differentiated	 PvsD	
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5.3.4 NR	co-expression	networks	in	different	normal	
breast	cell	lineages	
The observation that there is preferential expression of certain NRs in different 
normal breast epithelial cell lineages suggests that these NRs are potentially 
involved in regulating lineage-specific biological processes. This knowledge 
would be helpful in guiding future experiments to explore the roles of the NRs 
identified in the different normal breast cell types, perhaps through activating 
the signalling pathways for these NRs with specific ligands. 
One approach that can be applied to the present dataset to understand the 
different pathways or processes that are active in a lineage-specific manner is 
to perform differential gene expression analysis. While such an analysis would 
identify the genes that are differentially expressed and the associated 
biological processes, it would not give us information on the relationship 
between the lineage-differentially expressed genes and NRs. 
To identify genes potentially functionally related to NRs in each cell lineage, 
co-expression analysis was performed with the assumption that if the 
expression levels of two genes rise and fall together across cells, they are more 
likely to participate in the same pathway or protein complexes. Co-expression 
analysis has been applied by many to infer potential relationships between 
genes in expression dataset measured at bulk or tissue-level. However, at the 
single-cell level, it is not clear whether co-expression analysis would offer 
novel insights into gene regulatory networks that are not evident at the bulk 
level. On a conceptual level, one would think that networks derived from co-
expression analysis at the single-cell level would act as a more concrete basis 
to infer functional interaction between genes, as such data does not suffer 
from potential averaging artefacts. 
In this section, the co-expression analysis method described in Section 2.7.1 
was applied to identify genes significantly co-expressed with NRs in each of 
the Luminal (n=56) or Basal (n=56) cell types. Co-expression analysis was not 
performed for the Progenitor cells due to the low number of cells (n=14) 
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identified for this cell type. Figure 36 summarizes the number of genes found 
to be significantly co-expressed with each NR in each cell type. 
 
Figure 36: Number of NR co-expressed genes identified in the Luminal and Basal cell types.For 
each cell types, number of co-expressed genes are only tabulated for NRs expressed in at least 15 
cells of that cell type, for example THRA, RXRA, RARB and PGR are not expressed in >= 15 
Luminal cells therefore the number of their co-expressed genes in Luminal cells were not 
included in this graph. 
Within each cell type, genes significantly co-expressed with at least one NR are 
then clustered using unsupervised hierarchical clustering based on their co-
expression profiles. Figure 37 and Figure 38 below show the clustered heatmap 
of the matrices of significantly co-expressed NR-gene pairs obtained for 
Luminal and Basal cell types respectively. 
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Figure 37: NR co-expression network in Luminal cells. Clustered heatmap of the co-expression 
profiles of genes significantly co-expressed with NRs in the Luminal cell type. NRs are listed 
across the columns with identifiers in the format of  “Gene symbol | Entrez Gene ID”. NR co-
expressed genes are in rows. Only NRs with at least 20 significantly co-expressed genes are 
included in this heatmap. Cell values are the Pearson correlation of the significantly co-
expressed NR-nonNR gene pairs. Grey indicates absence of significant co-expression.  
 
Pearson"Correla5on"
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Figure 38: NR co-expression networks in basal cells. 
 Clustered heatmap of the co-expression profiles of genes significantly co-expressed with NRs in 
the Basal cell type. NRs are listed across the columns with identifiers in the format of  “Gene 
symbol | Entrez Gene ID”. NR co-expressed genes are in rows. Only NRs with at least 20 
significantly co-expressed genes are included in this heatmap. Cell values are the Pearson 
correlation of the significantly co-expressed NR-nonNR gene pairs. Grey indicates absence of 
significant co-expression.  
Pearson"Correla5on"
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The most striking feature of the co-expression heatmaps of Figure 37 and 
Figure 38 is the lack of shared co-expressed genes between NRs despite the 
sizable numbers of co-expressed genes identified for each individual NR. In 
other words, there is a lack of a network of highly inter-connected signalling 
between NRs that is often observed with co-expression networks constructed 
from bulk data (for example, see Figure 12 and Figure 13 which shows similar 
co-expression heatmaps constructed from bulk expression data of normal and 
cancer breast tissues respectively).   
This was a surprising observation. Publications of co-expression analysis at the 
single cell level are few and although none has emphasized the lack of shared 
co-expressed genes between different transcription factors or nuclear 
receptors, the following has been reported: 
1) Wang et al. compared expression profiles of glioblastoma at single cell 
and bulk level and reported that co-expressed genes detected at the 
single cell level showed poor overlap with co-expressed genes detected 
at bulk level [193]. 
2) Single cell co-expression exhibits low functional relatedness (poor or no 
enrichment for functional similarity) [193, 194]. 
These characteristics were also observed in our single cell dataset. Figure 30, 
Figure 31 and Figure 39 (below) collectively showed that 1) NR expression at 
the single cell level is highly variable; 2) the NR-NR co-expression is poor at 
single cell level compared to bulk level. Functional analysis of significantly co-
expressed genes for each NR at the single cell level also showed poor 
functional enrichment (data not shown).  
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Figure 39: Difference in distribution of NR correlations for single cell and bulk measurements. 
Distribution of Pearson correlation coefficients of all NR-NR gene pairs calculated over 1) 
expression profiles of 126 normal breast epithelial cells at single cell level and 2) expression 
profiles of 50 normal breast tissues at bulk level (Dataset 1: TLDA arrays of human primary 
breast tissues.) 
Given that NR-NR co-expression are low at the single-cell level, the possible 
reason for the lack of inter-connectedness of the NR co-expression network 
observed in our data may be: 
1) At the single cell level, NR signalling is extremely cell specific and larger 
sample sizes are needed to detect crosstalk between NR signalling. 
2) The nature of single cell expression profiling means that cells are 
captured at different stages in their cell cycle and differentiation 
trajectories. These may need to be taken into account in order to detect 
co-expression. For example, in a regulatory relationship between gene A 
and gene B in which gene A induces the expression of gene B, there is 
often a delay in expression of gene B. In such a situation, the two genes 
will show strong co-expression if the delay in time is taken into account 
but may show weak co-expression otherwise. Likewise, co-expression 
analysis in single cell data may need to take into account the different 
stages in the cell cycle and differentiation time points. This may be 
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done by first ordering the cells within each lineage according to 
similarity in gene expression or “pseudotime” and performing co-
expression analysis within cells that have been grouped based on 
pseudotime. 
5.3.5 Chapter	summary	
In this chapter, the single-cell level expression profiles of 126 normal breast 
epithelial cells were analysed with the aim to classify cells into the different 
cell types of the normal breast epithelial cell hierarchy and to characterizes the 
expression and co-expression networks of NRs in each of the different cell 
lineages. The main observation and findings are summarized below: 
1) Unsupervised clustering of highly variable genes grouped the cells into 
three broad cell types that displayed differential expression for markers 
often used to distinguish progenitors, luminal and basal epithelial cell 
types of the breast. 
2) NRs displayed differential expression in the different cell lineages. The 
nuclear receptors NR4A1, ESR1, ESRRG and RORC showed preferential 
expression in Luminal cells while PGR, RXRA, RARB showed 
preferential expression in Basal cells. Progenitor cells are associated 
with higher expression of PPARG, RORA, AR and NR2F1. 
Single-cell level co-expression networks of NRs in the Luminal and Basal cell 
types showed a distinct lack of inter-connectedness that are observed with NR 
networks constructed from bulk data. Further exploration is needed to explain 
this observation. It is thought that the inherent nature of single-cell expression 
profiling, the small sample size, and the highly cell-specific action of NRs are 
factors that contribute to this observed lack of crosstalk in NR co-expression 
networks constructed from this particular dataset. Currently more normal 
breast samples are being sequenced at single cell level in our laboratory. 
Future analyses of NR co-expression networks will be performed in this larger 
cell population using more sophisticated methods of cell classification that 
take into account cell states. 
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6 The functional roles of the 
mineralocorticoid receptors 
in breast cancer 
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6.1 Overview	
The mineralocorticoid receptor (MR) is a member of the steroid receptor sub-
family of nuclear receptors and is expressed in many tissues including kidney, 
heart, the central nervous system and the breast. MR can be activated by the 
primary adrenal cortical steroid hormones, aldosterone (ALDO), as well as the 
glucocorticoids cortisol and corticosterone although MR preferentially binds 
ALDO in epithelial tissues while in other tissues cortisol is the primary ligand 
[195]. MR has been prominently associated with modulation of ion transport 
and homeostasis, as well as membrane excitability in neurons and muscle 
cells, responses to injury, and early response to stress [196].  
There have been few reports of its functional role in the breast. MR has been 
reported to crosstalk with PGR to induce cell adhesion and growth inhibition 
in breast cancer cell [197]. In a published study from our team [62] which 
examined the expression of 48 nuclear receptors using Taqman low-density 
PCR array (TLDA) on a cohort of normal and cancer breast tissues, it was 
observed that: i) MR expression is lower in cancer compared to normal breast 
tissues; and iii) MR is an independent predictor of metastasis-free survival in 
tamoxifen-treated breast cancer patient.  
Chapter 3 of this thesis showed that pairwise expression correlations of MR 
with many NRs and co-regulators that are observed in normal breast tissues 
are disrupted in breast cancers. Additionally, in Chapter 4, MR was identified 
to part of a group of NRs with prognostic value in ER-, HER2 and Basal breast 
cancer subtypes (Section 4.3.1.2). These observations suggest a potential role of 
MR in both the normal breast and breast cancer. This chapter further 
investigates potential functional roles of MR in the normal breast and breast 
cancer through a combination of in-silico analyses of various datasets and in 
vitro experiments.  
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6.2 Potential	crosstalk	between	MR	and	
RAR	signalling	in	the	breast	
Described in this sub-section are results of analyses in two different datasets 
that suggest a potential functional crosstalk between MR and RAR signalling 
in the normal breast, which is possibly altered in breast cancer. 
6.2.1 Analysis	of	NR-coregulator	associations	identified	
potential	functional	crosstalk	between	MR	and	
RAR	signalling	
Coregulators are integral to the mechanisms by which nuclear receptors exert 
their physiological functions. Identification of changes in NR-coregulator 
interactions in breast cancer compared to the normal breast would therefore 
yield potentially useful insights into breast cancer biology. Using highly 
sensitive high throughput qRT-PCR expression profiles of 48 nuclear receptors 
and 238 coregulators (Dataset 1, described in Section 2.2.1), we investigated 
potential NR-coregulator associations based on gene expression correlations. 
To do this, we applied Sparse Canonical Correlation Analysis (SCCA) to detect 
independent maximally correlated groups of NRs and coregulators in different 
sample subgroups: premenopausal normals (n = 30), postmenopausal normals 
(n = 20), pre-menopausal cancers (n = 20, defined as cancers with age <= 50 
years) and post-menopausal cancers (n=46, defined as cancers with age > 50 
years). SCCA is a variant of the well-known Canonical Correlation Analysis 
(CCA) technique to characterize the relationship between two sets of 
variables. Here, the two sets of variables of interest are the NRs and co-
regulators. Within each sample subgroup, SCCA identified distinct, potentially 
functionally related, combinations of inter-correlating NRs and coregulators, 
analogous to tightly interconnected groups of genes in a gene co-expression 
network.   
SCCA analysis revealed that in pre-menopausal normal breast tissues, the 
strongest inter-correlation between NRs and co-regulators is observed 
between the five nuclear receptors MR, RARA, RARG, RXRB, LXRb and a 
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group of 20 co-regulators (Figure 40A). The co-regulators involved are known 
to participate in multiple pathways with various functions including apoptosis, 
immune response, proteolysis and RNA splicing. The inter-correlation 
between these nuclear receptors and co-regulators is much stronger in pre-
menopausal normal samples compared to that observed in post-menopausal 
normal (Figure 40B), pre-menopausal cancers (Figure 40C) or post-
menopausal cancers (Figure 40D). The observation that MR and three retinoic 
acid receptors are strongly correlated with the same group of co-regulators 
suggests potential a crosstalk between MR and RAR signalling in the 
premenopausal normal breast, at least in the context of co-regulator 
utilization, that may be altered in breast cancer. 
 
Figure 40: SCCA analysis of TLDA data Sparse Canonical Correlation Analysis using TLDA data 
(Dataset 1) identified strong inter-correlation between a set of nuclear receptors that include 
MR and 3 retinoic acid receptors and a set of co-regulators in Premenopausal Normal. This 
strong inter-correlation is decreased in Postmenopausal Normal, Premenopausal Cancer and 
Postmenopausal Cancer. Heatmap colours represent pairwise Spearman Rank correlations 
between each gene pair in the different sample cohorts of the TLDA dataset (Dataset 1, 
described in Section 2.2.1). 
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6.2.2 Data	mining	reveals	connections	between	MR	and	
RARB	co-expression	networks	
Inference of NR-NR functional interaction through co-expression profiles 
using RNA-Seq data obtained from the TCGA (described in Chapter 4, Section 
4.2.3) showed that MR shared a large percentage (68%, 724 genes) of its co-
expressed genes with RARB in normal breast tissues. In cancer tissues, the 
percentage of MR co-expressed genes shared with RARB dropped to 104 genes 
(21% of MR co-expressed genes identified in breast cancer) (Figure 41). 
 
Figure 41: Co-expression based identification potential functional crosstalk between MR and 
RARB. Percentage of MR co-expressed genes shared with other nuclear receptors based on RNA-
Seq expression profiles of normal and breast cancer tissues from the TCGA BRCA dataset 
(Dataset 4). 
Hierarchical clustering of the expression of MR and the three retinoic-acid 
receptors showed that the expression profile of MR more closely resembles 
that of RARB compared to RARA or RARG (Figure 42). The expression of both 
MR and RARB are higher in normal breast tissues and decreased in breast 
cancers while the expression of RARG and RARA remain high in both sample 
cohorts. 
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Figure 42: Expression of MR, RARB, RARG and RARA in normal breast and breast cancer samples 
of Dataset 4 (TCGA RNA-seq data of 106 normal and 988 breast cancer samples). 
6.2.3 Summary	
Expression correlation based analyses in two different datasets suggested 
possible crosstalk between MR and RAR signalling. There is a difference in the 
retinoic acid receptors identified to have potential crosstalk with MR in the 
two datasets (RARB is identified in the TCGA dataset while RARA and RARG 
are identified in the TLDA dataset). This may be due to the difference in the 
clinical characteristics of the sample cohorts. The pre-menopausal normal 
cohort of the TLDA dataset consists of 30 carefully curated true normal breast 
samples from pre-menopausal women. In contrast, the normal samples of the 
TCGA are normal tissues adjacent to paired tumour samples from all 
menopausal stages (the majority are post-menopausal). It may be that MR 
preferentially crosstalks with different members of the retinoic acid receptors 
depending on menopausal status. The normal samples from the TCGA dataset 
were chosen for subsequent analyses due to their genome-wide nature and its 
larger cohort size. 
6.3 Inference	of	the	functional	roles	of	MR	
through	co-expression	analysis	
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In the previous section (Section 6.2), it was observed in the TCGA dataset that 
MR and RARB showed decreased expression in breast cancer compared to 
normal tissues and that these two NRs shared a large proportion of co-
expressed genes specifically in the normal cohort. Furthermore, in Section 4.3.1 
of Chapter 4, differential co-expression analysis identified MR as a member of 
a group of NRs that have prognostic utility in ER- breast cancer. These 
observations suggest that MR may play a role in breast cancer biology and that 
there may be a crosstalk between MR and RAR signalling in the normal breast, 
which is altered or disrupted in breast cancer. 
To gain further insights into the potential functional roles of MR and RARB in 
the breast, gene ontology enrichment analysis was performed on the genes 
significantly co-expressed with either MR or RARB (identified in Section 4.2).  
MR or RARB co-expressed genes were categorized into different gene sets 
listed in Table 13 below.  
Table 13: Categories of MR or RARB co-expressed genes analysed in GO enrichment analyses. 
Category Numbers 
Genes positively co-expressed with MR in normal breast 917 
Genes positively co-expressed with MR in breast cancer 395 
Genes positively co-expressed with RARB in normal breast 2518 
Genes positively co-expressed with RARB in breast cancer 330 
Genes negatively co-expressed with MR in normal breast 144 
Genes negatively co-expressed with MR in breast cancer 102 
Genes negatively co-expressed with RARB in normal breast 928 
Genes negatively co-expressed with RARB in breast cancer 146 
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A) MR positively co-expressed genes 
 
B) RARB positively co-expressed genes 
 
C) MR negatively co-expressed genes 
 
D) RARB negatively co-expressed genes 
 
Figure 43: GO terms enriched in genes co-expressed with MR and RARB in normal breast tissues. 
Summary of Biological Processes GO terms significantly enriched in genes co-expressed with 
MR or RARB in normal breast samples identified by DAVID (Enrichment P-value <= 0.005 and 
FDR <= 10%) and visualized using REVIGO (http://revigo.irb.hr/) which clusters GO terms based 
on semantic similarity measures. The axes have no intrinsic meaning. REVIGO uses 
multidimensional scaling to reduce the dimensionality of the matrix of pair-wise GO semantic 
similarity as measured by the SimRel method. The guiding principle is that semantically similar 
GO terms are positioned more closely together. Colour of bubbles represents the enrichment P-
values with red to blue colour gradient representing weaker to stronger enrichment 
respectively. Size of bubbles represents the frequency of the GO term in the underlying GO 
database, larger bubble means more general GO term. GO terms marked with red boxes are 
enriched in both MR and RARB co-expressed genes. Metabolic and non-metabolic biological 
processes specifically enriched in co-expressed genes of MR or RARB alone are marked with 
blue and purple boxes respectively. 
In the normal breast (Figure 43), both MR and RARB positively co-expressed 
genes are enriched with genes involved in cilium assembly, mRNA processing, 
protein modification (ubiquitination, sumoylation), chromatin modification, 
cell cycle and DNA damage response (GO terms marked with red boxes in 
Figure 43A and Figure 43B). Additionally, RARB positively co-expressed genes 
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are also involved in the regulation of glucose transport, stem cell maintenance 
and signal transduction mediated by p53 while MR positively co-expressed 
genes are specifically enriched with genes involved in protein transport. 
Genes negatively co-expressed with MR or RARB in the normal breast are most 
strongly enriched for genes involved in metabolic processes. In particular, 
oxidative phosphorylation through the mitochondrial electron transport chain 
appears to be enriched in both MR and RARB co-expressed genes (GO terms 
marked with red boxes in Figure 43C and Figure 43D). Additionally, RARB 
negatively co-expressed genes are specifically enriched with genes involved in 
various metabolic processes (blue boxes in Figure 43D) as well as angiogenesis, 
cell adhesion, cell proliferation (purple boxes in Figure 43D).  
MR positively co-expressed genes 
 
RARB positively co-expressed genes 
 
MR negatively co-expressed genes 
 
RARB negatively co-expressed genes 
 
Figure 44: GO terms enriched in genes co-expressed with MR and RARB in breast cancer tissues. 
Summary of Biological Processes GO terms significantly enriched with MR or RARB in breast 
cancer samples identified by DAVID (Enrichment P-value <= 0.005 and FDR <= 10%) and 
visualized using REVIGO (http://revigo.irb.hr/) which clusters GO terms based on semantic 
similarity measures. The axes have no intrinsic meaning. REVIGO uses multidimensional 
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scaling to reduce the dimensionality of the matrix of pair-wise GO semantic similarity as 
measured by the SimRel method. The guiding principle is that semantically similar GO terms 
are positioned more closely together. Colour of bubbles represents the enrichment P-values 
with red to blue colour gradient representing weaker to stronger enrichment respectively. Size 
of bubbles represents the frequency of the GO term in the underlying GO database, larger 
bubble means more general GO term. GO terms marked with red boxes are enriched in both MR 
and RARB co-expressed genes. Metabolic and non-metabolic biological processes specifically 
enriched in co-expressed genes of MR or RARB alone are marked with blue and purple boxes 
respectively. 
In breast cancer (Figure 44), there is a divergence in the biological processes 
over-represented in MR and RARB co-expressed genes, although both 
receptors are co-expressed with genes involved in biological processes 
important to breast cancer biology. Both MR and RARB were positively co-
expressed with genes involved in transcriptional regulation, cell proliferation 
and signal transduction (GO terms marked with red boxes in Figure 44A and 
Figure 44B). MR positively co-expressed with genes specifically enriched for 
genes involved in angiogenesis, cell adhesion and response to estradiol (GO 
terms marked with purple boxes in Figure 44A). By contrast, RARB positively 
co-expressed genes were specifically enriched for genes involved in 
inflammatory response, apoptosis and protein phosphorylation (GO terms 
marked with purple boxes in Figure 44B).  
Genes negatively co-expressed with MR in breast cancer showed strong 
enrichment for genes involved in cell cycle regulation while RARB co-
expressed genes were strongly enriched with genes involved in cellular 
metabolism (Figure 44C and Figure 44D). 
Venn diagrams (Figure 45) showed that at the gene level, co-expressed genes 
of MR in normal and cancer showed poor overlap. The same is observed for 
RARB.  Figure 45 also highlights the strong overlap of MR and RARB co-
expressed genes in normal tissues reflecting the strong overlap in GO terms 
enriched in MR and RARB co-expressed genes in normal.   
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Figure 45: Overlap of MR and RARB co-expressed genes. Venn diagrams showing the overlap 
between co-expressed genes identified in normal and cancer samples for MR and RARB. 
The main observations from the analysis of MR and RARB co-expression 
network and associated gene ontology enrichment are:  
i) There appears to be a major re-wiring of the gene co-expression 
networks of MR and RARB in breast cancer compared to the normal 
breast;  
ii) There is the possibility of crosstalk between MR and RAR signalling 
through RARB in the normal breast, that is disrupted in breast 
cancer;  
iii) In the normal breast, MR and RARB signalling may converge in 
regulating general cell maintenance including regulation of cilium 
assembly, mRNA processing, protein modification (ubiquitination, 
sumoylation), chromatin modification, cell cycle and DNA damage 
response, which is disrupted in breast cancer with the decreased 
expression of these two NRs. Furthermore, in the normal breast, MR 
and RARB are also involved in the regulation (suppression) of genes 
involved in various metabolic processes including regulation of 
oxidative phosphorylation and the electron transport chain (MR); 
iv) In breast cancer, although there is a divergence of the biological 
processes that genes co-expressed with MR or RARB are involved in, 
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both MR and RARB show co-expression with genes that affect 
cancer biology.  
6.4 Activation	of	MR	and	RAR	signalling	
through	ligand	treatment	of	MR-inducible	
MCF-7	breast	cancer	cells	
To explore the biological relevance of our observations from in silico analysis 
of gene co-expression, we activated MR and/or RAR signalling in an 
experimental cell line model followed by microarray expression profiling. An 
MR-inducible MCF-7 breast cancer cell line created in Professor Peter Fuller’s 
laboratory (http://hudson.org.au/profile-prof-peter-fuller/) was treated with 
either aldosterone (ALDO), retinoic acid (RA) or both and expression profiling 
was performed as described in Section 2.5.  
In the previous sections, we observed firstly that MR and RARB are expressed 
at moderate levels in normal breast and that their expression decreased in 
breast cancer. Secondly, it appears that there is major re-wiring of the MR and 
RARB co-expression network in breast cancers, as demonstrated by the change 
in the co-expressed genes and associated enriched gene ontology terms. 
Therefore, we reasoned that activating MR and/or retinoic acid receptor 
signalling in an MR-inducible breast cancer cell line would exert two effects. 
The first would be facilitated through re-gaining of normal MR and/or RARB 
functions as a result of the re-introduction of MR and RARB signalling. The 
second effect is exerted through cancer-associated acquired connections in the 
MR and RARB networks. It is possible that activating MR and RARB signalling 
in a breast cancer cell induces both effects in parallel. The specific aims of this 
experiment are: 
1) To determine if there is crosstalk in MR and retinoic acid receptor 
signalling pathways as suggested by our analysis of gene co-expression. 
And if so, to explore the biological processes potentially regulated by 
the convergence of MR and RAR signalling in the breast. 
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2) To determine whether the genes and biological processes that show 
differential expression under ALDO, RA and ALDO+RA treatments in 
MR-inducible MCF-7 cells reflects those identified in our analysis of co-
expressed genes for MR and RARB in Sections 6.3. 
6.4.1 Identification	of	differentially	expressed	genes	
Figure 46A shows the number of genes differentially expressed (DE) on ALDO, 
RA or ALDO+RA treatment in MR-inducible breast cancer cells. Figure 46B 
shows the overlaps of the DE genes for the 3 treatment conditions. There are a 
substantial number of genes DE on ALDO+RA treatment that are not DE when 
cells are treated with ALDO alone or RA alone. This suggests convergence of 
mineralocorticoid and retinoic signalling affecting the expression of these 
genes. Figure 46C shows a clustered heatmap of the expression of all genes DE 
in any of 3 treatment conditions. DE genes are grouped into 7 clusters and 
further divided into sub-clusters depending on whether they are up or down 
regulated.  
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Figure 46: Differentially expressed genes in ALDO, RA and ALDO+RA treated MCF-7 cells. (A) 
Numbers of genes up or down regulated in each treatment condition. (B) Venn diagram of the 
gene overlaps between treatment conditions. (C) Heatmap of the log2 fold-change of genes 
differentially expressed in each treatment condition. Genes are grouped into different gene 
clusters as annotated in the right hand panel. 
6.4.2 Overlap	between	differentially	expressed	genes	
and	co-expressed	genes	
The Venn diagrams in Figure 47 below show the overlaps between MR or 
RARB co-expressed genes (as identified in Section 6.2) and genes differentially 
expressed on ligand treatment.  
A
B
ALDO
RAALDO+RA
667 431935
142
232 54
99
ALL GENES UP DOWN
ALDO
RA
ALDO+RA
526
1518
1932
363
711
910
163
808
1024
Log2(FC)
-3 .23 - 2 0 2 5.93
ALDO RA ALDO+RA
1a
1b
2a
2b
3a
3b
4a
4b
4c
4d
5a
5b
5c
6a6b7a
7b
CL
US
TE
R ID
C
The functional roles of the mineralocorticoid receptors in breast cancer 
 175 
 
Figure 47: Overlaps between co-expressed and differentially expressed genes on ligand 
treatments in MR inducible MCF-7 cells. 
The number of MR co-expressed genes that overlap with genes differentially 
expressed on ALDO single treatment is very small (total of 16 + 15 = 31 genes or 
2% of all MR co-expressed genes, Figure 47A). When comparing MR co-
expressed genes with genes differentially expressed on ALDO+RA co-
treatment, the number of genes shared increased to 189 genes (124 + 1 + 64 = 
189 genes or 12.5% of all MR co-expressed genes, Figure 47B). Likewise, the 
numbers of RARB co-expressed genes that overlap with genes differentially 
expressed on RA treatment is also small, although higher in comparison to 
that observed for MR (a total of 258 + 6 + 59 = 323 genes or 8% of all RARB co-
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expressed genes, Figure 47C). The number of RARB co-expressed genes that 
overlap with genes differentially expressed under ALDO+RA co-treatment is 
359 genes (280 + 5 + 74 = 359 genes or 9.3% or all RARB co-expressed genes, 
Figure 47D). The low percentage of co-expressed genes observed to be 
differentially expressed under ligand treatment could be due to a number of 
factors:  
i) Co-expression networks are based on gene correlations, which does 
not always imply a regulatory relationship. Therefore, not all genes 
co-expressed with MR are directly regulated by MR signalling. 
ii) It is possible that only a small percentage of MR co-expressed genes 
are regulated by ALDO signalling in isolation or by the crosstalk 
between MR and RAR signalling. The expression of the majority of 
MR co-expressed genes may be controlled through crosstalk of MR 
signalling with that of other nuclear receptors or transcription 
factors that are not activated in our experimental conditions. 
iii) Identification of differential expression is subject to significance and 
fold-change cutoffs. It may be possible that the expression level of 
co-expressed genes is only slightly changed under ligand treatment 
which did not make the 1.5 cutoff in expression fold change. 
iv) The response to MR and RAR signalling activation in a cell line 
model may be different to that observed in breast cancer tissues due 
to potential differences in the epigenetic landscape and coregulator 
expression. 
6.4.3 Examining	the	concordance	in	direction	of	change	
in	expression	on	ligand	treatment	with	that	
predicted	by	co-expression	analysis.	
We then examined whether MR co-expressed genes that showed differential 
expression on ligand treatment exhibit predicted direction of expression 
change. For example, genes negatively co-expressed with MR in normal breast 
cells are expected to show increased expression in cancer cells as MR 
expression is decreased. Therefore, when MR is expressed and activated in 
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MCF-7 breast cancer cells, these genes are expected to be down-regulated 
under ALDO or ALDO+RA treatments. Using similar reasoning, the expected 
directions of expression change in our cell model for MR co-expressed genes 
are as below: 
Category Expected direction of 
expression change 
Genes positively co-expressed with MR in normal breast cells Up-regulated 
Genes negatively co-expressed with MR in normal breast cells Down-regulated 
Genes positively co-expressed with MR in breast cancer cells Up-regulated 
Genes negatively co-expressed with MR in breast cancer cells Down-regulated 
Figure 48 shows a clustered heatmap presentation of the normalized overlap 
between co-expressed genes and genes differentially expressed on ligand 
treatment in the cell line experiment. Genes negatively co-expressed with MR 
in cancer and positively co-expressed with MR in normal show strongest 
overlap with down-regulated and up-regulated genes respectively, which is as 
expected. However, the direction of gene expression change on ligand 
treatment are not completely as expected for genes negatively co-expressed 
with MR in normal or positively co-expressed with MR in cancer.  
Table 14: Categories of MR co-expressed genes
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Figure 48: Expected versus observed changes in the direction of gene expression on ligand 
treatments. Heatmap columns represent gene lists of the gene clusters differentially expressed 
in the cell line experiment, annotated in Figure 46. Heatmap rows represent the lists of genes 
identified as positively or negatively co-expressed with MR (Figure 48A) or RARB (Figure 48B) in 
Normal or Cancer samples of the TCGA RNA-Seq dataset (Dataset 4, described in Section 2.2.4). 
Heatmap colours represent the normalized pairwise overlap (number of overlap genes 
normalized for the sizes of the two gene lists being compared).   
6.4.4 Gene	ontology	enrichment	analysis		
Gene ontology enrichment analysis was performed for genes differentially 
expressed on each ligand treatment, split into up-regulated and down-
regulated genes. 
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ALDO down-regulated genes 
 
RA up-regulated genes 
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Figure 49: GO terms enriched in genes differentially expressed on ligand treatments, 
categorized by the direction of gene expression change. GO enrichment was performed using 
DAVID (Enrichment P-value <= 0.005 and FDR <= 10%) and visualized using REVIGO 
(http://revigo.irb.hr/) which clusters GO terms based on semantic similarity measures. Colour 
of bubbles represents the enrichment P-values with red to blue colour gradient representing 
weaker to stronger enrichment respectively. Size of bubbles represents the frequency of the GO 
term in the underlying GO database, larger bubble means more general GO term. 
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Figure 49 shows the Biological Processes GO terms over-represented in up and 
down-regulated genes under ALDO, RA and ALDO+RA co-treatment. ALDO 
treatment up-regulates genes involved in cytoskeletal organization, stress 
response and apoptosis while down-regulating genes involved in 
transcriptional regulation, Notch signalling, cell migration, cell proliferation, 
glucose homeostasis and somatic stem cell maintenance. RA up-regulated 
genes are strongly enriched for those involved in cell-cell adhesion, rRNA 
processing, viral/inflammatory response, Notch signalling and hypoxia 
response. RA down-regulated genes are strongly enriched for those involved in 
energy metabolism through the mitochondrial electron transport chain 
(oxidative phosphorylation). Biological processes over-represented in genes 
up-regulated in ALDO+RA co-treatments reflect a combination of those up-
regulated in the single treatment (ALDO alone or RA alone), including cell 
adhesion, apoptosis and stress response. Genes down-regulated in the co-
treatment of ALDO+RA shows strong enrichment for those involved in energy 
metabolism through the mitochondrial electron transport chain.  
Although only a few of the over-represented GO terms are exactly matched in 
both genes differentially expressed on ALDO or ALDO+RA treatments and MR 
co-expressed genes (Figure 43 and Figure 44), many of the underlying 
biological processes over-represented in MR co-expressed genes are reflected 
in ALDO/ALDO+RA regulated genes. For example, oxidative phosphorylation 
and mitochondrial translation is enriched in MR negatively co-expressed genes 
in normal (and to a lesser extent in cancer) which is reflected in ALDO+RA 
down-regulated genes as expected. Transcriptional regulation, cell adhesion, 
cell migration and cell cycle regulation over-represented in MR positively co-
expressed genes are reflected in up-regulated genes on ALDO or ALDO+RA 
treatments. Therefore, although the overlap at the gene level and exact 
enriched GO terms are not strong between co-expressed and differentially 
expressed genes, the underlying biological processes enriched in the MR co-
expression network are well reflected in ALDO/ALDO+RA regulated genes. 
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On the other hand, biological processes predicted by analysis of RARB co-
expression networks are less well reflected in RA or ALDO+RA differentially 
expressed genes. For example, cell adhesion is strongly enriched in 
RA/ALDO+RA up-regulated genes but is not over-represented in RARB 
positively co-expressed genes. This may be a reflection of the complexity of 
retinoic signalling in the breast, where multiple retinoic receptors (RARA, 
RARB, RARG) with divergent functions are potentially activated by RA 
treatment. Despite this, as observed with MR, energy metabolism through the 
mitochondrial electron transport chain is over-presented in both 
RA/ALDO+RA down-regulated genes and RARB negatively co-expressed 
genes. 
To better understand the biological processes influenced by ALDO and RA 
signalling, gene ontology enrichment analysis was also performed on each of 
the gene clusters identified in Figure 46C. The result is summarized in Figure 
50 below. 
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Figure 50: Biological processes GO terms enriched in differentially expressed gene clusters. (A) 
Heatmap of the log2 fold-change of genes differentially expressed in each treatment condition. 
Genes are grouped into different gene clusters and annotated with whether the genes are 
annotated to be involved in the Glycolysis or Oxidative Phosphorylation Hallmarks according to 
MSigDB. (B) Heatmap presentation of Biological Processes GO terms significantly enriched 
(Enrichment P-value <= 0.005 and FDR < 10%) in gene clusters annotated in (A), only gene 
clusters with significantly over-represented GO terms are included in this heatmap. Cell colors 
represent the enrichment P-values. Grey indicates no significant GO term was identified. 
From Figure 50, the following observations can be made: 
1) Genes involved in oxidative phosphorylation (GO terms coloured blue) 
are down-regulated in both RA single treatment as well as ALDO+RA 
co-treatment. Furthermore, many genes involved in glycolysis are up-
regulated in ALDO, RA and ALDO+RA treatments (Figure 50A, side 
panel). Together, ALDO and RA signalling appear to promote glycolysis 
while suppressing oxidative phosphorylation. 
2) Co-treatment of ALDO+RA up-regulates a set of genes involved in the 
response to endoplasmic reticulum stress (GO terms in pink), these 
genes do not show significant expression change on ALDO or RA single 
treatments. 
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3) ALDO treatment appears to influence the expression of genes involved 
in the regulation of cell proliferation, Notch signalling, apoptosis and 
angiogenesis (GO terms in green). These genes are also differentially 
expressed in the co-treatment but not in RA single treatment 
suggesting these are processes influenced mainly by MR signalling. It is 
not clear whether MR signalling promotes or inhibits breast cancer 
because i) “Negative regulation of cell proliferation” is enriched in both 
ALDO up and down-regulated genes; ii) genes involved in negative 
regulation of angiogenesis are up-regulated (anti-cancer) while genes 
involved in negative regulation of apoptosis (presumably pro-cancer) 
are also up-regulated. Further investigation is needed to determine the 
effect of MR signalling on breast cancer. 
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6.4.5 Effect	of	MR	and	RAR	signalling	on	glucose	
metabolism	and	oxidative	phosphorylation	
In the previous section, we observed that activation of retinoic acid and 
aldosterone signalling in MR-inducible breast cancer cells up-regulates genes 
involved in glycolysis while suppressing genes involved in oxidative 
phosphorylation. This observation suggests that MR and RA signalling 
together promotes the Warburg effect, which describes a shift towards aerobic 
glycolysis in preference to oxidative phosphorylation as the major means of 
ATP generation in cancer cells. However, this contradicts other evidence 
suggesting that RARB is a tumour suppressor gene [17, 198-201] that inhibits 
breast cancer migration and growth. Since metabolic reprogramming is now 
recognized as a cancer hallmark [202], we investigated further the effect of MR 
and RAR signalling on glycolysis and oxidative phosphorylation in breast 
cancer cells by looking at the expression of key genes involved in the 
regulation of glycolysis and oxidative phosphorylation. 
 
Figure 51: Effect of ALDO+RA treatment on cellular metabolism. (A) Schematic diagram of the 
glycolysis pathways (adapted from Munoz-Pinedo et al. [203]), highlighting in red the key genes 
that show differential expression in the ALDO+RA treatment. (B) Heatmap of the expression 
level of key genes involved in glucose metabolism in Normal samples, Cancer samples, Cancer 
samples expressing high level of both MR and RARB and Cancer samples expressing low level of 
both MR and RARB (Dataset 4, TCGA BRCA RNA-Seq dataset). (C) The fold change in expression 
on ALDO+RA treatment in MR-inducible MCF-7 cells for the same metabolic genes shown in (B). 
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Figure 51A shows a schematic diagram of the key cellular metabolic pathways 
affecting glycolysis and oxidative phosphorylation in cancer cells. Highlighted 
in red are the key genes regulating glycolysis that showed increased expression 
in RA and ALDO+RA co-treatment. In addition to promoting glycolysis, and 
down regulating many genes involved in oxidative phosphorylation, 
ALDO+RA treatment also up-regulated PDK4, which is known to inhibit the 
Pyruvate Dehydrogenase (PDH) complex, an enzyme that catalyses the 
oxidative decarboxylation of pyruvate to acetyl-CoA which is the input into the 
Tricarboxylic acid cycle. Inhibiting PDH would therefore cause a 
disconnection between glycolysis and the TCA cycle preventing ATP 
generation by the electron transport chain (oxidative phosphorylation). 
Although it would appear that PDK4 activation would promote glycolysis and 
suppress oxidative phosphorylation, hence promoting the Warburg effect that 
has been reported to offer proliferative advantage to cancer cells, PDK4 
expression is actually higher in normal breast compared to breast cancer 
tissues as shown in Figure 51B. It can be observed in Figure 51B that in addition 
to PDK4, the expression profiles of some key pro-glycolysis genes including 
BNIP3L and BFKFB3 are higher in normal breast compared to breast cancer 
tissues. Furthermore, in breast cancer samples expressing high levels of both 
MR and RARB, the expression profile of these genes is closer to that observed 
in normal breast compared to breast cancer. In breast cancer samples 
expressing low levels of both MR and RARB, these genes are expressed at a 
lower level compared to that observed generally in all breast cancer samples. 
This is a puzzling observation which seems to suggest that in breast cancer, 
increased glycolysis does not benefit breast cancer cells. 
A possible explanation for this observation may lie in the “Reverse Warburg 
Effect” model and the role of HIF-1a activation in breast cancer cells proposed 
by Lisanti and colleagues [204, 205]. In the reverse Warburg model, which was 
first observed in human breast cancer cells, epithelial cancer cells induce the 
Warburg effect (aerobic glycolysis) in neighbouring tumour-associated 
fibroblasts while proliferating cancer cells themselves show a preference 
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towards oxidative phosphorylation. Cancer-associated fibroblasts then 
undergo autophagy or myo-fibroblastic differentiation, thereby secreting 
lactate and pyruvate (energy metabolites resulting from aerobic glycolysis) 
which are then taken up by the oxidative cancer cells to feed into their highly 
active oxidative phosphorylation processes. The characteristics of the reverse 
Warburg effect are summarized in Figure 52.  
 
Figure 52: Features of the reverse Warburg effect in oxidative cancer cells and cancer-associated 
fibroblast. 
The metabolic profiles of ALDO+RA treated MR-inducible MCF-7 breast 
cancer cells show striking similarity to that described for tumour-associated 
fibroblasts or hypoxic cancer cells. Specifically, on ALDO+RA treatment, we 
observed an increase in the expression of the GLUT1 receptor (SLC2A1), 
increased expression of HIF1A and genes related to hypoxia response, 
increased glycolysis, increased expression of MCT4 (SLC16A3) which facilitates 
lactate export across the cell membrane, as well as an increase in the 
expression of the HIF-associated mitophagy marker BNIP3L (Figure 51C). 
It appears that ALDO+RA treatment results in activation of HIF-1a and the 
hypoxia response, which has been shown to promote glycolysis and act as a 
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tumour suppressor in breast cancer cells, possibly due to induction of 
autophagy or “self-digestion” of the tumour cells. On the other hand, 
activating HIF-1a in cancer-associated fibroblasts enhances tumour growth, 
due to autophagy of the fibroblasts resulting in availability of lactate and 
pyruvate for the tumour cells [205].  
Therefore, it is possible that the metabolic phenotype observed in ALDO+RA 
treated cells (increased HIF-1a activation, increased aerobic glycolysis, 
decreased oxidative phosphorylation) is in fact tumour-suppressive. If so, it 
provides mechanistic insights into prognostic utility of MR in ER- breast 
cancers demonstrated in Section 4.3.1, and the potential for MR and RARB to 
influence breast cancer cell growth through altered energy metabolism.   
6.4.6 Effect	of	MR	and	RAR	signalling	on	breast	cancer	
cell	proliferation	and	patient	survival	
To further explore the effect of MR and retinoic acid signalling on breast 
cancer growth, we investigated the expression of proliferative genes when MR-
inducible MCF-7 breast cancer cells are treated with ALDO, RA, ALDO+RA. 
We also included 17b-estradiol (E2) and ALDO+E2 treatments as a reference 
for the well-known proliferative effect of E2 on breast cancer cells. We then 
investigated the expression of the meta-PCNA genes as well as calculated the 
meta-PCNA index as a measure of cell proliferation. Meta-PCNA genes are a 
set of genes highly correlated with the proliferating cell nuclear antigen 
(PCNA), a well-known proliferation marker in multiple tissue types [110]. Here, 
the meta-PCNA index is defined as the median expression of the meta-PCNA 
genes in each treatment condition. Figure 53A shows the meta-PCNA indices 
and Figure 53B shows a clustered heatmap of the expression of meta-PCNA 
genes. 
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Figure 53: Effect of MR and RAR signalling on breast cancer cell proliferation. (A) PCNA Index as 
a proliferation measure for MR-inducible cells under different treatment condition. Here Dox is 
used to induce MR, therefore Dox alone is equivalent to Vehicle treatment of MR containing 
cells. (B) Expression of Meta-PCNA genes under different treatment conditions of MR-inducible 
MCF-7 breast cancer cells. Yellow, pink and blue color bars on the right handside denotes 
different clusters of proliferative genes that are differentially expressed under different 
treatment conditions. 
The PCNA-index of E2-treated cells was highest, which reflected the known 
proliferative effect of E2 in breast cancer cells. DOX+ALDO treated cells had a 
lower PCNA-index compared to cells treated with DOX alone, and 
DOX+ALDO+RA treated cells showed an even further decrease in the PCNA-
index. The heatmap of meta-PCNA gene expression shows that E2 treatment 
activates a set of proliferative genes (yellow cluster) and that ALDO+E2 
treatment results in their suppression, suggesting that ALDO can counteract 
the E2 proliferative effect when both signalling pathways are active. 
Furthermore, ALDO+RA co-treatment results in even stronger suppression of 
these genes compared to DOX alone, ALDO alone or RA alone. The second set 
of proliferative genes (pink cluster) shows a response to E2 and/or RA 
signalling but not ALDO signalling. Finally, the third meta-PCNA gene cluster 
(blue) contains genes that show strongly decreased expression on 
RA/ALDO+RA treatments, but a lesser response to ALDO, E2 or ALDO+E2 
treatment.  
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This result suggests that ALDO and RA signalling can inhibit E2-dependent as 
well as E2-independent proliferation of breast cancer cells. It also shows that 
co-activation of ALDO and RA signalling results in a stronger anti-proliferative 
effect compared to activation of each alone, suggesting a co-operative crosstalk 
of the MR and RA signalling pathways to inhibit breast cancer growth. 
Given the strong suppressive effect of MR and RA signalling on proliferation in 
our MR-inducible breast cancer cell model, we proceeded to investigate 
whether high MR and RARB expression associates with better survival in 
breast cancer patients. To do this we classified breast cancer cases from the 
METABRIC breast cancer microarray dataset (Dataset 3, described in Section 
2.2.3) into four sample sub-groups based on the expression of MR and RARB as 
shown in Figure 54A. Kaplan Meier analysis was then performed to test the 
difference in the probability of disease-specific survival for each sample 
subgroup (Figure 54B). The result shows that high MR and RARB expression in 
breast cancer is associated with significantly different and possibly better 
survival outcome compared to high expression of only one of the two 
receptors or absence/low expression of both receptors. 
 
Figure 54: Survival analysis of breast cancer tissues expression high MR and RARB. (A) Scatter 
plot of expression of MR against RARB in breast cancer samples from the METABRIC dataset 
(Dataset 3, described in Section 2.2.3). A receptor is classified as highly or poorly expressed in a 
sample if its expression in that sample is in the top or bottom 20% of its expression range 
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respectively. (B) Kaplan Meier analysis showing samples expressing high level of both MR and 
RARB have better survival outcome. 
6.5 Chapter	summary	
This chapter explores the functional roles of MR in the breast and the 
potential crosstalk between MR and retinoic acid signalling through a 
combination of in silico analyses and cell line experiments. Starting with 
hypotheses generated from in silico analysis of NR co-expression and 
differential co-expression networks, which suggested that: 
i) MR plays a role in breast cancer biology due to its decreased 
expression in breast cancer, prognostic utility in ER- breast cancers, 
as well as the enrichment of cancer-relevant biological processes in 
the set of genes co-expressed with MR in the normal breast and 
breast cancer (MR was positively co-expressed with genes involved 
in angiogenesis, cell proliferation, cell migration, cell adhesion and 
transcriptional regulation while negatively co-expressed with genes 
involved in metabolic regulation) 
ii) There is potential crosstalk between MR and RAR signalling in the 
normal breast, likely mediated through RARB, which is disrupted in 
breast cancer. The convergence of MR and RARB signalling in the 
normal breast is most likely on the regulation of cellular metabolic 
processes as well as general cell maintenance including regulation of 
cilium assembly, mRNA processing, protein modifications 
(ubiquitination, sumoylation), chromatin modification, cell cycle 
and DNA damage response. 
We went on to demonstrate through expression profiling of ligand-treated 
MR-inducible breast cancer cells that: 
1) Co-activation of ALDO and RA resulted in differential expression of a 
large number of genes whose expression are not significantly changed 
The functional roles of the mineralocorticoid receptors in breast cancer 
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when ALDO or RA is activated singly, suggesting that there is 
convergence or crosstalk in the two signalling pathways. 
2) Although only a small percentage of MR co-expressed genes overlap 
with ALDO regulated (2%) or ALDO+RA regulated (12%) genes, 
activating MR signalling in MCF-7 breast cancer cells results in the 
change in expression of genes associated with functions closely related 
to that predicted through analysis of MR co-expression network. 
3) Activating MR and RAR signalling results in changes in expression of 
metabolic genes that together resemble the metabolic profile described 
for cancer-associated fibroblast or hypoxic cancer cells in the reverse 
Warburg effect model (activation of HIF-1A and hypoxia response, 
suppression of genes involved in oxidative phosphorylation and up-
regulation of genes in aerobic glycolysis).  
4) MR and RAR signalling can inhibit both E2-dependent and E2-indepent 
proliferation of breast cancer cells. 
5) High MR and RARB expression is significantly associated with better 
breast cancer disease-specific survival. It is possible that high 
expression of these two NRs facilitates signalling that is ‘closer’ in 
biology to the normal breast, hence the more favourable outcome. 
This chapter demonstrates the usefulness of analyzing the co-expression and 
differential co-expression networks of NRs to gain insights into their potential 
functional roles and generate novel hypotheses.  
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The motivation behind the work described in this thesis is the need to develop 
rational prognostic and therapeutic targets for subgroups of breast cancers 
that do not benefit from current treatment options, including ER- breast 
cancers [5], endocrine treatment resistant breast cancers [4], and cancers that 
recur in all age groups [6]. In this context, NRs are promising prognostic and 
therapeutic targets as they play diverse and important roles in regulating 
normal physiological functions in a tissue-specific manner, and are the subject 
of intensive drug research and development for a range of pathological 
conditions. Yet aside from intensive research focused on a few selected NRs, 
not much is known about the functional roles of the other members of the NR 
family in normal mammary gland development or in breast cancer. Recent 
work profiling the expression of all NRs in well-curated normal breast and 
breast cancer tissues showed that many NRs are differentially expressed in 
breast cancer compared to the normal breast [62, 63], implicating their 
involvement in breast cancer biology. Despite this, not much is known about 
the biological processes governed by each NR and whether or how their 
regulatory networks intersect.  
In this context, even though recent cistromic studies in cell lines have brought 
valuable insights into the gene regulatory networks of a number of nuclear 
receptors in breast cancer [26], technical difficulties associated with these 
methods prevents their routine use in clinical samples (discussed in more 
detail in Section 1.3.3.3). In the absence of detailed genomic localization maps 
and tissue-specific protein-protein interaction data for most nuclear receptors, 
and the impossibility of experimentally deriving functional data from human 
tissue cohorts, gene co-expression analysis using readily available expression 
profiles of primary breast tissues is an attractive alternative approach to gene 
network and functional inference. The work described in this thesis 
demonstrates the utility of co-expression analysis as a network and functional 
inference tool and highlights the usefulness of differential co-expression 
analysis in the identification of cancer associated changes in NR regulatory 
networks of clinical relevance. As a whole, this thesis represents a step towards 
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unravelling the functional roles of NRs in the breast and towards rational 
identification of NRs with prognostic or therapeutic utility for breast cancer. 
7.1 Distinction	of	the	approaches	utilized	in	this	
thesis	
There have been some debates about whether network-based approaches to 
breast cancer prognostication offer improved performance over single gene or 
gene-based approaches. Staiger et al. evaluated the predictive performance of 
reported network-based approaches on six breast cancer datasets and reported 
that gene signatures derived using a network approach do not offer any 
improvement over single genes classifiers [206, 207]. More recently, Barter et 
al. showed that while network based approaches do not offer significant 
improvement in classification accuracy, they correctly classify different 
subspaces of the patient cohort and therefore can be considered as a 
complementary approach to gene-based approaches [208]. 
One crucial aspect of many reported network-based approaches is that they 
utilize protein-protein interaction (PPI) networks or pre-defined pathways as 
the network context onto which gene expression data are superimposed as the 
basis to guide selection of signature genes [209-212]. Aside from the high level 
of noise inherent in PPI networks, the main drawback of PPI networks is that 
they are cell- and tissue-type agnostic. Given that several cistromic studies 
reported large differences in the genome-wide binding profiles for the same 
NR in different cell types [30, 31], it is perhaps not surprising that network-
based approaches to prognostic gene selection that utilized cell and tissue-
type agnostic PPI networks do not offer much improvement in comparison to 
gene-based approaches. Indeed, Staiger et al. observed that most of the 
predictive power of approaches based on PPI network appears to be derived 
from the gene expression data and that the PPI data mainly serve as a means 
to reduce the search space during the selection process but offer little 
additional prognostic information. 
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In this context, it is worth highlighting that while also utilizing a network-
based method to identify NRs with prognostic utility, our approach is quite 
distinct to PPI-based approaches mentioned above. Instead of relying on PPI 
or pre-defined pathways as the network context, we relied on gene co-
expression networks constructed from expression profiles of primary normal 
breast and breast cancer tissues. More specifically, we used the changes in 
gene co-expression networks observed between cancer and normal as the basis 
for selecting prognostic genes. Although more rigorous evaluation is needed to 
determine whether this approach can indeed provide improvement over PPI-
based or gene-based approaches, this approach is conceptually more relevant 
to breast cancer biology. The real strength of this approach is that in addition 
to identifying the NRs showing significant changes in their co-expression 
networks associated with breast cancer, and therefore more likely to be 
prognostic, this approach also gives insights into the potential biological 
processes influenced by these NRs. 
Others studies have demonstrated the utility of co-expression analysis in 
identifying breast cancer prognostic gene signatures [184], for gaining insights 
into the biology behind breast cancer prognostic signatures [112] or for 
defining NR-drug interaction and predicting cancer-drug sensitivity [155]. The 
main difference in our approach to that of the mentioned studies is that 
instead of using co-expression modules identified in breast cancer as the basis 
for prognostic gene selection, selection or grouping of prognostic NR 
signatures in this thesis were based on the changes in the NR co-expression 
networks associated with breast cancer compared to the normal breast. 
7.2 Main	research	outcomes	
Reflecting observations in cell line cistromic studies [26], Chapter 4 revealed 
that the co-expression networks of NRs in both the normal breast and breast 
cancer are highly interconnected, with extensive sharing of co-expressed genes 
among NRs. Yet, while being strongly interconnected, the identification of co-
expressed gene modules with relatively distinct and coherent functional 
Discussion 
 196 
enrichment suggests that there exists some degree of functional 
compartmentalization in the NR regulatory networks in the breast, where 
specific combinations of NRs are strongly co-expressed with genes involved in 
specific aspects of normal breast or breast cancer biology. Organization of the 
NR family into functional subgroups was previously reported in a study that 
performed anatomical profiling of NR expression in mouse tissues [142]. 
Identification of NRs responsible for specific aspects of breast cancer biology 
opens the way to rational selection of prognostic genes. For example, as a 
rational approach to prognostic gene selection, a combination of NRs can be 
selected to simultaneously capture multiple aspects of cancer biology. Such a 
prognostic gene signature may offer additional prognostic power compared to 
those that capture the effect of proliferation alone. 
Among the main findings of this thesis is the observation that there are major 
changes in NR co-expression networks associated with breast cancer compared 
to the normal breast and that these changes are relevant to clinical outcomes. 
This is evident in the work of Chapter 3 and Chapter 4. Chapter 3 presents the 
first combined profiling of NRs and coregulators in carefully curated cohorts of 
breast cancer and histologically normal breast tissues. In addition to revealing 
almost pan repression of coregulators in breast cancer, this work also 
highlights NR-coregulator interactions active in the normal breast but 
disrupted in breast cancer and vice versa. Of particular significance is the 
demonstration that NRs showing acquired correlations with multiple 
coregulators in ER- breast cancers have stronger prognostic utility in these 
cancers. This observation highlights the utility of examining changes in NR co-
expression networks and the importance of examining not only “loss-of-
function” disruptions but also “gain-of-function” perturbations as a mean of 
identifying prognostic and therapeutic markers for breast cancer.  
Chapter 4 expands on the work of Chapter 3 by applying a more rigorous 
analytical framework to identify NR co-expression networks and differentially 
co-expressed gene modules in an independent, genome-wide dataset. Aside 
from allowing inference of the potential functional roles of individual NRs in 
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the normal breast and breast cancer, Chapter 4 demonstrated the utility of 
differential co-expression analysis in identifying changes in NR co-expression 
networks of relevance to breast cancer biology. We identified in Chapter 4 
functionally coherent gene modules differentially co-expressed with specific 
combinations of NRs in breast cancer compared to normal breast tissues, 
namely modules associated with metabolic regulation, cell adhesion and 
immune response, cell cycle regulation, general transcriptional regulation. 
Although not fully explored in this thesis, identification of functionally 
coherent differentially co-expressed gene modules centered around NRs opens 
the way to more rational design of prognostic gene signatures or NR-centered 
therapeutic strategies that encompass multiple aspects of breast cancer 
biology. 
It is well recognized that proliferation underlies the prognostic ability of the 
majority of current molecular prognostic gene signatures for breast cancer and 
that most current signatures perform well in ER+ but not ER- breast cancers 
[108, 110, 112]. In this context, the identification of a group of NRs (NRs in 
Group 6 of Section 4.3.1.2) showing cancer-associated acquired co-expression 
with metabolic, cell adhesion, and immune response genes that display 
prognostic utility in ER-, HER2, and Basal breast cancers independent of 
tumour grade, nodal status and ER status is of particular significance. It 
highlights the utility of differential co-expression based approaches as a means 
of identifying breast cancer prognostic gene signatures and elucidating the 
signature’s underlying biology. 
In addition to identifying cancer associated changes in NR regulatory 
networks, Chapter 6 demonstrated that co-expression based analysis of gene 
expression data is also a useful tool for the inference of potential crosstalk in 
the signalling networks of different NRs. We showed through a combination of 
in silico and in vitro analyses the convergence of MR and RAR signalling, most 
likely through RARB, in normal breast cells to regulate cellular metabolism 
and general cell maintenance which is disrupted in breast cancer due to the 
decreased expression of both MR and RARB. Crosstalk in MR and RARB 
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signalling has not been reported in the breast, although MR and RARB are 
members of a group of NRs reported to regulate CNS, Circadian and Basal 
Metabolic Response through anatomical profiling of NR expression in mouse 
by Bookout et al. [142]. Our results therefore support the functional grouping 
of MR and RARB observed in mouse, and suggest that MR and RARB also 
converge in the metabolic regulation of normal breast cells. 
While RARB is known to suppress breast cancer through inducing apoptosis 
and inhibiting metastasis [17, 199, 201], relatively little is known about the role 
of MR in breast cancer. MR was recently reported to suppress cancer 
progression through suppressing the Warburg effect in a hepatocellular 
carcinoma cell line [213]. We showed that while co-activation of MR and RARB 
resulted in both E2-dependent and E2-independent inhibition of cell 
proliferation, it exerts the opposite effect on the metabolic response of breast 
cancer cells, specifically promoting glycolysis and suppressing oxidative 
phosphorylation. Although opposite to that observed in hepatocellular 
carcinoma, the resulting metabolic profile resembles that reported for cancer-
associated fibroblasts or hypoxic cancer cells hence the MR effect on breast 
cancer cell growth would still be suppressive if the reverse Warburg model is 
the prevalent model for breast cancer cell metabolism. Modulating cellular 
metabolic response is therefore likely one of the means through which MR and 
RAR signalling exert their anti-proliferative effect in breast cancer. It is likely 
though that in addition to the modulation of metabolic response, the tumour 
suppressive effect of MR is mediated through other means not fully explored 
in this thesis, including the regulation of apoptosis and angiogenesis, as 
suggested by the enrichment of these biological processes in genes 
differentially expressed under ALDO treatment in MCF-7 cells. Finally, the 
suppressive effect of MR and RAR signalling in breast cancer is supported by 
the observation that tumours expressing high MR and RARB are associated 
with better survival outcome. 
Although less apparent, the observation that activating MR and RARB in 
cancer cells resulting in suppression of genes inversely co-expressed with MR 
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and RARB in normal cells highlights the need for understanding the normal 
physiological functions of NRs as a mean of understanding their effects in 
breast cancer. Examination of NR expression and co-expression in different 
cell types of the normal breast at single cell level is a step towards this effort. 
Furthermore, it is believed that the different breast cancer subtypes arise from 
oncogenic transformation of normal breast epithelial cells at different points 
in the differentiation hierarchy [189]. Hence, elucidating normal epithelial 
differentiation hierarchy and the biological processes differentially regulated 
in different normal epithelial cell types is an important step towards 
understanding molecular perturbation that drive the different subtypes of 
breast cancer. Although Lawson et al. reported a 49-gene differentiation 
signature developed from single cell profiling of normal breast epithelial cells 
[214], theirs was a targeted approach in which normal breast epithelial cells 
were pre-sorted into basal/stem, luminal and luminal progenitor cells based 
on marker expressions before expression profiling of 116 genes. By contrast, we 
profiled the genome-wide transcriptome of normal breast epithelial cells and 
perform unsupervised cell type classification to identify different normal 
breast cell types based on their transcriptomic profiles. To our knowledge, this 
is the first systematic examination of NR expression in normal breast epithelial 
cells types at single cell level. The identification of several NRs showing 
preferential expression in different normal breast epithelial cell types paves the 
way for future targeted studies of their functions in both normal breast 
development and the biology of different breast cancer subtypes  
The low connectivity of NR co-expression networks at single cell level and the 
low functional enrichment of genes co-expressed with specific NRs were un-
expected. It is possible that the small sample size, and the highly cell-specific 
action of NRs are factors that contribute to this observed lack of connectivity 
in the co-expression networks of different NRs. However our findings are 
consistent with recent publications of co-expression analysis of single cell 
expression data, which reported that co-expressed genes from single cells and 
bulk tumours have little overlap and that bulk level and single cell level co-
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expression networks may be capturing functional gene modules that are 
regulated by different modes of regulation [193]. Another study reported that 
single cell network connectivity is less likely to overlap with known function 
compared to co-expression derived from bulk data and that both network 
connectivity and functional enrichment of single cell co-expression network 
are heavily influenced by gene expression levels [194]. Therefore, it is possible 
that the lack of connectivity observed in NR co-expression networks at the 
single cell level may reflect both a real biological phenomenon and technical 
artefacts. Future analysis of larger cell populations, sequenced at greater depth 
and using more sophisticated bioinformatics methods will hopefully help to 
mitigate compounding technical factors to reveal real biological insights. 
7.3 Limitations	of	this	study	and	direction	
for	future	research	
Central to this whole thesis is the use of gene-gene correlations as proxy 
measures for functional relatedness. While a very strong correlation threshold 
is used in Chapter 3 and a more rigorous statistical method of determining co-
expression significance through permutation tests were employed in 
subsequent chapters, we acknowledge that correlated expression suggests, 
but does not prove, functional co-operation.  Furthermore, the study is based on 
RNA measurements, which offer many benefits but is also a limitation because 
ultimately gene function is imparted by protein products. Currently, very little is 
known about the RNA-protein relationships for most NRs. Systematic examination 
of NRs at the protein level is unfortunately beyond the scope of this thesis.
While Chapter 3 examines NR and co-regulator expression in breast cancer 
against true normal breast tissues, Chapter 4 relies on the expression profiles 
of adjacent normal tissues. Tumour adjacent morphologically normal tissues 
have been reported to display both cancer associated transcriptomic and 
epigenetic changes and therefore are not ideal controls [215-217]. 
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However, adjacent normal were used in this study due to the lack of genome-wide 
expression profiles of true normal breast tissues with enough sample size to facilitate 
correlation-based analysis. In addition, Chapter 4 of this thesis made use of the 
TCGA's RNA-seq data for breast cancer. Although it is one of the larger breast 
cancer RNA-seq dataset currently available, the number of samples is still 
considerably less than the number of genes being examined and therefore will suffer 
the "curse of dimensionality" common to most genomic and transcriptomic studies 
to date. Being mindful of this, we have applied rigorious resampling method to 
determine co-expression and differential co-expression significance to minimize 
false discovery rate. The large number of genes identified to be co-expressed with 
the NR super-family of nuclear receptors is not surprising. Nuclear receptors are 
known to be master regulators of multiple facets of cell biology. Therefore it is 
expected that a large number of genes are correlated with their expression.
While this thesis explored NR co-expression and differential co-expression 
networks in breast cancer and normal breast, application of this analytical 
framework to different breast cancer subtypes were not explored. 
Identification and characterization of subtype-specific changes in NR co-
expression networks would likely bring novel insights and enable rational 
design of subtype-specific prognostication and therapeutic tools and will 
form the basis for future research.  
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Abstract
Nuclear receptors (NRs) have been targets of intensive drug development for decades 
due to their roles as key regulators of multiple developmental, physiological and disease 
processes. In breast cancer, expression of the estrogen and progesterone receptor remains 
clinically important in predicting prognosis and determining therapeutic strategies. 
More recently, there is growing evidence supporting the involvement of multiple nuclear 
receptors other than the estrogen and progesterone receptors, in the regulation of 
various processes important to the initiation and progression of breast cancer. We review 
new insights into the mechanisms of action of NRs made possible by recent advances in 
genomic technologies and focus on the emerging functional roles of NRs in breast cancer 
biology, including their involvement in circadian regulation, metabolic reprogramming 
and breast cancer migration and metastasis.
Introduction
Breast cancer is the most common cancer diagnosed 
in women worldwide (Ferlay  et al. 2015). Over the past 
decades, substantial progress toward treatment of primary 
estrogen receptor-positive (ER+) breast cancer has been 
made with the development of endocrine therapies 
targeting the estrogen biosynthesis and signaling 
pathways. Despite the success of endocrine therapies, 
there remain subgroups of women for whom available 
treatment offers little help. These include patients with 
ER+ breast tumors who develop endocrine treatment 
resistance (Dixon 2014), patients with estrogen receptor-
negative (ER−) breast cancers (Hudis & Gianni 2011) 
and cancers that recur in all age groups (EBCTCG 2005). 
Women in these subgroups currently face the challenge 
of living with advanced disease; therefore, there exists 
the need to develop rational treatments targeting these 
subgroups of breast cancer.
Nuclear receptors (NRs) are potential promising targets 
due to the importance of NRs as master regulators of 
nearly all physiological aspects of life and the availability 
of drugs targeting NRs that resulted from intensive drug 
development targeting NRs for a range of pathological 
conditions. The human NR superfamily consists of 48 
highly evolutionarily conserved transcription factors with 
the ability to act as molecular sensors of physiological 
and environmental stimuli (Mangelsdorf  et  al. 1995). 
Development of technologies that allow genome-wide, 
unbiased profiling of genomic binding sites and gene 
expression has allowed deeper insights into the molecular 
mechanisms of NR actions. These studies highlight the 
complexity of gene regulatory networks governed by 
NRs, the extensive nature of NR crosstalk and the role 
of coregulators and the chromatin landscape of the cell 
as important modulators of NR cell type-specific and 
context-dependent function.
In the context of breast cancer, it is recognized that 
estrogen receptor (ESR1) and progesterone receptor (PGR) 
play critical roles in the development and progression 
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of breast cancer, and moreover, their expression in a 
breast tumor remains the single most robust predictor of 
disease outcome. Consequently, measurement of ESR1 
and PGR expression in breast cancers is a mainstay of 
clinical management programs and treatments targeting 
the estrogen signaling axis are standard of care for ER+ 
disease (Cordera & Jordan 2006). More recently, the 
androgen receptor (AR), which is frequently expressed 
in primary breast tumors (Park  et al. 2010, Grogg  et al. 
2015), has emerged both as a marker of outcome and 
as a potential treatment target (Cordera & Jordan 2006, 
Barton et al. 2015). A number of other nuclear receptors, 
including the vitamin D3 receptor (VDR) (Krishnan et al. 
2010, Mehta et al. 2013) and the glucocorticoid receptor 
(GR) (Vilasco  et  al. 2011, Abduljabbar  et  al. 2015b) 
have also been investigated for their anti-proliferative 
and anti-apoptotic effects in breast cancer. Members 
of the retinoid receptor subfamily have also received 
considerable attention, particularly the crosstalk between 
the retinoic acid receptor alpha (RARA) and estrogen 
signaling (Hua  et  al. 2009, Ross-Innes  et  al. 2010), and 
the anti-migratory effect of the retinoic acid receptor beta 
(RARB) in breast cancer (Yang  et al. 2002, Flamini  et al. 
2014). However, the functional roles of the majority 
of the remaining members of the human NR family in 
the normal breast and breast cancer have largely been 
unexplored. Recent studies are establishing that the 
involvement of NRs in breast cancer extends beyond their 
involvement in regulating proliferation and apoptosis 
and that NRs are important regulators of several aspects 
of breast cancer tumorigenesis and progression including 
regulation of the circadian clock, metabolism, migration 
and metastasis. In this review, we will discuss evidence for 
these emerging functional roles of NRs in breast cancer, 
as well as new insights into the molecular mechanisms 
of action of NRs made possible through advances in 
genomic technologies.
The nuclear receptor superfamily
The human nuclear receptor superfamily consists of 48 
members. These transcription factors include the receptors 
for steroid hormones, thyroid hormones, lipophilic 
vitamins and cholesterol metabolites including retinoic 
acid and oxysterols (Mangelsdorf  et  al. 1995). Members 
of the NR superfamily are identified through their highly 
evolutionarily conserved structural organization (Evans & 
Mangelsdorf 2014), which consists of four major domains: 
The N-terminal A/B domain with activation function1 
(AF1); the DNA-binding domain (DBD) consisting of 
two zinc finger motifs which confers response element 
specificity and the hinge region linking the DBD to the 
ligand-binding domain (LBD), which may or may not 
have an AF2 region that mediates coactivator interaction 
(Giguere et al. 1986, Kumar et al. 1987, Mangelsdorf et al. 
1995) (Fig.  1A). Approximately half of the NRs are 
designated as orphans because endogenous physiological 
ligands for these NRs have not been found (Table 1). The 
48 human NRs are organized into six evolutionary groups 
based on sequence alignment and phylogenetic tree 
construction (Auwerx  et al. 1999, Germain  et al. 2006). 
Organization of NRs into functional groupings is also 
feasible, based on profiling the anatomical expression of 
NRs. In the mouse, this revealed a hierarchical organization 
of NRs into integrated physiologic functional groups 
(Fig. 1B), which partially reflect the functional groupings 
observed in human, especially for NRs that are involved 
in circadian and metabolic pathways (reviewed here).
In the classical model of NR action, upon ligand 
activation, NRs regulate gene transcription by binding 
response elements within the regulatory regions of target 
genes as monomers, homodimers or heterodimers with 
another family member. For example, steroid hormone 
receptors generally bind as homodimers, whereas VDR, 
THR, RAR and RXR can form both homodimers and 
heterodimers. RXRs in particular can act as promiscuous 
heterodimerization partners for VDR, THR, RAR and 
orphan receptors. Dimerization is a general mechanism 
to increase binding affinity, specificity and diversity. 
Nuclear receptor response elements are derivatives of the 
canonical hexameric sequence RGGTCA. Modifications 
and duplications (organized as direct, inverted or everted 
repeats separated by a spacer with variable length) of 
this canonical hormone response element allow for 
selective recognition by different NR subclasses (Laudet & 
Gronemeyer 2002, Gronemeyer et al. 2004).
Ligand binding also allosterically controls the 
interaction of NRs with coregulators by influencing the 
conformation of the AF2 region. Coregulators are integral 
to the mechanisms by which NRs exert their functions 
and include both coactivators and corepressors. The 
majority of coregulators function as members of large 
complexes that affect NR transcriptional regulation of 
target genes through interactions with other transcription 
factors, the chromatin landscape as well as non-coding 
RNAs (Millard  et  al. 2013). Both the interaction with 
coregulators and the chromatin landscape of the cell have 
been shown to affect the cell type specificity of NRs.
NRs regulate the transcription of genes that control a 
wide variety of biological processes in normal physiology 
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including embryonic development, reproduction, 
metabolism, homeostasis and cell proliferation. NRs 
are also known to play a role in various pathological 
processes including cancer, inflammation and metabolic 
disorders (McKenna & O’Malley 2010) and as such have 
been targets of intensive drug development for decades 
(Ottow & Weinmann 2008).
NR expression in the normal breast and 
breast cancer
Recent studies have begun to provide a global view of the 
functional roles and expression of the NR superfamily 
in primary normal breast (Muscat  et  al. 2013) and 
breast cancer tissues (Muscat et al. 2013, Lin et al. 2015). 
Muscat and coworkers found that the majority of NRs 
are expressed in the breast (41 of 48). Many NRs showed 
differential expression in breast cancer compared to the 
normal breast indicative of potential involvement in 
breast cancer biology (Muscat et al. 2013). In particular, 
breast cancer is associated with the overexpression of the 
NR4A subgroup as well as EAR2, and pan-repression of 
the majority of NRs relative to the normal breast. High 
expression of the NR4A subgroup in breast cancer was 
also observed by Lin and coworkers (Lin  et  al. 2015). 
In addition to ESR1, PGR and AR, expression levels of other 
NRs were shown to be associated with histological grade 
(THRB, NUR77, RORC, COUP-TF2 and LRH-1), to classify 
breast tissues (THRA, ESR1, NURR77, EAR2 and RARG) and 
to predict metastasis-free survival in tamoxifen-treated 
patients (THRB, COUP-TF2, MR and PPARG). Thirty-three 
of the 48 human NRs were also observed to be expressed 
in stromal cells and four of these (RORA, THRB, VDR and 
PPARG) were shown to have differential expression profiles 
in cancer-associated fibroblasts compared to normal 
breast adipose fibroblasts (Knower et al. 2013). Together, 
these studies highlight that multiple members of the NR 
family are likely to play important roles in breast cancer 
growth and development and to have discriminant and 
prognostic value in breast cancer.
NR expression in breast cancer subtypes
Breast cancer is a heterogeneous disease encompassing 
multiple subtypes with distinct molecular profiles, 
therapeutic response and clinical outcomes (Prat  et  al. 
2015). Several NRs have been shown to either act 
co-operatively with ESR1 and/or have differential 
Figure 1
(A) Schematic diagram of the structural and functional organization of nuclear receptors (reprinted by permission from Macmillan Publishers Ltd: Nature 
Reviews Drug Discovery (Gronemeyer et al. 2004), copyright 2004). The evolutionary conserved regions C and E are indicated as boxes (green and 
orange, respectively), and a black bar represent the divergent regions A/B, D and F. Domain functions are depicted above and below the scheme (AD, 
activation domain; AF1, activation function 1; NLS, nuclear localization signal). (B) Hierarchical clustering of NR tissue expression profile (reprinted from 
Cell, volume 126, Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM & Mangelsdorf DJ, Anatomical profiling of nuclear receptor expression reveals a 
hierarchical transcriptional network, pages 789–799, copyright (2006), with permission from Elsevier). The relationship between receptor expression, 
function and physiology is depicted as a circular dendrogram using the hierarchical, unsupervised clustering of NR tissue expression distribution profiles 
in mouse. The analysis reveals the existence of a higher order network tying nuclear receptor function to reproduction, development, central and basal 
metabolic functions, dietary-lipid metabolism and energy homeostasis. The NRs in red boxes are discussed in this review with a focus on their functional 
roles in circadian regulation, metabolism and breast cancer migration and metastasis.
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Table 1 Human nuclear receptors.
 
Name
 
Nomenclature
 
Symbol
 
Entrez ID
 
Ligands
Expression in BC 
vs normal
Association with 
ESR1 expression
Steroid hormone receptors
Estrogen receptor NR3A1 ESR1 2099 Estogens Increased Yesa,b
 NR3A2 ESR2 2100 Estradiols Decreased  
3-Ketosteroid receptor NR3C1 GR 2908 Cortisols 
(hydrocortisone)
Increased  
 NR3C2 MR 4306 Aldosterone Decreased  
 NR3C3 PGR 5241 Progesterone Expressed in BC Yesa,b
 NR3C4 AR 367 Testosterone, 
dihydrotestosterone
Increased Yesa,b
Non-steroid hormone receptors
Thyroid hormone receptor NR1A1 THRA 7067 Thyroxine (T4), 
triiodothyronine (T3)
Decreased  
 NR1A2 THRB 7068 Thyroxine (T4), 
triiodothyronine (T3)
Decreased Yesa,b
Retinoic acid receptor NR1B1 RARA 5914 All-trans and 9-cis 
retinoic acid
Increased Yesa,b
 NR1B2 RARB 5915 All-trans and 9-cis 
retinoic acid
Decreased  
 NR1B3 RARG 5916 All-trans and 9-cis 
retinoic acid
Decreased  
RAR-related orphan receptor NR1F1 RORA 6095 Oxysterols Decreased  
 NR1F2 RORB 6096 Cholesterol, cholesteryl 
sulphate
Decreased Yesb
 NR1F3 RORC 6097 Retinoic acid Decreased Yesb
Vitamin D receptor NR1I1 VDR 7421 Calcitriol (1′,25′ 
dihydroxy vitamin D3)
Decreased  
Adopted orphans
Peroxisome proliferator-
activated receptor
NR1C1 PPARA 5465 Fatty acids Decreased Yesb
 NR1C2 PPARD 5467 Fatty acids Decreased  
 NR1C3 PPARG 5468 Fatty acids Decreased  
Rev-erbs NR1D1 REV-ERBa 9572 Heme Decreased  
 NR1D2 REV-ERBb 9975 Heme Decreased  
Liver X receptor-like NR1H2 LXRb 7376 Retinoic acid Decreased  
 NR1H3 LXRa 10062 Oxysterols Decreased  
 NR1H4 FXRa 9971 Bile acids Not expressed  
Vitamin D receptor-like NR1I2 PXR 8856 Bile acids Decreased  
 NR1I3 CAR 9970 Androstanol, 
androstenol
Not expressed  
Retinoid X receptor NR2B1 RXRA 6256 9-cis-retinoic acid Decreased  
 NR2B2 RXRB 6257 9-cis-retinoic acid Decreased  
 NR2B3 RXRG 6258 9-cis-retinoic acid Decreased  
Steroidogenic factor-like NR5A1 SF-1 2516 Phospholipids Not expressed  
 NR5A2 LRH-1 2494 Phospholipids Decreased Yes
Orphan nuclear receptors
DSS-AHC critical region on the 
X chromosome, gene 1
NR0B1 DAX-1  Not known Not expressed Yes
Short heterodimeric partner NR0B2 SHP 8431 CD437 retinoids Not expressed  
Hepatocyte nuclear factor 4 NR2A1 HNF4a 3172 Fatty acids Not expressed  
 NR2A2 HNF4g 3174 Fatty acids Decreased  
Testicular orphan receptors NR2C1 TR2 7181 All-trans retinoic acid Decreased  
 NR2C2 TR4 7182 All-trans retinoic acid Decreased  
Tailess-related receptor NR2E1 TLX 7101 Not known Not expressed Yesb
Photoreceptor cell-specific 
receptor
NR2E3 PNR 10002 Benzimidazoles Decreased Yesa,b
Chicken ovalbumin upstream 
promoter-transcription factor
NR2F1 COUP-TF1 7025 Not known Decreased  
 NR2F2 COUP-TF2 7026 Retinol/ATRA Decreased  
(Continued)
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actions in ER+ vs ER− breast cancers. For instance, AR 
has different roles in ER+ vs ER− breast cancers. AR has 
been investigated extensively as a therapeutic target in 
ER− breast cancer. It was reported that in ER−/HER2+ 
breast tumors, AR stimulates oncogenic Wnt and HER2 
signaling pathways thereby stimulating cancer cell 
growth (Ni  et  al. 2011). However, the role of androgen 
signaling in ER+ breast cancer is less clear. Expression of 
AR is associated with good prognosis in ER+ breast cancer 
(Hu et al. 2011, Hilborn et al. 2016), with anti-estrogenic 
and anti-proliferative effects in ER+ breast cancer being 
reported (Peters  et  al. 2009, D’Amato  et  al. 2015). The 
anti-proliferative effect of AR is partly attributed to its 
inhibitory effect on ESR1 signaling in ER+ breast cancer 
cells (Peters et al. 2009, Fioretti et al. 2014). However, AR 
has also been reported to contribute to therapy resistance 
in ER+ breast cancer cells overexpressing AR, with increase 
in AR-to-ESR1 ratio associated with worse outcome for 
tamoxifen-treated patients (Cochrane  et  al. 2014) and 
increased agonist activity of Tam in AR overexpressing 
cells. In this context, AR reportedly increased tamoxifen 
agonist activity via the activation of EGFR in ER+ breast 
cancer, and this was blocked by dual treatment with the 
anti-androgen enzalutamide and EGFR inhibitor gefitinib 
(Ciupek et al. 2015). In addition, AR appears to promote 
proliferation of molecular apocrine breast cancer; a 
subset of TNBC expressing AR, through activation of 
genes that are normally regulated by ESR1 in ER+ cancer 
(Robinson et al. 2011).
Similarly, the expression of GR has been shown 
to be differentially associated with survival in 
ER+  vs  ER−  breast  cancers. In ER+ breast cancers, 
high GR expression is associated with better survival 
(Pan  et  al. 2011, Abduljabbar  et  al. 2015b), whereas in 
ER− breast cancers, high GR expression is correlated with 
poorer breast cancer-specific survival (Pan  et  al. 2011, 
Abduljabbar et al. 2015b).
Recent studies profiling the expression of NRs in 
ER+ and ER− cancers have also identified other NRs 
whose expression levels differ significantly between ER+ 
and ER− breast cancers (Table 1). In particular, AR, PGR, 
PNR, RARA and THRB were reported to be significantly 
differentially expressed between ER+ and ER− breast 
cancers (Muscat et al. 2013) and significantly associated 
with ESR1 expression (Lin et al. 2015). The expression of 
DAX-1, LRH-1, PPARA, RORB, RORC and TLX were also 
reported to be significantly associated with ESR1 expression 
in multiple microarray datasets (Lin et al. 2015).
Mechanisms of NR action
Alterations in normal transcriptional programs are 
a fundamental feature of cancer pathogenesis and 
progression. Nuclear receptors are important regulators 
that directly couple small-molecule signaling with 
transcriptional regulation. An understanding of their 
mechanisms of action at the genomic and network level, 
and how these processes are altered in breast cancer, is of 
 
Name
 
Nomenclature
 
Symbol
 
Entrez ID
 
Ligands
Expression in BC 
vs normal
Association with 
ESR1 expression
ErbA2-related gene 2 NR2F6 EAR2 2063 Not known Increased  
Estrogen receptor-related 
receptor
NR3B1 ESRRA 2101 Isoflavones, 
diethylstilbestrol, 
chlordane
Decreased  
 NR3B2 ESRRB 2103 Isoflavones, 
diethylstilbestrol, 
4-hydroxy tamoxifen
Decreased  
 NR3B3 ESRRG 2104 Isoflavones, 
diethylstilbestrol, 
4-hydroxy tamoxifen
Decreased Yesb
Nerve growth factor IB-like NR4A1 NUR77 3164 Cyclosporone-B, 
diindolylmethane 
analogs
Increased  
 NR4A2 NURR1 4929 6-Mercaptopurine, 
benzimidazoles, 
C-DMIs
Increased  
 NR4A3 NOR1 8013 6-Mercaptopurine, 
prostaglandin A2
Increased  
Germ cell nuclear factor NR6A1 GCNF 2649 Not known Decreased  
aMuscat et al. (2013); bLin et al. (2015).
Table 1 Continued. 
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fundamental importance to our understanding of breast 
cancer development.
The development of technologies such as ChIP-
chip, ChIP-Seq and GRO-Seq has enabled profiling of the 
genomic locations of NR binding in an unbiased, genome-
wide manner. Studies employing these methods have 
revealed new insights into the mechanisms of action of 
nuclear receptors and highlight the complexity of nuclear 
receptor regulatory networks in breast cancer. In this sub-
section, we review new insights of NR mechanisms of action 
in breast cancer made possible by these genomic methods.
Shifts from the ‘classical’ model of NR action
Traditionally, studies on nuclear receptor action at 
hormone-responsive genes gave rise to the model that NRs 
bind proximally to the promoters of target genes, through 
recognition of stringent paired half-sites with highly specific 
orientation (Mangelsdorf  et  al. 1995). However, these 
classical models have been challenged by recent studies 
that profiled the genome-wide binding sites of several 
nuclear receptors and transcription factors using ChIP-chip 
or ChIP-Seq. In the context of breast cancer, genome-wide 
mapping of ESR1 genomic localization in the MCF-7 breast 
cancer cell line showed that most ESR1 binding occurs at 
distal regions of the genome and that many ESR1 sites did 
not contain the canonical ESR1-binding motif (Carroll et al. 
2006). Kittler and coworkers examined the genomic 
distribution of the binding sites of 24 NRs in MCF-7 cells 
and found that NR varied significantly in their genomic 
localization, with both proximal-biased and distal-biased 
NRs being observed (Kittler et al. 2013). The observation 
that NRs localize not only to proximal promoter regions 
but also to distal regions and the prevalence of non-
canonical motif and half-site recognition is also confirmed 
in a meta-analysis of NR cistromes in different cell types 
(Tang et al. 2011). NR binding at non-canonical response 
elements can be a mechanism to fine tune transcriptional 
responses of NR. For example, the glucocorticoid receptor 
(GR) is capable of binding a negative response element 
(nGRE) that confers transrepression in addition to the 
canonical glucocorticoid response elements (GRE) that 
confers transactivation to liganded GR in epidermis and 
intestinal epithelial cells (Surjit et al. 2011). Furthermore, 
NRs are capable of mediating long-range transcriptional 
regulation that involves chromatin looping as illustrated 
by studies on the estrogen receptor-mediated long-range 
chromatin interactions (Liu & Cheung 2014). Together, 
these studies suggest a more complex model of NR 
genomic action in which NRs frequently act on long-range 
enhancers whose actions can be fine-tuned by recognition 
of different response elements.
Cell type specificity and the chromatin landscape
Studies investigating NR cistromes highlight the 
remarkable difference in the genome-wide binding profiles 
of the same NR in different cell types (Krum et al. 2008, 
Clarke & Graham 2012). In addition to the influence 
of coregulators in determining the cell type-specific 
transcriptional response of NRs (discussed in the next 
section), another major aspect of NR action illuminated 
through advances in genomic technologies is the dynamic 
and complex interactions between NR and the chromatin 
landscape of the cell. It is becoming clear that chromatin, 
existing in a dynamic continuum of condensation states, 
regulates as well as is regulated by, NR actions, and that 
NR–chromatin interaction is a major determinant of NR 
cell type-specific transcriptional regulation. Due to the 
widely accepted model of NR binding to DNA only after 
conformational changes induced upon ligand binding, 
several groups have investigated the question of pre-
induction vs post-induction chromatin as a determinant 
of NR action. Genome-wide screening of DNAse I 
hypersensitive sites (DHS) in breast cells revealed that the 
majority (>70%) of GR binding occurs at pre-induction 
DHS sites, whereas only ~20% of GR binding occurs at 
hormone-induced remodeled chromatin (John  et  al. 
2011). A recent study of long-range interactions before 
and after dexamethasone induction in HeLa cells found 
that, similar to breast cells, the majority of GR binding 
occurs at pre-accessible chromatin. Binding of GR to a 
subset of sites containing the consensus GRE results in 
the formation of active enhancers and increased long-
range interactions (Kuznetsova  et  al. 2015). Profiling of 
ESR1 revealed a similar pattern. The majority of ESR1-
binding sites coincide with pre-existing open chromatin, 
co-occurrence of other transcription factor binding, and 
correspond to cell type-specific gene regulation, whereas 
ESR1-binding sites shared by multiple cell types are 
characterized by inaccessible chromatin containing high-
affinity estrogen response elements (Gertz  et  al. 2013). 
Profiling of the PGR by DNase and Micrococcal nuclease 
(MNase) followed by next-generation sequencing showed 
that PGR binding upon hormone stimulation corresponds 
with DHS regions that still exhibit high nucleosome 
occupancy. Upon hormone treatment, remodeling of 
nucleosomes containing functional PGR-binding sites 
occurs, and progesterone-responsive genes are associated 
with PGR-binding sites that show strong nucleosome 
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remodeling upon hormone induction (Ballare et al. 2013). 
The chromatin landscape of the cell therefore plays an 
important role in determining the genomic binding 
profiles of specific NRs. Although some NRs such as 
ESR1and GR rely mostly on pre-programmed sites made 
accessible by other cell- and tissue-specific pioneer DNA-
binding factors, other NRs such as PGR require ligand-
dependent active chromatin remodeling.
Pioneer factors and coregulators as modulators of  
NR function
Pioneer factors are transcription factors that can bind 
condensed chromatin and influence transcription by 
facilitating subsequent recruitment of other transcriptional 
regulators. Recent studies have highlighted the importance 
of pioneer factors in facilitating chromatin accessibility and 
also in determining the cell type-specific response of NRs. 
This is exemplified by the dependence of ESR1 on FOXA1 
in breast cancer. FOXA1 expression is luminal restricted 
(Perou et al. 2000) and is thought to function as a pioneer 
factor (Cirillo et al. 2002). FOXA1 has been observed to 
influence genome-wide chromatin accessibility and is 
a key determinant of cell type-specific ESR1 genomic 
localization (Lupien  et  al. 2008, Hurtado  et  al. 2011), 
reflecting the importance of interaction with other factors 
on control of cell specificity of ESR1. Similarly, AP-1 has 
been shown to recruit GR to regions of the genome that 
are basally accessible prior to hormonal treatment. AP-1 
is thought to maintain chromatin accessibility for GR 
binding as well as recruiting GR indirectly in the absence 
of a canonical GR motif (Biddie et al. 2011).
In addition to pioneer factors, coregulators interact 
with NRs and other transcription factors to facilitate 
transcription of target genes. According to the Nuclear 
Receptor Signaling Atlas (NURSA: www.nursa.org), there 
are 320 NR coregulators identified to date. However, this 
number is likely to be a gross underestimation according 
to a recent proteomic study (Malovannaya  et  al. 2011). 
Coregulators can assist in transcriptional regulation of 
NRs by facilitating chromatin accessibility, stabilizing 
NR–DNA interaction or facilitating indirect NR–DNA 
interaction through tethering (McKenna & O’Malley 
2002, Millard et al. 2013).
Selective recruitment of coregulators to subsets of 
NR-binding sites can also be a mechanism through which 
transcriptional regulation of subsets of NR target genes are 
fine-tuned. An early study of ESR1 and steroid receptor 
coactivator protein (SRC) binding using promoter tiling 
arrays showed E2-dependent recruitment of ESR1 and 
SRC to E2-stimulated genes while the absence of SRC 
was observed at E2-repressed genes (Kininis et al. 2007). 
In a subsequent study, Zwart and coworkers mapped the 
genome-wide binding sites of several ESR1 coregulators 
(SRC1, SRC2, SRC3, p300 and CBP) in MCF-7 cells and 
showed a complex network of ESR1-coregulator binding, 
with preferential binding sites for each coregulator. 
They identified a subset of ESR1-regulated genes that are 
co-occupied by SRC3, but not SRC1 or SRC2, that predicts 
poor or good survival outcome depending on whether 
the genes were upregulated or downregulated (Zwart et al. 
2011). Lupien and coworkers also identified association 
between a subset of E2-induced ESR1 binding sites 
co-occupied by CARM1 and gene repression, independent 
of the presence of FOXA1 binding. They also identified 
another subset of E2-induced, FOXA1-independent, ESR1 
and CARM1 co-occupied sites that result primarily in 
repression of expression (Lupien et al. 2009). These studies 
demonstrate that selective interaction with different 
coregulators at specific subsets of target genes may be an 
important mechanism through which the specificity of 
NR action is modulated.
Due to their central role in regulating NR-mediated 
transcription, many coregulators are known to be 
involved in human diseases (Lonard et al. 2007, Lonard 
& O’Malley 2012). In the breast, changes in expression 
levels of coregulators have been implicated in the tissue-
specific response to tamoxifen (Keeton & Brown 2003). 
The majority of coregulators show differential expression 
between breast cancer and normal breast tissues, as well as 
between ER+ and ER− breast cancers. This is accompanied 
by changes in the expression correlations between subsets 
of coregulators and specific NRs, whose expression showed 
prognostic value in breast cancer (Doan et al. 2014).
Coregulators are therefore critical determinants of 
NR-mediated transcriptional regulation in the breast and 
disruptions in the normal NR–coregulator interaction 
network are potentially an important aspect of breast 
cancer biology.
Combinatorial control of gene expression by NRs in 
breast cancer
Recent large-scale integrative analyses of transcription 
factor genomic localization data from the ENCODE 
project highlighted the extraordinary complexity of 
transcriptional regulation and the extensive functional 
crosstalk between transcription factors (ENCODE Project 
Consortium 2012, Gerstein  et al. 2012, Xie  et al. 2013). 
This observation also holds for NR in breast cancer. 
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Kittler and coworkers (Kittler et al. 2013) built a regulatory 
map from cistromic data of 24 NRs and 14 breast cancer-
associated coregulators in MCF-7 breast cancer cells. 
They showed that the resulting network is highly inter-
connected and there are many regions in the genome 
coordinately occupied by multiple NRs (HOT regions). 
These HOT regions are enriched with features associated 
with active regulatory elements, including active 
chromatin marks and increased chromatin accessibility. 
These regions are also enriched with breast cancer-
relevant genes and are hypothesized to be important 
active regulatory regions in breast cancer cells.
On a smaller scale, other studies have also revealed 
convergence in genomic binding between ESR1 and 
various other NRs in breast cancer cells by individually 
comparing the overlap of their cistromes. ESR1 is known 
to drive growth and proliferation in the majority of breast 
tumors. Mounting evidence indicates that ESR1 does 
not act on its own and that other transcription factors, 
including other NRs, are important determinants of ESR1 
action in breast cancer cells. For example, retinoic acid has 
been known to inhibit proliferation in breast cancer cells 
and antagonize the growth stimulation effect of estrogen 
(Fontana et al. 1992). Studies of ESR1 and RARA cistromes 
showed that ESR1 and RARA share very similar binding 
profiles, although whether the interaction is antagonistic 
or co-operative is still controversial (Hua et al. 2009, Ross-
Innes  et  al. 2010). Likewise, cistromic profiling of ESR1 
and GR in mouse mammary epithelial cell lines revealed 
significant co-operation of these two NRs, through an 
assisted loading mechanism, in which binding of one NR 
facilitates chromatin remodeling thereby enabling access 
to DNA for the other NR (Miranda et al. 2013). Another 
study profiling ESR1 and GR genomic localization in 
MCF-7 cells revealed that, although GR co-occupies 
several ESR1-binding sites in cells treated with both E2 and 
dexamethasone, GR recruitment to these sites is associated 
with displacement of ESR1 leading to the repression of 
estrogen receptor-mediated transcriptional activation of 
target genes (Karmakar et al. 2013). Therefore, although 
ESR1 co-occupies many target genes with RARA as well as 
GR, the nature of their interaction is reported to be both 
co-operative and antagonistic, perhaps reflecting different 
time, target and cell-specific modes of co-operation 
between these NRs.
In addition to RARA and GR, ESR1 was reported to 
share genomic binding sites with PGR and LRH-1. In the 
presence of both estrogen and progesterone, PGR was 
shown to be recruited to the ESR1 complex and to redirect 
ESR1-binding events, resulting in a gene expression profile 
associated with better clinical outcome (Mohammed et al. 
2015). However, in the presence of estrogen alone, 
un-liganded PGRB activated a subset of ER target genes 
by acting as a molecular scaffold for the formation of a 
transcriptional complex with ESR1 and PELP1, resulting 
in a more aggressive proliferative response to estrogen 
(Daniel et al. 2015). It is likely that the action of ESR1 and 
PGR and their crosstalk are highly context dependent. 
Furthermore, the majority of data are derived from cell 
line models, and the implications for breast cancer in vivo 
are yet to be established. LRH-1 was reported to share a 
substantial portion (~35%) of its binding sites with that 
of ESR1 and synergistically regulate a subset of estrogen-
responsive genes in MCF-7 cells (Lai et al. 2013).
These studies highlight the complexity of cross talk, 
particularly between ER and other NRs, in gene regulatory 
networks and the utility of integrated, genome-wide 
analyses in unraveling this complexity. Whether the 
studies so far reflect transcriptional plasticity that is 
particularly a feature of ER or whether data will emerge 
supporting this as a mechanism common to other NRs 
is still to be determined; nevertheless, these insights into 
the functional interactions between NRs in breast cancer 
have the potential to lead to novel therapeutic strategies.
Reprogramming of NR binding and disease progression
It is becoming increasingly evident that transcriptional 
regulation is a highly dynamic process with transcription 
factors displaying temporal, cell type specific and 
disease-associated shifts in their genomic binding 
profiles. The transcriptional targets of PGR in T-47D 
breast cancer cells and AB-32 immortalized normal 
breast cells display remarkably low overlap (Clarke & 
Graham 2012), reflecting cancer-associated and cell 
type-specific changes in PGR transcriptional regulation. 
Recent studies have highlighted the effect of changes 
in NR transcriptional programs and their association 
with breast cancer disease progression and clinical 
outcomes. Ross-Innes and coworkers performed ChIP-
seq of ESR1 in clinical samples with different prognoses 
to directly explore the correlation between ESR1 binding 
and cancer progression (Ross-Innes  et  al. 2012). They 
observed high signal intensity at ESR1-binding sites in 
metastatic samples, whereas lower ESR1 signal intensity 
was observed in samples with good prognosis. Further, 
they showed that ESR1 binding is a highly dynamic 
process, with distinct ESR1-binding regions observed 
in samples with different outcomes. This dynamic 
change in ESR1 action was shown to be influenced by 
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the action of other NRs, such as PGR (Mohammed et al. 
2015), as well as the signaling context leading to 
ESR1 activation. For example, ESR1 displayed distinct 
genomic binding profiles depending on whether ESR1 
was activated by estrogen or through the epidermal 
growth factor (EGF) pathway (Lupien  et al. 2010). The 
EGF-induced ESR1 cistrome specifically regulates genes 
that are overexpressed in ERBB2-positive breast cancers 
and associated with poor clinical outcomes. The EGF 
pathway can therefore be an alternative activator for 
ESR1 signaling in breast cancer and provides a molecular 
explanation for the endocrine therapy resistance often 
seen in ER+ERBB2+ breast cancers. Analysis of ESR1 and 
ESRRA cistromes in tamoxifen-sensitive vs -resistant 
breast cancer cells showed that despite regulating 
distinct transcriptional networks, their cistromes are 
reprogramed in tamoxifen-resistant breast cancer cells 
toward the regulation of genes functionally relevant 
to resistance (Thewes  et  al. 2015). These studies show 
that NR binding profiles can be shifted in a context-
dependent manner, resulting in altered transcriptional 
networks that affect disease progression and outcome.
Emerging functional roles of NR in BC
It is now clear that a number of NRs are implicated in 
breast cancer growth and development (Conzen 2008). It 
is emerging that, in addition to influencing cell growth 
and proliferation, NRs also play important roles in other 
aspects of breast cancer biology. Table  2 summarizes 
reported involvement of NRs in selected aspects of breast 
cancer biology. This section outlines some of the emerging 
functional roles of NRs in breast cancer.
Nuclear receptors as key components of the  
circadian clock
A circadian rhythm is any biological process that displays 
an endogenous, entrainable oscillation cycle of roughly 
24 h, driven by a self-sustained timekeeping mechanism, 
the circadian clock. The circadian clock governs many 
aspects of human physiology, including body temperature, 
sleep–wake cycle, blood pressure, hormone secretion and 
metabolism. In line with this, at least 10% of all genes 
are under the control of the circadian system and display 
Table 2 NR function in breast cancer.a
 
 
Nomenclature
 
 
Symbol
 
Anti-proli-
ferative
 
Pro-
apoptotic
 
Anti-
migratory
Pro-oxidative 
phosphoryla-
tion
 
Pro-
proliferative
 
Anti-
apoptotic
 
Pro-
migratory
 
Pro-
glycolytic
Circadian 
involve-
ment
NR3A1 ESR1     Y  Y  Y
NR3A2 ESR2 Y  Y    Y   
NR3C1 GR      Y   Y
NR3C3 PGR   Y  Y Y Y   
NR3C4 AR Y    Y     
NR1B1 RARA Y Y        
NR1B2 RARB Y Y Y       
NR1B3 RARG Y Y        
NR1F1 RORA         Y
NR1F2 RORB         Y
NR1F3 RORC         Y
NR1I1 VDR Y Y        
NR1C1 PPARA     Y     
NR1C2 PPARD     Y     
NR1C3 PPARG Y Y   Y Y    
NR1D1 REV-ERBa Y   Y     Y
NR1D2 REV-ERBb Y       Y Y
NR2B1 RXRA  Y        
NR2B2 RXRB  Y        
NR2B3 RXRG  Y        
NR2F1 COUP-TF1       Y   
NR2F2 COUP-TF2       Y   
NR3B1 ESRRA       Y Y  
NR3B3 ESRRG   Y Y      
NR4A1 NUR77       Y   
aNR effect on cancer-related biological processes based on studies in breast primary tissue or cell lines. The influence of NR on breast cancer proliferation, 
apoptosis, migration, metabolism as well as involvement in circadian regulation/response is tabulated.
Y, indicates reported involvement.
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circadian oscillation (Akhtar et al. 2002, Oishi et al. 2003, 
2005). There is mounting evidence linking circadian 
disruption to various clinical and pathological conditions 
including cancer. Here, we discuss the emerging link 
between NRs and circadian regulation, as well as the 
growing body of evidence linking circadian disruption 
and breast cancer.
Initially, the circadian clock was defined to be a 
relatively simple feedback loop consisting of the key 
transcription factors CLOCK and BMAL and their 
co-repressors, PER and CRY (Fig.  2). It is now emerging 
that the circadian clock contains other auxiliary loops 
that involve multiple NRs, most prominently REV-ERBs 
and RORs (Fig.  2, reused from Bechtold  et  al. (2010), 
with permission from Elsevier). RORs recognize the same 
regulatory elements as REV-ERBs, and a range of studies 
have demonstrated their importance in the regulation 
of clock gene expression (Akashi & Takumi 2005). Gene 
deletion studies and cistrome analyses have confirmed 
the pivotal role of REV-ERBs in the universal circadian 
machinery (Preitner et al. 2002).
In addition to REV-ERBs and RORs, several other NRs 
have been shown to regulate as well as being regulated 
by the circadian clock, most notably GR (Conway-
Campbell  et  al. 2010) and ESRRA (Dufour  et  al. 2011). 
The list of other NRs potentially under control of the 
circadian clock is extensive, with at least 35 NRs known to 
display circadian expression in various metabolic tissues 
(Zhao et al. 2014).
Figure 2
The molecular clock machinery (reprinted from Trends in Pharmacological Sciences, volume 31, Bechtold DA, Gibbs JE & Loudon AS, Circadian 
dysfunction in disease, pages 191–198, copyright (2010), with permission from Elsevier). The molecular machinery that provides circadian timekeeping 
consists of a complex circuitry of transcriptional/translational regulatory feedback loops (clock components shown in gray). In mammals, the current 
model involves a primary loop with CLOCK (or homologue NPAS2) and BMAL1 as transcriptional activators, and PERIOD (PER1, PER2 and PER3) and 
CRYPTOCHROME proteins (CRY1 and CRY2) as transcriptional repressors. As levels of cytosolic PER and CRY proteins rise, they associate, translocate to 
the nucleus and repress their own gene transcription through direct interaction with the CLOCK/BMAL1 complex. This feedback cycle provides near 24-h 
timing and drives the rhythmic expression of several clock-controlled and clock-modulated genes, which in turn mediate circadian rhythms in behavior 
and physiology. Acting on the primary feedback loop are auxiliary loops, which appear to increase the stability and robustness of the oscillations. The 
most notable interlocking loop is that involving the nuclear hormone receptors (NRs), REV-ERB and ROR. In addition to REV-ERB and ROR, several other 
NRs (shown in green) interact closely with the circadian feedback loops and are responsive to the clock (exhibit rhythmic expression) and able to 
feedback onto the clock genes themselves. NR regulation of clock genes also renders the clock responsive to numerous circulating hormones (e.g. 
cortosol, estrogen), nutrient signals (e.g. derivatives of fatty acids and retinoids) and cellular redox status (NADH/NAD+ ratio).
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To date, epidemiological studies reported mixed 
findings on the association between increased risk of 
breast cancer and circadian disruption in the form 
of night shift work. Although a few studies reported 
no significant association between breast cancer and 
night work (O’Leary  et  al. 2006, Pronk  et  al. 2010), 
the majority of recent studies reported significant or 
borderline associations, with the strongest association 
found with long-term exposure to night work (Hansen 
2001, Schernhammer et al. 2001, 2006, Hansen & Lassen 
2012, Hansen & Stevens 2012, Knutsson  et  al. 2013, 
Menegaux et al. 2013, Rabstein et al. 2013, Akerstedt et al. 
2015, Papantoniou et al. 2015). Meta-analysis studies have 
also reported a positive association between night work 
and breast cancer risk (Jia et al. 2013) and that a positive 
dose–response gradient is observed for breast cancer with 
increased years of night shift and cumulative night work 
(Wang et al. 2013).
Although circadian disruption is prominently linked 
to breast cancer tumorigenesis through epidemiological 
studies, the molecular mechanisms and NRs involved 
are still largely unknown, with most published studies 
focusing on the ESR1 as a link between the circadian system 
and breast cancer development. Many studies suggest that 
lowered melatonin level due to exposure to night light 
contributes toward breast cancer development and drug 
resistance. Melatonin is thought to exert its oncostatic 
effect through multiple mechanisms including anti-
mitosis, anti-angiogenesis, anti-oxidation and regulation 
of immune response (Viswanathan & Schernhammer 
2009). The oncostatic effect of melatonin in breast cancer 
is thought be mediated through its anti-estrogenic actions 
as well as its role in regulating the activity of aromatases, 
the enzymes responsible for the local biosynthesis of 
estrogens from androgens (Cos et al. 2006). Recent studies 
using MCF-7 breast cancer xenografts in mice showed 
that suppression of melatonin production by dim light 
exposure at night leads to both tamoxifen (Dauchy et al. 
2014) and doxorubicin resistance (Xiang et al. 2015).
In addition to the effect of melatonin, there is 
evidence linking the core clock genes as well as the REV-
ERBs with breast cancer growth and metastasis. The 
rhythmic expression of the PER genes are reported to be 
altered in primary breast tumors (Chen et al. 2005) as well 
as in breast cancer cell lines (Xiang et al. 2012). A recent 
study demonstrated the association of the core clock gene 
BMAL2 in ER breast cancer metastasis (Ha  et  al. 2016). 
Furthermore, activation of REV-ERBA and REV-ERBB by a 
synthetic ligand is anti-proliferative in breast cancer cells.
ESR1 has been shown to be an important regulator 
linking the circadian system and breast cancer 
tumorigenesis, acting as a regulator of (as well as being 
regulated by) the core clock genes. ESR1 appears to 
participate in a feedback loop involving the clock protein 
PER2, which was shown to be a tumor suppressor in 
luminal breast cancer. Although PER2 is E2 inducible, 
PER2 itself is thought to mediate ESR1 degradation 
through the proteasome pathway. Suppression of PER2 
leads to ESR1 stabilization (Gery et al. 2007). In addition, 
ESR1 was shown to bind estrogen response elements in the 
promoter region of CLOCK leading to the upregulation 
of CLOCK in breast cancer cells. Knockdown of CLOCK 
attenuated proliferation in breast cancer cells (Xiao et al. 
2014). Therefore, CLOCK appears to be an important 
mediator of the proliferative effect of E2 in breast cancer.
In summary, NRs play important regulatory roles in 
both the universal and tissue-specific circadian systems. 
In particular, REV-ERBs and RORs are integral regulators 
of the universal circadian clock, and various other NRs 
exhibit circadian expression. Although epidemiological 
studies have linked circadian disruption and breast cancer 
tumorigenesis, a lot remains to be learned about the 
underlying molecular mechanism. Lowered melatonin 
due to night light exposure is thought to play a role and 
there is evidence supporting the involvement of ESR1 
as an integral regulator linking circadian regulation and 
breast cancer development.
Regulation of energy metabolism
As the initial observation by Warburg that proliferating 
tumor cells converted the majority of their glucose to 
lactate even in oxygen-rich condition and his hypothesis 
that altered metabolism is a characteristic of cancer 
cells, metabolic reprogramming has now attained cancer 
hallmark status (Ward & Thompson 2012). Specifically, 
the Warburg effect describes a shift toward aerobic 
glycolysis in preference to oxidative phosphorylation as 
the major means of ATP generation in cancer cells, even 
in oxygen-rich conditions. Although aerobic glycolysis 
is not as efficient as oxidative phosphorylation (yielding 
only 2 mol of ATP/mole of glucose instead of 36 mol ATP/
mole of glucose), it has certain benefits for tumor cells. 
Glycolysis results in more rapid production of ATP, fatty 
acids and nucleotides that are needed by proliferating 
tumor cells that need to double their biomass to divide. 
Furthermore, the generation of lactic acid promotes 
a tumor microenvironment that is protective against 
 
  
Appendices 
 213 
AUTHOR COPY ONLY
Jo
ur
na
l o
f 
M
ol
ec
ul
ar
 E
nd
oc
ri
no
lo
gy
DOI: 10.1530/JME-16-0082
http://jme.endocrinology-journals.org © 2017 Society for Endocrinology
Printed in Great Britain
Published by Bioscientifica Ltd.
180Review T B DOAN and others Nuclear receptors in  
breast cancer
58 3:
immune attack (Calcinotto  et  al. 2012). It has also 
been suggested through glucose flux modeling that 
accumulation of glucose actually promotes aerobic 
glycosis in preference to oxidative phosphorylation 
(Vazquez et al. 2010); hence, glucose flux can potentially 
act as a trigger for the Warburg effect.
It has emerged that NRs are centrally placed in 
many of the pathways controlling energy metabolism, 
from regulating glucose transporters to controlling the 
downstream pathways involved in glucose metabolism. 
Their altered expression in breast cancers is potentially 
intimately linked to the metabolic reprogramming of the 
tumors cells. Here, we review our current understanding 
of the roles of NRs in breast cancer cellular metabolism.
REV-ERBs In addition and related to their prominent 
roles in circadian regulation, REV-ERBs are recognized 
as integrators of circadian regulation and metabolic 
pathways (Cho et al. 2012, Gerhart-Hines & Lazar 2015). 
A recent study looking at genome-wide location of REV-
ERBA in various tissues reported different mechanisms 
of gene regulation employed by REV-ERBA with regard 
to circadian control and metabolic control. Although 
circadian regulation requires direct DNA binding of 
REV-ERBA to its cognate site, metabolic control involves 
the recruitment of HDAC3, which is tethered by cell 
type-specific transcription factors (Zhang  et al. 2015). A 
recent publication suggests that although REV-ERBA has 
a dominant role in normal cells, REV-ERBB seems to be 
the dominant isoform controlling both circadian rhythm 
and metabolic pathways in cancer cells, including breast 
cancer (De Mei et al. 2015). REV-ERBB is significantly more 
abundant in cancer cells compared to REV-ERBA, whereas 
the opposite is observed in normal cells. Knockdown of 
REV-ERBB resulted in the enhanced expression of both 
circadian and metabolic target genes in breast cancer 
cells while knockdown of REV-ERBA had no effect. 
However, ERBB2-positive breast cancer cells appear to 
have higher expression of REV-ERBA compared to ERBB2-
negative cells, consistent with a previous study reporting 
co-expression of REV-ERBA and ERBB2 and pro-survival 
function of REV-ERBA in ERBB2-positive breast cancer cells 
(Kourtidis et al. 2010). These studies suggest that the two 
REV-ERB isoforms probably have redundant functions in 
transcriptional regulation, and functional predominance 
in a particular cell type depends on the relative expression 
level of each isoform.
Estrogen-related receptors (ERRs) The estrogen-
related receptors (ESRRA/NR3B1, ESRRB/NR3B2 and 
ESRRG/NR3B3) have become recognized as the master 
regulators of energy metabolism in multiple tissues with 
high energy demand (Giguere 2008, Deblois & Giguere 
2013). Both ESRRA and ESRRG have dominant roles in 
maintaining energy homeostasis through the regulation 
of metabolic gene networks. In the heart, ESRRA and 
ESRRG co-operate to control genes involved in uptake 
of energy substrates, production and transport of ATP 
across the mitochondrial membrane (Alaynick et al. 2007, 
Dufour  et  al. 2007). ESRRA was reported to co-operate 
with the peroxisome proliferator-activated receptor-
gamma coactivator alpha gene (PGC-1α) in a double-
positive feedback loop to regulate the expression of many 
oxidative phosphorylation genes in mouse myoblast cells 
(Mootha et al. 2004). In the liver, ESRRA was reported to 
co-operate with PROX1 and BMAL1 to regulate circadian 
and metabolic gene networks (Dufour  et  al. 2011). 
Together, the three ERR isoforms recognize the proximal 
regulatory regions of 705 genes involved in all aspects 
of mitochondrial biogenesis and function (Eichner & 
Giguere 2011).
In the breast, ESRRA and ESRRG are associated with 
distinct survival outcomes (Ariazi et al. 2002). Although 
ESRRA is associated with increased recurrence and 
poor outcome (Thewes  et  al. 2015), ESRRG expression 
is correlated with ESR1 and ERBB4, which are markers 
of favorable outcome (Ariazi  et  al. 2002). It has been 
suggested that ESRRA and ESRRG have opposite roles 
in the regulation of metabolic reprogramming of breast 
cancer cells (Deblois & Giguere 2013). Although ESRRA 
promotes aerobic glycolysis through the upregulation 
of enzymes that regulate the glycolysis pathway 
(Cai  et al. 2013), ESRRG is thought to sustain oxidative 
phosphorylation through regulation of genes that control 
the tricarboxylic acid cycle (Eichner et al. 2010). However, 
metabolic reprogramming by ERRs in breast cancers 
probably involves much greater complexity, given that 
overexpression of ESRRG also leads to increased expression 
of enzymes in the glycolytic pathways (Cai  et al. 2013) 
and that ESRRA and ESRRG readily form heterodimers 
and bind to regulatory regions of many shared target 
genes (Dufour et al. 2007).
ESRRs also interact with oncogenes that are known 
modulators of metabolic pathways such as MYC, HIF 
and ERBB2. Many genes in the glycolytic pathways are 
regulated by MYC. ESRRA was found to participate in 
a complex with MYC to co-regulate glycolytic genes 
(Cai et al. 2013). HIF directly activates glucose transporters 
and the majority of genes in the glycolytic pathways. 
All three ESRR isoforms were identified as coactivating 
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factors of HIF and to enhance HIF-induced glycolytic and 
angiogenic gene expression in hypoxic condition (Ao et al. 
2008). ESRRA also regulates the expression of ERRB2 
(Deblois  et al. 2010), which was reported to translocate 
to the mitochondria of tumor cells and regulate energy 
metabolism. Overexpression of mitochondrial ERBB2 
decreases mitochondrial electron transport chain activity 
and enhances cellular glycolysis (Ding  et  al. 2012). In 
addition, ERBB2 influences the glycolytic phenotype 
through upregulation of lactate dehydrogenase (Zhao et al. 
2009) as well as REV-ERBA, an NR that was reported to be 
involved in glycolysis and fatty acid synthesis in breast 
cancer cells (Kourtidis et al. 2010).
In summary, the ERRs are prominent regulators 
of gene networks controlling glycolysis and oxidative 
phosphorylation in metabolic tissues. In the breast, 
ESRRA expression is associated with poor outcome and 
appears to be involved in reprogramming the cell to 
favor aerobic glycolysis, a metabolic state characteristic of 
cancer cells. ESRRG, on the other hand, is associated with 
better outcome and is involved in maintaining oxidative 
phosphorylation, a metabolic state characteristic of 
normal cells. However, given that ESRRA and ESRRG can 
form heterodimers and readily bind to many shared target 
genes, the complexity of the mechanisms for controlling 
their specificity of action is still to be deciphered.
Peroxisome proliferator-activated receptors 
(PPARs) PPARs function as heterodimers with the 
retinoid receptors (RXR) and regulate various genes that 
are involved in lipid metabolism and energy homeostasis. 
Through these pathways, PPARs influence various 
cancer-related cellular processes such as proliferation, 
differentiation and survival (Michalik et al. 2004). Three 
PPAR isotypes (PPARA/NR1C1, PPARD/NR1C2 and 
PPARG/NR1C3) are known, each with unique expression 
profile and functional roles. The PPARs showed decreased 
expression in breast cancer compared to normal breast 
(Muscat et al. 2013). The role of PPARD in breast cancer 
tumorigenesis is unclear. Although activation of PPARD 
has been shown to inhibit breast cancer cell line 
tumorigenicity (Yao  et  al. 2014), inhibition of PPARD 
by inverse agonists was reported to inhibit breast cancer 
cell invasion (Adhikary  et  al. 2013). PPARG is the best 
studied of the 3 PPAR subtypes and has been reported 
to have an anti-proliferative effect on breast cancer cells 
(Pon et al. 2015) and is associated with better outcomes 
based on survival analysis of PPARG protein expression 
level in BC tissue microarrays (Abduljabbar et al. 2015a). 
The downstream effect of PPARG seems to be dependent 
on the cell compartment in which PPARG is activated 
though, with activation in cancer cells resulting in growth 
inhibition while activation in stromal cells results in 
growth enhancement of co-injected breast cancer cells 
(Avena et al. 2013). Recent studies have also suggested an 
involvement of PPARG and energy metabolism in breast 
cancer. Firstly, several genes controlling the glycolytic 
pathways are found to have peroxisome proliferator 
response element (PPRE) suggesting their regulation by 
PPARs (Sakharkar et al. 2013). Secondly, overexpression of 
PPARG in fibroblasts increased the production of L-lactate 
and mitochondrial dysfunction. In addition, PPARG 
induces the activation of HIF1A, a transcription factor 
that promotes glycolysis (Avena et al. 2013).
Control of breast cancer migration and metastasis
Breast cancer metastasis accounts for the majority of 
deaths from breast cancer. Early detection and a deeper 
understanding of the metastatic process are critical to 
develop therapeutic interventions. Metastasis involves a 
complex cascade of steps starting with invasion by the 
primary tumor of the surrounding host tissues, followed by 
intravasation and dissemination of the tumors cells via the 
blood or lymphatic system, infiltration and colonization 
at the distant site. Several factors and pathways are known 
to influence cancer metastasis including disintegration 
of cell-to-cell adhesion, proteolytic remodeling of the 
extracellular matrix, cell motility, evasion of immune and 
apoptotic signals and angiogenesis. Although substantial 
information is known about the process of metastasis, the 
molecular basis of breast cancer metastasis remains poorly 
understood. NRs, being master regulators of almost every 
physiological aspect of life, are likely to be intimately 
involved in the metastasis process. Here, we summarize 
the current understanding of the roles of various NRs in 
biological pathways affecting breast cancer metastasis.
Estrogen receptors The estrogen receptors alpha 
(ESR1) and beta (ESR2) appear to have distinct roles in 
breast cancer progression and metastasis, with reports of 
ESR1 signaling enhancing breast cancer cell migration and 
invasion, whereas ESR2 signaling has the opposite effects.
Emerging evidence suggests that estradiol’s positive 
effect on cell migration and invasion appears to be 
mediated through ESR1’s extranuclear signaling. ESR1 
extranuclear signaling is mediated through the PI3K, 
MAPK and c-Jun N-terminal kinase pathways (Li  et  al. 
2010, Zheng et al. 2011) with the involvement of PELP1 
(Chakravarty  et  al. 2010), focal adhesion kinase (FAK) 
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(Sanchez  et  al. 2010), c-Src and paxillin (Li  et  al. 2010) 
for activation. Downstream activation of the RhoA/
ROCK-2 cascade has also been reported (Giretti  et  al. 
2008, Zheng et al. 2011). Recruitment of the actin-binding 
protein moesin (Giretti et al. 2008) and phosphorylation 
of the actin-binding protein ezrin (Zheng et al. 2011) were 
reported as possible mechanisms through which ESR1 
signaling influences the cytoskeletal organization. These 
E2-mediated signaling pathways induce features of motile 
cells such as dynamic actin cytoskeleton remodeling and 
formation of ruffles and filopodia-like structures, which 
resulted in enhanced motility and migration of breast 
cancer cells (Chakravarty et al. 2010).
ESR2, on the other hand, has been associated with 
less invasive and proliferative tumors (Jarvinen  et  al. 
2000, Lazennec et al. 2001). Overexpression of ESR2 leads 
to reduced cell growth and mobility (Li et al. 2012) and 
ESR2 was reported to upregulate E-cadherin (Zhou et al. 
2015), integrin alpha1, integrin beta1 and enhance the 
formation of vinculin-containing focal complexes and 
actin filaments (Lindberg et al. 2010), which consequently 
strengthens cell adhesion and reduces migration 
and invasion.
However, ESR2’s influence on cell migration is possibly 
more complex than simply having an anti-migratory 
and anti-proliferative effect, with contradictory reports 
of ESR2 having both pro-invasive and pro-migratory 
effects, especially in specific breast cancer subtypes, due 
to crosstalk with ESR1 as well as differential effect of 
different ESR2 variants. ESR2 and PEA3 were reported 
to co-activate IL-8 resulting in increased invasiveness 
in ER+ MCF-7 cells (Chen et al. 2011). In inflammatory 
breast cancer cells, which express both ESR2 and ESR136 
(an ESR1 variant), it was suggested that non-genomic 
signaling involving ESR136, ESR2 and GPR30 through 
activation of p-ERK1/2 to have pro-migratory and 
pro-invasive effect (Ohshiro  et  al. 2012). Furthermore, 
expression of an ESR2 variant, ESR2cx in primary 
tumors, was reported to correlate with higher risk of 
lymph node metastasis (Rosin et al. 2014). In summary, 
the effects of estrogen receptor signaling on breast 
cancer cell metastasis is complex with different isoforms 
having opposing roles, which is further complicated by 
divergent effects of subtype variants and crosstalk. The 
emerging picture is that of ESR1 exerting pro-migratory 
and pro-invasive effects through extranuclear signaling 
to regulate cell adhesion and cytoskeletal remodeling 
while ESR2 exerts the opposite effect through as yet 
unclear mechanisms.
Progesterone receptors PGR in the human is 
expressed as two functionally different forms (PGRA and 
PGRB) arising from alternate promoter activities driving 
a single gene (Kastner  et  al. 1990). PGRA and PGRB 
are equivalently expressed in most normal cells, but 
commonly their expression becomes deregulated in breast 
cancer resulting in a predominance of one isoform (usually 
PGRA) (Graham et al. 1995). This disruption is seen early 
in disease progression (Mote et al. 2002) and is associated 
with a poorer response to the anti-estrogen tamoxifen 
(Mote et al. 2015). A number of studies have demonstrated 
progestin effects on breast cancer cell adhesion, migration 
and invasive potential. However, these effects are ligand, 
PGR isoform and context dependent. In general, progestins 
acting through nuclear PGR inhibit cell migration and 
invasiveness (Lin  et  al. 2000, 2001, McGowan  et  al. 
2004, Carnevale  et  al. 2007). In cells transfected with 
PGR, progestin treatment increases actin stress fibers 
and focal contacts, consistent with increased adhesion 
and decreased migration (Lin et al. 2000, 2001). Invasion 
of T-47D breast cancer cells, expressing equivalent PGR 
isoform levels, is inhibited by progestins (McGowan et al. 
2004). However, predominance of PGRA results in an 
altered progestin response, including increased focal 
adhesion signaling (Graham  et  al. 2005), enhanced 
migration and increased invasion (McGowan et al. 2004), 
potentially contributing to the poorer outcomes seen in 
PGRA-predominant breast cancers.
Crosstalk between PGR and cytoplasmic signaling 
pathways is implicated in breast cancer migration 
and metastasis. Using a DNA-binding mutant PGR, 
Carnevale and coworkers (Carnevale et al. 2007) reported 
that PGR activated cytoplasmic signaling cascades 
that contributed to breast cancer metastasis. Progestin 
activation of MAPK, PI3K/Akt and GTPase/RhoA 
modulated the expression of genes such as urokinase 
plasminogen activator (uPA), uPA receptor (uPAR), 
matrix metalloproteases (MMPs), β1-integrin and PAI-1 
(Carnevale  et  al. 2007, Fu  et  al. 2008, Bellance  et  al. 
2013) suggesting a mechanism through which migration 
is increased by progestins. In addition, progesterone/
progestins also enhance the phosphorylation of focal 
adhesion kinase (FAK) (Graham et al. 2005, Fu et al. 2008, 
Bellance  et  al. 2013), and this is enhanced with PGRA 
predominance (Graham  et  al. 2005), promoting the 
formation and turnover of focal adhesion points and 
cytoskeletal reorganization involved in cellular motility 
and influencing breast cancer progression and metastasis 
(Luo & Guan 2010).
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PGR has also been reported to exert ligand-
independent effects on breast cancer cell morphology 
and migration (Jacobsen et al. 2005, Carnevale et al. 2007, 
Bellance  et  al. 2013). Un-liganded PGRA was shown to 
differentially regulate genes involved in cell adhesion 
and increase adhesiveness and migration in inducible 
cells expressing just one isoform (Jacobsen  et  al. 2005). 
However, in a recent study using bi-inducible MDA-MB-231 
cells, un-liganded PGRB but not PGRA increased cell 
migration via differential effects on focal adhesion 
signaling (Bellance et al. 2013). Furthermore, it has been 
demonstrated that extensive ligand-independent action 
of PGRB are dependent on specific post-translational 
modifications, particularly phosphorylation, and 
associated with pro-survival pathways (Daniel et al. 2007, 
Faivre et al. 2008, Knutson et al. 2012). These findings in 
the absence of ligand suggest that disrupted PGR isoform 
expression may have particular importance in the context 
of post-menopausal breast cancer, where circulating 
progesterone is low or absent.
In summary, the emerging picture is that the effects 
of PGR and progesterone on breast cancer metastasis, 
adhesion and invasion are context dependent and 
influenced by the relative ratio of PGR isoforms being 
expressed, the presence of ligands and whether PGR 
functions as a transcription factor or activator of signaling 
cascades, but that PGR contributes to increased invasive 
and metastatic behavior in a number of contexts.
Retinoic acid receptors Several studies demonstrated 
the anti-proliferative and anti-migratory effect of retinoids 
on breast cancer cells. Specifically, all-trans retinoid acid 
(ATRA) was reported to modulate several migration-related 
proteins such as downregulation of MMP-1, MMP-2, 
MMP-9, FAK, NF-κB and p-ERK and upregulation of 
E-cadherin in breast cancer cell lines (Liu  et  al. 2003, 
Dutta  et  al. 2009, 2010). The anti-migratory effect of 
retinoids on breast cancer cells were shown to be 
mediated through RARB with treatment of RA or RARB 
agonist resulting in significantly reduced cell migration 
while treatment with RARA or RARG agonists did not 
(Flamini  et  al. 2014). RARB is the only member of the 
RARs showing decreased expression in breast cancers 
(Muscat et al. 2013). RARB showed progressively decreased 
expression during breast carcinogenesis, with only 
around 50% of invasive breast carcinoma expressing 
RARB (Xu  et  al. 1997). Transduction of RARB2 resulted 
in significant reduction in metastasis rate in a mouse 
xenograft model (Treuting  et  al. 2002). Together, these 
findings highlight that RARB is necessary for mediating the 
anti-migratory effect of retinoic acid through modulation 
of expression of genes involved in cell migration.
Estrogen-related receptors Aside from their 
prominent role as master regulators of energy metabolism, 
the ERRs have been reported to influence the migratory 
potential of breast cancer cells. Knockdown of ESRRA 
dramatically decreased the migratory potential of breast 
cancer cells (Stein  et  al. 2008), later determined to be 
mediated through VEGF (Stein  et al. 2009) and WNT11 
(Dwyer et al. 2010) signaling pathways, which are known 
regulators of angiogenesis. Inactivation of ESRRA also 
resulted in impaired directional migration of breast cancer 
cells, mediated through enhanced stability of RHOA, a 
protein involved in controlling oriented cellular migration 
(Sailland et al. 2014). ESRRA itself was found to be a target 
of miR-137 (Zhao et al. 2012). Therefore, consistent with 
reports of its association with poor prognosis, activation 
of ESRRA has a pro-migratory effect on breast cancer cells. 
By contrast, and consistent with its association with better 
breast cancer outcome, ESRRG was reported to promote 
mesenchymal-to-epithelial transition and decrease 
breast cancer cell invasiveness through activation of 
E-cadherin (Tiraby et al. 2011). Therefore, similar to their 
opposing roles in metabolic reprogramming, ESSRA and 
ESSRG display opposing influences on breast cancer cell 
migration and invasiveness.
NUR77 NUR77 (NR4A1) expression is elevated in both 
ER+ and ER− breast tumors (Muscat  et  al. 2013), and 
NUR77 expression is correlated with decreased relapse-
free survival in breast cancer (Alexopoulou  et al. 2010), 
consistent with reports of its pro-oncogenic role in 
breast cancer (Hedrick  et  al. 2015). Contradictory to a 
previous report of NUR77 having anti-migratory effects in 
MCF-10A breast cancer cells, recently, NUR77 expression 
was shown to have pro-migratory effects through activation 
of TGF-beta signaling (Zhou et al. 2014), which is known 
to have an important role in breast cancer metastasis 
(Moore et al. 2008, Kohn et al. 2012, Luwor et al. 2015).
COUP-TF1 and COUP-TF2 COUP-TFs are orphan 
nuclear receptors primarily known for their important 
roles in organogenesis including angiogenesis, cellular 
growth, differentiation and migration (Boudot  et  al. 
2011). Their roles in breast cancer growth and progression 
have recently been highlighted. Both COUP-TF1 and 
COUP-TF2 expression are lower in breast tumors 
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compared to normal breast tissue (Muscat  et  al. 2013). 
COUP-TF1 expression was reported to be higher in 
dedifferentiated breast cancer cells and correlated with 
low expression of E-cadherin and expression of vimentin 
(Le Dily  et  al. 2008). Overexpression of COUP-TF1 in 
MCF-7 cells results in a decrease in CXCL12 and increase 
in CXCR4 expression, mediated by EGF signaling, and 
leads to enhanced motility and invasiveness of MCF-7 
breast cancer cells (Le Dily et al. 2008, Boudot et al. 2014). 
CXCL12 expression in primary tumors has recently been 
reported to drive breast cancer metastasis (Ray et al. 2015). 
The other COUP-TF member, COUP-TF2, may also have 
a role in breast cancer cell migration and invasion with a 
report that transfection of COUP-TF2 into MDA-MB-231 
resulted in increased migration and invasion of these 
cells (Navab et al. 2004). Together these findings suggest 
a potential involvement of COUP-TFs in epithelial-
to-mesenchymal transition and migration of breast 
cancer cells.
Concluding remarks
Advances in genomic technologies have enabled more 
integrated insights into the roles of NRs in breast 
cancer biology: their expression, genomic distribution, 
mechanisms of action, as well as the complexity of their 
functional interactions. Expression profiling studies have 
shown that many NRs, in addition to ESR1 and PGR, are 
expressed and are potentially functional in breast cancer. 
Cistromic profiling studies highlight the complexity of 
NR transcriptional regulation, how multiple NRs often 
work together as well as with other coregulators and 
the chromatin landscape to fine tune the cell-specific 
expression of target genes, and how changes in the gene 
regulatory programs of NR are associated with the tumor 
state. Finally, it is evident that in addition to regulating 
proliferation and apoptosis, NRs are critical regulators 
of a diverse range of other cancer-associated biological 
processes including the circadian clock, metabolic 
reprogramming and migration and metastasis.
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Appendix	B	–	Supplementary	Materials	to	Paper	2	
Supplementary Materials to Paper 2 – Supplementary Figure 1 
Boxplot of coregulator delta Ct values in each of the 4 sample cohorts. Y-axis 
represents delta Ct values 
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Supplementary Materials to Paper 2 – Supplementary Figure 2 
Schematic diagram of survival analysis approach. Diagram outlines approach 
employed to identify nuclear receptors and coregulators whose expression 
significantly associates with breast cancer patient survival 
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Supplementary Materials to Paper 2 – Supplementary Figure 3 
Principal component analysis. (A) Scatter plot of factor loadings for the first 2 
principal components. (B) Proportion of variance captured by each of the first 
10 principal components. 
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Supplementary Materials to Paper 2 – Supplementary Figure 4 
Kaplan Meier plots of the probability of survival for samples classified into 
Low, Intermediate and High risk groups based on the expression profile two 
different groups of nuclear receptors: Group 1 (REV-ERBb, GR, NOR1, LRH-1 
and PGR) and Group 2 (AR, ESRRg RORg RXRa and RXRg. Samples from the 
Validation Sets (Supplementary Figure 2) were used for this analysis (1094 
breast cancers profiled on Affymetrix Hg133A arrays). Log rank Pval represent 
the log rank p-value for the Kaplan Meier curves. Cox.Reg.Pval is the 
univariate Cox Regression P-value for the association of sample risk scores 
with patient survival. C-index represents the Concordance Index calculated as 
detailed in [218]. 
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Supplementary Materials to Paper 2 – Supplementary Figure 5 
Effect of PCNA adjustment. (A) Concordance indices obtained for the 48 
published signatures and 3 NR/coregulator based signatures computed using 
ER positive samples profiled on Affymetrix Hg133a arrays unadjusted (black) or 
adjusted for meta-PCNA expression (grey). (B) similar to 5A but values 
computed using ER- samples 
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Supplementary Materials to Paper 2 – Supplementary Table 1 and 2 
These supplementary tables contains expression data of all NR coregulators in 
106 breast tissues samples and is too big to be included here. It can be 
downloaded from the Journal of Molecular Oncology website using the link 
provided below. 
http://dx.doi.org/10.1016/j.molonc.2014.03.017  
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Supplementary Materials to Paper 2 – Supplementary Table 3 
Microarray	datasets	used	in	survival	analysis  
Study	 GEO	accession	
	Number	
of	samples	 Platform	
Schmidt	et	al.,	2008	[148]	 GSE11121	 200	 Affymetrix	HG133A	
Pawitan	et	al.,	2005	[149]	 GSE1456	 159	 Affymetrix	HG133A	
Symmans	et	al.,	2010	[150]	 GSE17705	 298	 Affymetrix	HG133A	
Wang	et	al.,	2006	[151]	 GSE2034	 286	 Affymetrix	HG133A	
Hatzis	et	al.,	2011	[152]	 GSE25055	 310	 Affymetrix	HG133A	
Hatzis	et	al.,	2011	[152]	 GSE25065	 198	 Affymetrix	HG133A	
Miller	et	al.,	2005	[153]	 GSE3494	 251	 Affymetrix	HG133A	
Loi	et	al.,	2007	[154]	 GSE6532	 327	 Affymetrix	HG133A	
Desmedt	et	al.,	2007	[154]	 GSE7390	 198	 Affymetrix	HG133A	
Curtis	et	al.,	2012	(METABRIC)	[83]	
EGAS0000000
0083	 1992	 Illumina	HT-12	v3	
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